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Kidney transplantation is the preferred treatment of end-stage renal disease, because of the 
recipient’s improved life expectancy, better quality of life, and the lower total healthcare 
costs, compared to dialysis treatment.1,2 Since the first successful kidney transplantation in 
1954, patient and graft survival increased tremendously.3,4 Despite all the improvements in 
immunosuppressive drugs and surgical techniques, it appears that during the last decade a 
plateau in long term allograft survival has been reached.
As the demand for kidney grafts is ever increasing, the number of kidney transplantations 
is limited by the availability of organ donors. Almost half of all kidney transplantations 
are living donor kidney transplantations, whereas the others are transplantations with 
deceased donor kidney grafts.5 Deceased donor kidney grafts are retrieved from either 
brain dead donors or cardiac dead donors. Graft survival for living unrelated donor kidney 
transplantation is superior compared to that of deceased donor kidney transplantation, even 
though the average human leukocyte antigen (HLA) matching is worse in living unrelated 
transplantation.6 Therefore, the limited graft survival of deceased donor kidneys cannot 
be attributed exclusively to differences in immunogenicity; other causes of damage are 
probably more important. The most prominent of these causes is ischemia/reperfusion 
(I/R) injury, characterized by the exacerbation of tissue damage upon reestablishment of 
circulation after a period of ischemia. I/R injury is an important cause of delayed graft 
function, having a major influence on both graft function as well as graft survival.7
Renal ischemia/reperfusion injury 
Renal I/R injury occurs in a multitude of clinical situations. Periods of hypotension with 
impaired blood flow to the kidney can cause renal I/R injury, whereas more acute ischemia 
occurs in renal arterial thrombosis. In kidney transplantation renal ischemia is inevitable, 
and the duration of ischemia is often beyond control. Preventive and therapeutic measures 
in I/R injury would be required to reduce the severity of graft dysfunction and failure thus 
allowing safe expansion of the donor pool with marginal donor kidneys that have suffered 
more initial injury before organ retrieval. Unfortunately, current treatment for renal I/R 
injury is still primarily supportive, and experimental therapies aimed at minimizing I/R injury 
have been applied in animal models generally, not clinical trials. In order to design better 
therapeutics for clinical renal I/R injury, detailed knowledge on the pathophysiological 










































Pathophysiology of renal ischemia/reperfusion injury
The pathophysiology of I/R injury is multifactorial and only partially understood. 
Inflammation however, is regarded the crucial event in the development of tissue injury and 
graft dysfunction in renal I/R injury. Based on animal experiments, many individual factors 
such as cytokines and complement have been suggested to be involved in the inflammatory 
response. However, intervention studies aimed at specific inhibition of a single factor have 
generally shown disappointing results.8,9 Cooperation, redundancy and interactions make the 
involved mechanisms more complex than previously thought. Pharmacological inhibition of 
the entire inflammatory cascade would appear a logical intervention, however the negative 
side-effects appear larger than the anticipated beneficial effects.10
Although there may be differences in the exact pathophysiological mechanisms of I/R injury 
between different organs, some processes appear to play a universal role. The endothelium 
and microvasculature are very sensitive to hypoxia and are easily affected in I/R injury. 
Upon reperfusion, the vascular endothelial cell lining can undergo swelling which may lead 
to narrowing of the vascular lumen.11,12 Moreover, vasorelaxation can be impaired, together 
contributing to the no-reflow phenomenon.13 Endothelial injury can increase microvascular 
permeability which may lead to inflammatory cell trafficking into the reperfused kidney. 
There have been many reports of invading granulocytes, monocytes, dendritic cells (DC’s) 
and lymphocytes into various tissues after reperfusion.14-20 Together with leukocytes, 
platelets can be activated by injured endothelium. In myocardial infarction, platelets 
mediate thrombotic occlusion and increase damage by causing microvascular occlusions, 
contributing to the no-reflow phenomenon.21 On the other hand, platelets are also able to 
invade tissue.22 This is essential since platelets can contribute to the inflammatory response 
through release of cytokines, chemokines and growth factors from their granules.23-25 In 
fact, platelets have been suggested to be involved in the inflammatory response of I/R 
injury in various organs. They are able to roll and adhere to post-reperfusion endothelium 
in a P-selectin dependent mechanism.26-32 In mouse myocardial tissue, the first activated 
platelets are present within two minutes after reperfusion, and then accumulate in the 
infarcted myocardium.33,34 
The ensuing inflammatory response which follows is considered to exacerbate damage. Both 
the innate as well as the adaptive immune system can be activated after reperfusion. 
Activation of the innate immune system is probably mediated by activation of pattern-
recognition receptors such as toll-like receptors that recognize their endogenous ligands 
that are released upon tissue damage.35 The complement system is part of the humoral 
immune response and can play a role both as first line innate defense, but may also 












































(terminal) complement activation in I/R injury has been suggested,37-41 although recent 
animal experiments doubt the involvement of the complement system itself in the initiation 
of injury.42 The role of complement activation in human I/R injury is even more complex. 
While a role of complement activation was suggested in human myocardial I/R injury,43,44 
diverse anti-complement intervention studies did not lead to major improvements.45-50
Ischemia-related metabolic adaptations and dysregulated mitochondrial homeostasis are 
thought to result in substantial release of reactive oxygen and nitrogen species (RONS) upon 
reintroduction of oxygen. The RONS overload can overwhelm the endogenous antioxidant 
system, resulting in oxidative damage. This may trigger secondary processes and contribute 
to the pro-inflammatory response upon reperfusion.51-54 Numerous animal studies clearly 
demonstrate that antioxidant therapy ameliorates I/R injury.55-57 Despite these findings, 
studies in humans consistently fail to show any clinically relevant effect.55,58-61 The basis for 
this discrepancy between human and animal studies is still unclear. Yet, it may suggest that 
the contribution of RONS to I/R injury in humans is less than commonly thought.
Ultimately, when I/R injury to the cell is severe, various programs of cell death can be 
activated. Three major forms of cell death can be distinguished: necrosis, apoptosis, and 
autophagy. Besides acute cell death by necrosis or apoptosis during and directly after the 
ischemic period, cell death continues for several days following reperfusion. All three types 
of cell death can contribute to the continued loss of cells for days and even weeks in the 
reperfused tissue. In animal models, both necrosis and apoptosis continued after reperfusion 
with a maximum severity three days after reperfusion.62,63 Autophagy during the ischemic 
episode appears to keep cells viable and might play a protective role. It can be suggested, 
however, that activation of autophagy after reperfusion is detrimental. Indeed, a mouse 
model of myocardial I/R illustrates that protein levels of the autophagic mediator beclin 
can be greatly upregulated during reperfusion. Mice with reduced beclin levels exhibited 
smaller myocardial infarct sizes.64,65
Long term impact
Although short term results of kidney transplantation are excellent, 5 year graft loss can be up 
to 30% in older recipients.66 Protocol biopsies obtained in the first years after transplantation 
have shown rapid increase in the prevalence of interstitial fibrosis/tubular atrophy (IF/
TA). This finding has been correlated with later graft dysfunction and graft loss, mostly in 
cases of concomitant interstitial inflammation and fibrosis.67,68 Both allogen dependent and 
independent factors determine IF/TA. I/R injury is an important non-allogeneic factor and 
the duration of the cold ischemic period is directly correlated to delayed graft function and 










































shown to cause interstitial fibrosis and glomerulosclerosis in experimental models (Figure 
1).71-73 
Figure 1: Experimental renal I/R injury induces severe patchy renal fibrosis, although kidney function 
partially recovers. Sirius red staining shows A) normal mouse kidney and B) severe fibrosis 3 weeks after 
mice underwent 25 minutes of warm renal I/R injury. (Non published data)
Opportunities in studying renal I/R injury
Until now, results of renal I/R experiments in small animal models have not been 
translatable into clinical kidney transplantation. The most probable reason is that the exact 
mechanism involved are probably different between species. Detailed knowledge on the 
pathophysiological mechanisms leading to I/R injury in human kidney transplantation is 
required to form a basis for experimental therapies. 
Studying the pathophysiology of human renal I/R injury requires careful techniques that 
specifically assess the processes that occur in the kidney at the moment of reperfusion and 
thereafter. Two complementary approaches have been chosen in previous studies: assessment 
of processes in the intravascular compartment or assessment of changes in the renal tissue. 
Intravascular changes have been assessed frequently in renal I/R injury, and almost all 
studies measured changes in circulating factors by collecting sequential peripheral blood 
samples. In these peripheral blood samples however, the source of the released factors 
can never be ascertained to be the kidney. Even more since haemodynamics change upon 
reperfusion of the kidney graft, and the leg is reperfused simultaneously with the kidney 
upon removal of the iliac arterial clamp. Furthermore, release of factors into the circulation 
may be undetected because of their dilution in the total circulating volume. By collecting 
arteriovenous blood samples over the kidney during reperfusion, specific measurements can 
be done studying those factors that are released from the kidney, i.e. that have a higher 
concentration in renal venous blood compared to arterial blood. Moreover, the release of 













































largest concentration difference in the efferent vein. Finally, by measuring time-series of 
these arteriovenous differences a dynamic and specific footprint of the processes occurring 
in the reperfused kidney can be reconstituted. In Figure 2 the technique of arteriovenous 
measurements over the transplanted kidney is illustrated. The renal artery and vein are 
selectively cannulated before reperfusion, and during the first half hour of reperfusion, 
timed and paired arterial and venous samples can be collected from the kidney. This 
technique is applied in many of the studies described in this thesis. 
Figure 2: Schematic representation of the arteriovenous sampling method over the reperfused kidney 
by simultaneous blood collection from the renal artery (left) and renal vein (right). Illustration by 
Manon Zuurmond© (www.manonproject.com). Adapted from de Vries et al. 77
Aims of this thesis
The aims of this thesis were to explore the factors and processes involved in the 
pathophysiology of renal I/R injury in clinical kidney transplantation, in order to establish 
a basis for the development of specific therapies preventing and limiting renal I/R injury in 
kidney transplantation. Exact knowledge on the sequence of events by which graft damage 
is initiated after reperfusion in human kidney transplantation was still lacking. In chapter 
2, 3 and 4, the release of pro-inflammatory cytokines from the reperfused graft is assessed 
and compared between living and deceased donor kidney transplantations. In chapter 5, an 
important actor of the innate immune system, the complement system, is assessed in human 
kidney transplantations. Whether endothelial activation and concomitant platelet activation 
are present in early reperfusion of transplanted kidneys is investigated in chapters 6, 7 and 
8. Finally, oxidative damage, the most commonly mentioned process in the pathophysiology 










































10 shows new insights as I/R injury is approached from an unbiased, hypothesis generating 
angle, in which gene expression profiles are compared to assess changes upon reperfusion 
and baseline differences between different donor types. Chapter 11 and 12 summarize the 
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The pathophysiology of ischemia/reperfusion (I/R) injury is complex and current knowledge 
of I/R injury in humans is incomplete. In the present study, human living donor kidney 
transplantation was used as a highly reproducible model to systematically study various 
processes potentially involved in early I/R injury. Unique, direct measurements of 
arteriovenous concentration differences over the kidney revealed massive release of 
interleukin (IL)-6 in the first 30 minutes of graft reperfusion and a modest release of IL-8. 
Among the assessed markers of oxidative and nitrosative stress only 15(S)-8-iso-PGF2a was 
released. When assessing cell activation, release of prothrombin fragment 1+2 indicated 
thrombocyte activation, whereas there was no release of markers for endothelial activation 
or neutrophil activation. Common complement activation complex sC5b-9 was not released 
into the bloodstream, but was released into urine rapidly after reperfusion. To investigate 
whether IL-6 plays a modulating role in I/R injury, a mouse experiment of renal I/R injury 
was performed. Neutralizing anti-IL-6 antibody treatment considerably worsened kidney 
function. In conclusion, this study shows that renal I/R in humans is dominated by local 














































Ischemia/reperfusion (I/R) injury is the exacerbation of tissue damage upon reestablishment 
of circulation after a period of ischemia. I/R injury is an inevitable consequence of organ 
transplantation, and a major determinant of patient and graft survival. The pathophysiology 
of I/R injury is complex and incompletely understood. Numerous animal experiments 
and limited human studies have shown that free radicals,1-3 complement,4;5 neutrophils,6 
and thrombocytes 7;8 may contribute to I/R injury. To our best knowledge, none of the 
interventions targeting these processes had an appreciable impact on morbidity or mortality 
in humans, despite their beneficial results in animal models.3;9-21 Previous studies of I/R injury 
in humans mostly relied on measurements in peripheral blood. Unfortunately, peripheral 
blood measurements lack sensitivity and do not discriminate between the release of factors 
from the allograft and systemically released factors. We used a renewing approach to 
avoid the limitations of systemic measurements. Consecutive arteriovenous concentration 
differences of various factors were assessed directly over the reperfused organ to reveal 
the locally active processes in human I/R. Because of the maximal homogeneity in donor 
and patient characteristics, minimal variation in ischemia duration and the possibility to 
collect control blood and urine samples from the donor (i.e. over the same kidney that was 
studied after reperfusion in the recipient), it was decided to study I/R in living-donor kidney 
transplantation. Our results show that the early phase of reperfusion is dominated by IL-6 
release from the kidney. Furthermore, immunoneutralization of IL-6 in mice resulted in 
aggravation of I/R injury. 
Methods
Patient population
Twelve eligible patients undergoing renal allograft transplantation from living donors were 
recruited (Table 1). None of the donors had current illness and all were free of medication. 
For technical reasons (renal vein sampling) only patients receiving a left kidney were 
included. The study protocol was approved by the local ethics committee, and informed 











































Table 1: Donor, recipient and transplant characteristics
Donor Recipient Ischemia time (min)
Age Gender Age Gender Disease Cold Warm
1 30 Male 53 Male polycystic kidney disease 156 28
2 38 Male 55 Male glomerulonephritis 173 32
3 37 Female 33 Male IgA nephropathy 170 24
4 53 Female 32 Female reflux nephropathy 193 33
5 39 Male 34 Female systemic lupus erythematosus 
nephritis
195 31
6 45 Male 50 Male polycystic kidney disease 180 30
7 56 Female 37 Female IgA nephropathy 160 33
8 52 Male 53 Female polycystic kidney disease 190 25
9 48 Male 51 Female renal failure with unknown cause 200 36
10 25 Male 27 Male glomerulonephritis 175 29
11 52 Male 48 Female renal failure with unknown cause 145 30












Living donor kidney transplantations were performed according to the local protocol. Prior 
to implantation of the graft, a 5 French umbilical vein catheter was placed in the renal vein 
through one of its side branches. At 30 sec., 1, 3, 5, 10, 20 and 30 min. after reperfusion 
(i.e., t=0) 10 ml blood aliquots were sampled. Paired arterial blood samples were obtained 
at 0, 3, 5, 10, 20 and 30 min. after reperfusion. Thirty minutes after reperfusion the 
abdominal wall was closed and the endpoint of sampling was reached.
Recipients were pre-treated with the following immune suppressants at the day of 
transplantation: basiliximab (20 mg), mycophenolatemofetil (1440 mg), cyclosporine (6 
mg/kg in two doses) and prednisolone (100 mg in two doses). Donors underwent open 
nephrectomy. For cold perfusion and storage of the kidney, Custodiol® HTK solution 
(Tramedico, Weesp, The Netherlands) was used. Mean cold ischemic period was 177±17 min. 
The above described method was also used to obtain a control arterial and renal venous 
blood sample during donor nephrectomy prior to the induction of renal ischemia. All blood 
and urine samples were collected in tubes containing EDTA and immediately stored on ice. 
Blood and urine samples were centrifuged (1550 g, 20 min, 4ºC) and the derived plasma/
supernatant was re-centrifuged (1550 g, 20 min, 4ºC) to deplete it from leukocytes and 












































A renal cortical biopsy was obtained after the period of cold storage. Control biopsies were 
acquired immediately (within the first minute) after completion of nephrectomy. Biopsies 
were fixed in formalin or immediately snap frozen in liquid nitrogen and stored at -70ºC. 
The initial urine produced by the graft within 10 minutes after reperfusion was collected 
directly from the ureter. Control urine was collected from the urethral catheter of the 
donor during the nephrectomy procedure before kidney ischemia. 
Plasma measurements
The arteriovenous sampling method was validated by blood gas analysis of the arterial and 
venous samples. Kidney function directly after reperfusion was estimated by comparing 
the arterial and venous creatinine levels. Because cholesterol is not secreted, filtered or 
re-absorbed by the kidney, plasma cholesterol was measured to evaluate potential blood 
concentrating effect of the kidney. Lactate dehydrogenase (LDH) activity was determined 
as measure of cell lysis. Blood gases, creatinine, cholesterol and LDH activity were all 
measured in a certified facility, using routine laboratory assays. 
We measured various markers for each of the processes potentially involved in I/R injury. 
Plasma was analyzed for biomarkers of oxidative and nitrosative stress. Total 15(S)-8-iso-
PGF2a was measured in plasma by gas chromatography-tandem mass spectrometry (GC-
tandem MS) as described previously.22 Malondialdehyde (MDA) was measured in 100-µl 
aliquots of plasma by GC-tandem MS by a procedure similar to that reported previously for 
nitrite and nitrate.23 Thiobarbituric acid reactive substances (TBARS) were determined by 
a high-performance liquid chromatography (HPLC) method.24 As indicators of NO synthesis, 
its major metabolites nitrite and nitrate were measured by GC-MS as described previously.23 
Nitrotyrosine in proteins was measured by ELISA in accordance with the manufacturer’s 
instructions (Biotech nitrotyrosine EIA, Oxis, Portland, Oregon, USA). 
The soluble complement complex C5b-9 (sC5b-9) was measured by ELISA as described 
previously by Molness et al.25 (reagents for sC5b-9 measurements were generously provided 
by professor T.E. Mollnes, Institute of Immunology, University hospital Oslo, Norway). 
sICAM-1 and sP-selectin levels were measured by a commercially available ELISA (human 
sICAM-1, DY720, human sP-selectin, DY137, R&D systems, Abingdon, UK) following the 
manufacturer’s instructions. Neutrophil activation was assessed by measuring lactoferrin, a 
neutrophil degranulation product. Lactoferrin concentrations in plasma were quantified by a 
human lactoferrin-specific ELISA as described by van Berkel et al.26 with minor modifications. 
A standard curve was constructed with recombinant human lactoferrin (a generous gift of 
Dr. H.A. van Veen, Pharming, Leiden, The Netherlands); the lower limit of detection was 25 










































using polyclonal rabbit antibodies to human vWF (Dako, Copenhagen, Denmark).27 Plasma 
concentration units were calculated as percentage of pooled plasma level. Prothrombin 
fragment (F) 1+2 was measured by ELISA conform manufacturer’s instructions (Enzygnost 
F1+2, Dade Behring, Marburg, Germany).
Multiplex cytokine array (Evidence investigator cytokine array, Randox Laboratories, 
Crumlin, UK) was used to evaluate cytokine release in three patients’ arterial and venous 
sample taken 30 minutes after reperfusion. Detection limits were 0.9 ng/l for IL-1a, 1.6 ng/l 
for IL-1b, 4.9 ng/l for IL-2, 6.5 ng/l for IL-4, 1.0 ng/l for IL-6, 7.8 ng/l for IL-8, 1.8 ng/l for 
IL-10, 14.6 ng/l for vascular endothelial growth factor (VEGF), 4.6 ng/l for tumor necrosis 
factor a (TNF-a), 3.5 ng/l for interferon g (IFN-g) and 2.9 ng/l for endothelial growth factor 
(EGF). Based on the results of the cytokine array, all samples were analyzed for IL-1b, IL-6 
and IL-8 by ELISA (PeliKine, Sanquin Reagents, Amsterdam, The Netherlands) and for TNF-α 
by high sensitivity ELISA (Quantikine HS, R&D systems, Abingdon, UK). Detection limits were 
2 ng/l for IL-6 and IL-8, 3 ng/l for IL-1β and 0.12 ng/l for TNF-α. 
Measurement of renal IL-6 mRNA content and IL-6 immunohistochemistry
All biopsy specimens were analyzed for IL-6 mRNA by semi-quantitative PCR (TaqMan 
method of Applied Biosystems, Perkin Elmer, Groningen, The Netherlands) by using a 
combination of a forward and a backward primer and a specific (6-carboxy-fluorescein/6-
carboxy-tetramethyl-rhodamine [FAM/TAMRA]) double-labeled probe.28 Specific amplicons 
were chosen according to the manufacturer’s recommendations. IL-6 probes and primers 
were obtained from Isogen (Maarsen, The Netherlands) and the VIC labelled GAPDH primer-
probe combination was purchased from Applied Biosystems (Nieuwekerk aan de IJssel, 
The Netherlands). Results were corrected for glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) expression. Three kidney biopsies, obtained directly after the period of cold 
storage were stained for IL-6 as described before.28 
Animals and surgical procedure
To assess the dose of rat anti-IL-6 antibody (Ab) (MAB406, R&D systems, Abingdon, UK) 
needed to substantially inhibit the IL-6 response, a preliminary study in CRP knock-in mice 
was conducted. In 5 human CRP transgenic (huCRPtg) mice 29 baseline CRP levels were 
measured (mean 5.4(3.3) µg/ml). Administration of recombinant murine IL-6 (cat no. 
216-16; PreproTech Inc., New Jersey, USA) caused a significant increase in CRP levels to 
17.1(9.0) µg/ml (measured 18 hours after administration), which was completely inhibited 
by administration of 100 ug anti-mouse IL-6 Ab per mouse i.p. (R&D systems, Abingdon, UK) 
Renewed IL-6 administration 30 hours after anti-IL-6 Ab administration did not cause an 
increase in CRP levels. This pilot study shows that the administration of 4 mg/kg anti-IL-6 












































Normal male (C57BL/6J/BALB/c/Cr1BR) F1 mice of 10 weeks old were used in this study. 
They were divided into the following three groups: 1) I/R pre-treated with anti-IL-6 Ab 
group (n=10); 2) I/R pre-treated with control Ab group (n=10); and 3) sham operated with 
control Ab treatment group (n=4). Mice in the pre-treated groups received either 4 mg/
kg anti-IL-6 Ab or 4 mg/kg non-specific IgG1 Ab (R&D systems, Abingdon, UK) i.p. 24 hours 
preoperatively. Mice were anaesthetized with i.p Hypnorm®, midazolam mixture in a dose 
of 0.8 mg/kg fentanyl citrate, 25 mg/kg fluanisone and 12.5 mg/kg midazolam. Core body 
temperature was maintained at 37 ºC using a thermic blanket. A baseline blood sample was 
obtained from the tail vein. Via a midline laparotomy the renal pedicles were identified 
and bilaterally clamped for 30 minutes using microvascular clamps (S&T, Neuhausen, 
Switzerland). In the sham group identical surgical procedures were used, except that clips 
were not applied. After the renal pedicle clamps were removed, the kidneys were observed 
for color change indicating reflow. One milliliter of warm saline was left in the abdominal 
cavity before the incision was sutured in two layers and the mice were allowed to recover 
from anesthesia. As analgesic 0.05mg/kg buprenorfine was administered s.c. After 48 hours 
the mice were anesthetized again. The final blood sample was obtained using cardiac 
puncture. Immediately after blood collection, the kidneys were removed and sagitally 
cut. One halve was snap frozen in liquid nitrogen and the other halve kept on formalin. 
Blood samples were collected in heparin coated capillary tubes. Plasma urea concentration 
was measured using the reflotron system (Roche diagnostics, Almere, The Netherlands) as 
indicator of kidney function at baseline and 48 hours after reperfusion. Throughout the 
whole experimental period the mice were maintained on standard diet and given water ad 
libitum. The study was approved by the veterinary authorities of the LUMC. 
Histological evaluation
The kidneys were fixed in formalin for 24 hours and then embedded in paraffin for light 
microscopy and immunohistochemistry. Longitudinal sections of 4 mm thick were prepared 
and stained with Periodic Acid Schiff (PAS). Histological tissue injury was scored by an 
experienced pathologist (E.H.), blinded for the groups. Kidney injury was scored semi-
quantitatively on amount of proximal tubule necrosis (score 0-3), band necrosis of cortex 
and medulla (score 0-1) and protein casts in the tubules (score 0-1). 
Statistical analysis
Statistical analysis was performed using SPSS 14.0 statistical analysis software (SPSS Inc, 
Chicago, Ill). For the various outcome variables random coefficients mixed models were 
fitted with time as continuous predictor and with a categorical dichotomous predictor 
indicating whether the measurement was in a venous or arterial sample. This resulted in 










































venous curve as a whole was significantly elevated as compared to the mean arterial curve 
as a whole, instead of performing separate tests for the various points in time. Stated 
otherwise; it was tested whether there was an extra intercept for the venous compared to 
arterial curve. 
Other variables were compared using the paired t-test and Mann-Whitney U test as 
appropriate. Histological score was tested by Chi-square test or Fisher’s exact test as 
indicated. Data are expressed as mean ± standard error of the mean (SEM). Graph error bars 
represent the SEM. A p-value of less than 0.05 was considered significant. 
Results
Patient and graft characteristics and ischemia times are summarized in table 1. Post-
operative course was uneventful in all patients. One year patient and graft survival was 
100%. 
Arteriovenous measurements
Various valid markers were measured for each of the processes potentially involved in I/R 
injury (Figure 1). First, the arteriovenous sampling method was validated by blood gas 
analysis which reflected normal arterial and venous blood gas levels. Similar LDH levels in 
arterial and venous samples (p=0.73) excluded the release of intracellular constituents by 
cell lysis. Creatinine levels were consistently lower in the renal venous blood as compared 
to the arterial values (p<0.001), indicating immediate function of the kidney graft. Equal 
cholesterol levels (p=0.94) over the kidney excluded a blood concentrating effect of the 
kidney, therefore all results are presented without normalization.
Oxidative and nitrosative stress
We found a small but significant transrenal difference for 15(S)-8-iso-PGF2a (p=0.003, Figure 
2A). Arteriovenous measurements over the non-ischemic kidney in the donor revealed similar 
15(S)-8-iso-PGF2a levels showing its release is specific for I/R (p=0.69, Figure 2B). Urinary 
15(S)-8-iso-PGF2a levels did not change upon reperfusion (p=0.35, Figure 2C). In contrast, 
there was no transrenal MDA concentration difference after reperfusion as established both 
by GC-tandem MS (p=0.17) and the TBARS method (p=0.064). MDA levels (TBARS method) 
were similar in urine from recipients and in control urine (p=0.40). Measurement of nitrite and 
nitrate, indicators and measures of nitric oxide (NO) biosynthesis, as well as of nitrotyrosine, 
a biomarker of nitrosative stress, did not show arteriovenous differences (p=0.14, p=0.097 
and p=0.93, respectively). Likewise, urinary nitrite and nitrate concentrations remained 












































Figure 1: Schematic view of processes potentially involved in early I/R injury, showing the biomarkers 
measured in this study. Grey boxes indicate local release of F1+F2, 15(S)-8-iso-PGF2a , sC5b-9, IL-6 and 
IL-8 from the human kidney, indicating involvement of thrombocyte activation, complement activation, 










































Figure 2 A: Significant differences between arterial and renal venous plasma concentrations of 15(S)-
8-iso-PGF2a during the first 30 minutes of reperfusion indicated local release from the graft (p=0.003, 
n=6); 
B: Control arterial and renal venous plasma was collected from the donor during the nephrectomy 
procedure, before renal ischemia was induced. Concentrations of 15(S)-8-iso-PGF 2a did not reveal 
arteriovenous differences in non-ischemic conditions (p=0.69, n=6); 
C: Concentration of 15(S)-8-iso-PGF 2a corrected for creatinine concentration in the initial urine 
produced within minutes after reperfusion did not differ from control urine collected from the donor 















































To evaluate complement activation during reperfusion, we measured the common terminal 
end product of the three complement activation pathways. sC5b-9 concentrations were 
similar in arterial and venous samples (p=0.37). In contrast, sC5b-9 levels were significantly 
higher in urine produced immediately after reperfusion than in control urine from the donor 
(3.1 versus 0.11 U/mol creatinine, p< 0.001, Figure 3). 
Figure 3: Concentration of sC5b-9 complex, corrected for creatinine concentration, was significantly 
higher in the initial urine produced in the graft within minutes after reperfusion as compared to 
the control urine from the donor collected during nephrectomy, before renal ischemia was induced 
(p<0.001, control: n=6, reperfusion: n=9). 
Cell activation
Prothrombin F1+2 levels showed a significant (p=0.001, Figure 4) concentration difference 
between arterial and renal venous blood, suggesting rapid thrombocyte activation during 
early I/R. Concentrations of sICAM-1 and sP-selectin in plasma were measured as indicators 
of endothelial activation. sICAM-1, sP-selectin and vWF levels were equal in arterial and 
renal venous blood (p=0.50, p=0.31 and p=0.12, respectively), providing no evidence for 











































Figure 4: Renal venous plasma concentrations of prothrombin fragment 1 and 2 (F1+2) were significantly 
higher as compared to arterial concentrations, demonstrating local release from the kidney during 
reperfusion (p=0.001, n=6).
Cytokine and chemokine response
The cytokine response after reperfusion was dominated by the local release of IL-6. IL-6 
levels were significantly elevated in renal vein blood (p<0.001, Figure 5A), peaking directly 
after reperfusion. The IL-6 release was specific for I/R, as control measurements over the 
non-ischemic kidney in the donor did not show a transrenal difference in IL-6 levels (p=0.44, 
Figure 5B). This indicates that IL-6 release is not a consequence of manipulation of the 
kidney during surgery or a reaction to anesthetics. Urinary IL-6 release immediately after 
reperfusion was ten times higher than baseline release (41.2 vs 4.1 pg IL-6/mmol creatinine, 
p=0.003, Figure 5C). 
To investigate whether IL-6 release from the reperfused kidney reflected enhanced IL-6 
transcription before reperfusion or relates to release of pre-stored IL-6, we analyzed IL-6 
mRNA levels and performed immunohistochemical IL-6 staining on kidney biopsies. This 
analysis demonstrated that IL-6 mRNA levels remained similar during the cold ischemic 
period (p=1.0, Figure 5D) but showed abundant granular cytoplasmatic IL-6 staining in 
the tubular epithelial cells of kidney biopsies collected before reperfusion. Glomeruli and 












































Figure 5 A: Arterial and renal venous plasma concentrations of IL-6 showed a substantial and continuous 
release of IL-6 from the reperfused kidney during the first 30 minutes of reperfusion (p<0.001, n=9); 
B: Control, pre-ischemic arterial and renal venous plasma concentrations of IL-6 in the donor during 
nephrectomy procedure were comparable, indicating IL-6 release is specific for I/R (p=0.44, n=5); C: 
Concentration of IL-6, corrected for creatinine concentration, was significantly higher in the first urine 
produced by the graft after reperfusion, as compared to control urine of the donor collected before 
renal ischemia was induced in the donor nephrectomy procedure (p=0.003, control: n=5, reperfusion: 
n=7); D: IL-6 expression relative to GAPDH expression in kidney tissue collected at the end of the cold 
preservation period (ischemia) did not differ from baseline expression in biopsies collected before 
ischemia in donor nephrectomy procedures (p=1.0, control: n=5, ischemia: n=6). 
Figure 6: Typical example of immunohistochemical staining for IL-6 in human kidney biopsies collected 
before reperfusion showing abundant granular cytoplasmatic IL-6 staining in the tubular epithelial 
cells, whereas the interstitial cells and glomeruli are negative. Magnification × 20, inset magnification 














































The findings of the multiplex cytokine screening assay (table 2) were validated by individual 
ELISA measurements. Besides IL-6, also IL-8, TNF-α and IL-1β concentrations were assessed. 
There was a small but significant arteriovenous difference in IL-8 levels over the kidney 
(p<0.001, Figure 7A). Control arteriovenous measurements over the non-ischemic kidney 
did not indicate IL-8 release (p= 0.95, Figure 7B). Urinary IL-8 levels after reperfusion were 
equal to pre-ischemic concentrations (p=0.11). Plasma TNF-α levels did not show transrenal 
arteriovenous concentration differences (p=0.81). Plasma IL-1β, and urinary IL-1β and 
TNF-α levels were all below the detection limits of the assay.
Figure 7 A: Arterial and renal venous plasma concentrations of IL-8 during the first 30 minutes of 
reperfusion showed a modest but significant IL-8 release from the graft (p<0.001, n=9); B: Pre-ischemic 
arterial and renal venous plasma concentrations of IL-8 were similar in the samples obtained from the 














































Table 2: Pilot measurements of plasma cytokine concentrations using multiplex cytokine 
array. 
Pt no 30 min 
after rep. 
IL-1a IL-1b IL-2 IL-4 IL-6 IL-8 IL-10 VEGF TNF-a IFN-g EGF
1 Arterial < < < 0,33 14,32 < 10,41 15,32 < < <
1 Venous < < < 0,68 18,48 < 10,79 9,38 < < <
2 Arterial < < < 0,23 45,22 4.13 7,96 0.94 < < <
2 Venous < < < 0,12 127,49 7,73 9,33 4,01 < < <
3 Arterial < < < 0,17 22,51 < 16,71 21,6 < < <
3 Venous < < 4,69 0,12 30,78 0.08 15,97 15,98 4.57 < <
<: lower than the detection limit
Anti-IL-6 treatment 
Given the dominance of IL-6 release in the arteriovenous measurements, we investigated 
the role of IL-6 in the pathophysiology of I/R injury in a mouse experiment. The day after 
undergoing bilateral renal ischemia and reperfusion, one control antibody treated mouse 
and two anti-IL-6 treated mice had died. Autopsy did not reveal any bleeding or other 
obvious cause of death. Baseline urea concentration was identical in all mice, however at 
48 hours after reperfusion, urea concentration in anti-IL-6 treated mice was significantly 
higher than in control antibody treated mice (p=0.046) (Figure 8). These results concerning 
kidney function are supported by the histological analysis of the kidneys at 48 hours after 
reperfusion. There seemed to be considerably more kidney injury in the anti-IL-6 antibody 
treated group as compared to the control antibody treated group (Figure 9). However, 
the difference in semi-quantitative histological score was not statistically significant. The 
histological score of sham operated mice was 0 for all three categories (Figure 10). 
Figure 8: Plasma urea levels measured 48 hours after kidney reperfusion were significantly higher in 
anti-IL-6 treated mice compared to untreated mice. * p=0.046, ** p=0.004, *** p=0.20. The box runs 
from the lower to upper quartile, the whiskers indicate the 5 to 95 percentile, while the horizontal line 




















































































Figure 9: The effect of anti-IL-6 treatment on renal histology, 48 hours after kidney reperfusion.
G: glomerulus, &: protein casts, #: proximal tubule necrosis. 
A: Specimen from sham operated mouse showing normal renal cortex; B: Sham operated mouse showing 
intact renal medulla; C: Cortex of control antibody treated mouse showing protein casts; D: Medullar 
necrosis in control antibody treated mouse; E: Cortex section of anti-IL-6 antibody treated mouse, 
showing numerous protein casts and proximal tubule necrosis; F: Medulla section showing extensive 
band necrosis and protein casts. All sections show a representative image of the group, magnification × 












































Figure 10: Semi-quantitative histological damage score for kidneys 48 hours after reperfusion. 
Differences between anti-IL-6 Ab treated and control Ab treated groups did not reach statistical 
significance. Sham group scored 0 for all measures. BN=band necrosis, PTN=proximal tubule necrosis, 
PC=protein casts, sum=sum of the three scores. Co Ab (n=8) vs anti-IL-6 Ab (n=7): BN p=0.49, PTN 
p=0.11, PC p=0.29, sum p=0.35 (BN, sum: chi-square test; PTN and PC: Fisher’s exact test).
Discussion
Although many studies have focused on I/R injury, the pathophysiological mechanisms 
underlying this phenomenon are only partially understood. Studies in humans performed thus 
far largely rely on peripheral measurements, which have a limited sensitivity and validity. 
Instead, measurement of arteriovenous concentration differences over the graft provides a 
unique and accurate means to assess local processes implicated in human I/R injury. In the 
present study, living donor kidney transplantation was used as a highly reproducible clinical 
model of I/R. The results of this study show that the early phase of reperfusion is dominated 
by the release of soluble mediators, predominantly IL-6. Immunoneutralization of IL-6 in 
mice resulted in aggravation of kidney I/R injury. We therefore hypothesize that the renal 
IL-6 response upon reperfusion is protective in human I/R injury.
Free radicals, and oxidative and nitrosative stress have been considered the pivot of I/R 
injury for years. However, interventions using antioxidants show contradicting results.10;11;21;30 
To assess the involvement of oxidative and nitrosative stress in renal I/R injury, we measured 
a combination of independent markers. Since assessment of oxidative and nitrosative stress 
in biological samples is difficult, measurement of multiple factors is an established method 










































and nitrosative stress, i.e. 15(S)-8-iso-PGF2a, MDA, 3-nitrotyrosine, nitrite and nitrate were 
measured in arteriovenous plasma samples. Apart from a small but significant release 
of 15(S)-8-iso-PGF2a from the reperfused kidney, we found no evidence for oxidative or 
nitrosative stress. In the absence of release of other biomarkers for oxidative/nitrosative 
stress from the kidney, it can be doubted whether the observed release of 15(S)-8-iso-PGF2a 
indeed reflects increased oxidative stress levels. Moreover, the 15(S)-8-iso-PGF2a plasma 
concentrations measured in our patients are close to those measured in plasma of healthy 
humans 23 and the urinary excretion of 15(S)-8-iso-PGF2a did not change after reperfusion. 
It is known that 15(S)-8-iso-PGF2a can be formed by cyclooxygenase (COX)-1 activity in 
thrombocytes as well.31-34 As we found indications for thrombocyte activation in the early 
phase of I/R, 15(S)-8-iso-PGF2a production directly after reperfusion is more likely to 
relate to COX-1 activation in thrombocytes,31 rather than to oxidative or nitrosative stress 
mediated production. The thrombocyte activation itself could be explained as a result of 
activation upon crossing disrupted endothelial cell lining in the graft.35;36
We did not observe an arteriovenous concentration difference for the sC5b-9 complex, but 
sC5b-9 levels in recipients’ urine after reperfusion were more than ten times higher than in 
control urine. With the absence of detectable sC5b-9 release in donor urine we show that 
sC5b-9 release is specific for I/R, and does not relate to anesthesia or manipulation of the 
kidney during surgery. Besides urinary release, local complement depositions may be formed 
in the kidney that could not be demonstrated in this experimental set-up. An explanation for 
the selective urinary excretion of sC5b-9 could be the local production and release of sC5b-
9 in renal tubular epithelium upon I/R. This is supported by a mouse experiment showing 
C9 deposition mainly in tubular epithelium after reperfusion.37 Remarkably, in their animal 
model elevated renal C5b-9 formation was not detected up to 12 hours after reperfusion, in 
contrast to the immediate urinary release we observed in the present study. 
Our results show a substantial local release of IL-6 from the kidney during the first 30 
minutes of reperfusion. Control arteriovenous measurements immediately prior to donor 
nephrectomy did not show any release of IL-6 from the kidney in non-ischemic conditions, 
indicating that renal IL-6 release is specific for I/R, rather than a response to anesthesia 
or surgery. IL-6 release upon reperfusion is not specific for kidney tissue. IL-6 was found to 
be released locally from the gastrointestinal tract,38;39 the liver,40 the coronary sinus,41;42 
and the lower extremity 43 after reperfusion. Sources of the released IL-6 in the kidney 
may be circulatory or resident renal cells. Renal tubular epithelial cells have the potential 
to produce numerous cytokines and chemokines, including IL-6.44 Furthermore, IL-6 can be 
generated by many different types of circulating cells.45 The low baseline arterial IL-6 levels 












































kidney cells (Figure 5A and 5B). It is known that immunosuppressive medication, especially 
corticosteroids, are able to suppress cytokine response.46 This difference in baseline 
concentrations of IL-6 suggests that the immunosuppressive regimen the recipients are pre-
treated with is able to fully suppress the procedure related systemic IL-6 response. Since the 
transplanted kidney itself is not exposed to immunosuppressive agents before reperfusion 
it maintains the potential to produce and or release IL-6. Immunohistochemical staining of 
IL-6 in kidney biopsies collected immediately before reperfusion showed abundant presence 
of IL-6 in tubular epithelium in a granular pattern, suggesting that the kidney itself is 
a potential source of the released IL-6. Semi-quantitative realtime PCR did not indicate 
enhanced IL-6 transcription during cold storage, suggesting that IL-6 is released from pre-
existing storage pools.
IL-6 is a pleiotropic cytokine produced by various types of cells under various circumstances. 
It has been described as having both pro- as well as anti-inflammatory effects. IL-6 binds 
to a membrane bound IL-6 receptor (IL-6R) and this complex associates with two molecules 
of signal transduction protein gp130. While gp130 is present on almost all cells, IL-6R is 
not. However, a soluble form of IL-6R (sIL-6R) can bind its ligand IL-6 and this complex can 
activate gp130 and induce ‘trans-signaling’ in cells lacking IL-6R.47 
The protective role of IL-6 in I/R injury is demonstrated in studies of liver and myocardial 
I/R injury. Several studies show that IL-6 plays a protective role in liver I/R injury by 
reducing cell damage and stimulating hepatocyte proliferation.48-50 Furthermore, infarcted 
area and myocardial apoptosis after coronary occlusion and reperfusion were reduced by 
IL-6/sIL-6R complex.51 In kidney tissue, the protective effect of IL-6 has been described as 
well. Nechemia et al. concluded from a murine model of HgCl2 induced acute kidney injury 
that IL-6 first mediates early kidney damage by an inflammatory response. Subsequently, 
when more sIL-6R becomes available, IL-6 is responsible for resolving the tissue damage via 
trans-signaling.52 Moreover, Homsi et al. showed that IL-6 stimulated tubular regeneration in 
a time-dependent pattern early after glycerin induced acute renal failure. After 24 hours, 
there was a predominance of proliferative activity in the renal medulla that shifted to 
the cortical zone at 72 hours.53 However, the role of IL-6 in kidney I/R injury is not fully 
univocal. The studies by Patel et al. and Kielar et al. have demonstrated that IL-6 -/- mice 
are protected against renal I/R injury.54;55 Concerning anti-IL-6 Ab treatment, Patel et al. 
and Kielar et al. reported conflicting results. Moreover, the value of a knockout model for 
IL-6 can be questioned as redundancy may play a role. Because IL-6 belongs to a family of 
cytokines that all use the same receptor gp130 subunit for signal transduction, they may 
induce similar responses to IL-6 signaling and therefore knockout mice may functionally 










































A hypothesis explaining the difference between our findings and those by Patel et al. 
and Kielar et al. concerning the effects of neutralizing anti-IL-6 Ab can be derived from 
studies on non-ischemic kidney damage. Both the studies by Nechemia et al.52 and Homsi 
et al.53 demonstrated a time-dependent effect of IL-6 in kidney injury. Consequently, the 
discrepancy between the results of Patel et al. and Kielar et al. and our results could 
be due to differences in timing of the experiment. These groups evaluated the degree of 
kidney injury at 24 hours after reperfusion, whereas the endpoint in our study was 48 hours 
after reperfusion. It can be suggested that between 24 and 48 hours after reperfusion the 
protective effect of IL-6 becomes apparent. Moreover, it should be noted that Patel et al. did 
not ensure that the administered antibody completely inhibited the IL-6 response; whereas 
in the study of Kielar et al., it was actually shown that the treatment only partially inhibited 
the IL-6 response. Finally, we can not rule out that the differences relate to different 
immunological responses in the mice strains used. In both prementioned studies C57BL/6J 
mice were used, which have a different inflammatory response than the C57BL/6J/BALB/c 
F1 mice used in this study.56
Beside IL-6, IL-8 also showed an arteriovenous difference. Control measurements did not 
show any release of IL-8 under non-ischemic conditions and urinary IL-8 excretion did not 
change upon reperfusion. Nevertheless, as the absolute arteriovenous differences in IL-8 
concentration over the graft were rather small, the clinical relevance of IL-8 in kidney 
transplantation appears limited. This is supported by the lack of evidence for neutrophil 
activation and degranulation, a main action of IL-8.57 Although neutrophils contain large 
amounts of IL-8, in the absence of lactoferrin release it is highly unlikely that they are 
responsible. Alternatively, thrombocytes are an established source of IL-8,58 and activated 
thrombocytes could also be proposed as a source of IL-8 release in renal I/R injury. 
In the present study we investigated I/R injury in living donor kidney transplantation. We 
intentionally chose this model because of the excellent homogeneity in donors and ischemia 
times, thereby minimizing the influence of donor state and variations in cold ischemia time. 
As the goal of this study was to assess the basic pathophysiological processes of I/R injury 
instead of correlating findings to clinical outcome, small patient numbers were sufficient. 
For ethical reasons our study was limited to a sample collection time of 30 minutes, which 
was the timeframe needed to anastomose the ureter to the bladder. I/R injury is generally 
considered an acute process that is initiated directly after reperfusion.20 However, we can 
not exclude that processes, other than those identified in this study, play a role in I/R injury 












































We used a mouse model of renal I/R injury to assess the effects of IL-6 neutralization. Results 
show that inhibition of IL-6 significantly aggravates renal I/R injury in mice, suggesting that 
IL-6 may play a protective role in the post-reperfusion phase. Obviously, it should be noted 
that an animal model can only approximate the human situation and that some components 
might be different, i.e. in the animal model the kidney is not cooled whereas in clinical 
transplantation the grafts sustain a period of cold ischemia. Since the animal experiment 
was primarily intended to determine the effect of IL-6 inhibition, the pathophysiological 
mechanisms remain to be elucidated in consecutive studies.
In summary, in this study we present a renewing approach of arteriovenous measurements 
in human clinical I/R during kidney transplantation. Our results show that thrombocyte 
activation, inflammation and complement activation are potentially involved in human 
renal I/R injury. Systematic measurement of a series of biomarkers revealed that early renal 
I/R is dominated by a local release of IL-6. Immunoneutralization of IL-6 in a mouse model 
resulted in a significant aggravation of renal injury.
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Interleukin-9 release from human kidney grafts and 
its potential protective role in renal ischemia/
reperfusion injury
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Background: The pathophysiology of ischemia/reperfusion (I/R) injury is dominated by 
an inflammatory response. In the identification of new therapeutic agents, the role of 
individual cytokines may be essential. Interleukin (IL)-9 is a pleiotropic cytokine recently 
identified to be involved in various immune responses. In this study, the role of IL-9 in renal 
I/R injury was assessed. 
Methods: We performed repeated direct measurements of arteriovenous IL-9 concentration 
differences over the reperfused graft in human kidney transplantation. 
Results: Substantial renal IL-9 release was observed from deceased donor kidneys (P = 
0.006). In contrast, living donor kidneys, which have a more favourable clinical outcome, 
did not release IL-9 during early reperfusion (P = 0.78). Tissue expression of IL-9 did not 
change upon reperfusion in both living and deceased human donor kidneys. To assess the 
role of IL-9 in I/R injury, an experimental study comprising IL-9 inhibition in mice undergoing 
renal I/R was performed. Although there was no difference in kidney function, structural 
damage was significantly aggravated in anti-IL-9 treated mice. 
Conclusions: Deceased donor grafts show a substantial IL-9 release upon reperfusion in 
clinical kidney transplantation. However, inhibition of IL-9 aggravated kidney damage, 













































Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ transplantation and 
a major determinant of patient and graft survival. I/R injury induces delayed graft function, 
which complicates around 20%1, 2 of deceased donor kidney transplantations and has a major 
influence in graft function and survival.3 The pathophysiology of I/R injury is complex and 
incompletely understood, although both preclinical4-6 and clinical studies7-9 have shown that 
inflammation is an important mediator of I/R injury. The exact functions of the various 
cytokines involved in regulating the complex inflammatory events after I/R injury are not 
fully unraveled yet.10 Insight in the role of individual cytokines may be essential in the 
identification of new therapeutic agents. 
Interleukin (IL)-9 is a pleiotropic cytokine recently discovered to be involved in various 
immune responses. Studies on the etiology of asthma and allergies have demonstrated an 
evident pro-inflammatory role of IL-9.11, 12 IL-9 is produced by T helper cells13, regulatory T 
cells14, and mast cells15 and is able to modulate their production of various other cytokines.12 
In a preceding study, we described for the first time a renal release of IL-9 after kidney 
transplantation.10 
The aim of the present study was to explore the potential pathophysiologal role of IL-9 in 
renal I/R injury. IL-9 release during reperfusion of both living and deceased human donor 
kidney grafts was assessed, and the effects of IL-9 inhibition on renal I/R injury were 
evaluated in an animal experiment.
Methods 
Patient population
Twenty-four patients undergoing renal allograft transplantation were included; of these, 
eight patients received a kidney from a living donor and sixteen patients received a kidney 
from a deceased donor (nine brain-dead donors and seven cardiac-dead donors). Kidney 
transplantations were performed according to the local standardized protocol.16 In living 
donors open nephrectomy was performed and Custodiol® histidine–tryptophan–ketoglutarate 
solution (Tramedico, Weesp, The Netherlands) was used for cold perfusion and storage of 
the kidney. Brain-dead and cardiac-dead donor kidneys were perfused and stored with 
either University of Wisconsin solution or Custodiol® histidine–tryptophan–ketoglutarate 
solution. The immunosuppressive regimen was based on induction therapy with basiliximab 










































steroids. For technical reasons (renal vein sampling) only patients receiving a left kidney 
were included. Patient and graft characteristics and ischemia times are summarized in 
Table 1. The postoperative course was uneventful in all patients. One-year patient and graft 
survival was 100%. The study protocol was approved by the local ethics committee, and 
informed consent was obtained from each patient.
Table 1. Transplantation and outcome characteristics in living donor (LD) and deceased 
donor (DD) kidney transplantation (mean ± SD). 








Donor age (years)  
mean ± SD 









179.1 ± 18.6  1117.7 ± 299.1 <0.001
WIT§ (min.)
mean ± SD
34.0 ± 6.3 33.5 ± 6.1 0.85
* HTK: Histidine–tryptophan–ketoglutarate
† UW: University of Wisconsin
‡ CIT: cold ischemia time
§ WIT: warm ischemia time 
IL-9 plasma measurements in arteriovenous samples
Arterial and renal venous blood samples were obtained during human kidney transplantation 
as described previously.16 In short, blood aliquots were sampled at 30 seconds, 3, 10 and 
30 minutes after reperfusion via a catheter placed in the renal vein. Paired arterial blood 
samples were obtained at 0, 3, 10 and 30 minutes after reperfusion. The same method was 
used to obtain a control arterial and venous blood sample during donor nephrectomy prior 
to the induction of renal ischemia. All samples were collected in tubes containing EDTA 
(BD Vacutainer, Plymouth, UK) and centrifuged twice (1550 g, 20 min, 4ºC) to deplete it of 
leukocytes and thrombocytes. Plasma was aliquotted and stored at –70ºC until analysis. IL-9 
was measured in a custom-made multiplex assay in accordance with the manufacturer’s 












































Immunohistochemical evaluation of IL-9 source in human kidney biopsies
A renal cortical biopsy was obtained before transplantation, after cold storage of a 
deceased donor graft. Kidney tissue was fixed in formalin for 24 hours and then embedded 
in paraffin for light microscopy. Longitudinal sections of 4 μm were prepared. After EDTA-
retrieval, IL-9 deposition was assessed using a human IL-9 mAb in a 1:100 dilution (cat. no. 
507602, Biolegend, Cambridge, UK). Staining was visualized using Nova RED (Vector Labs, 
Peterborough, UK). Sections were counterstained with hematoxylin (Merck, Darmstadt, 
Germany). 
IL-9 expression in human kidney biopsies
A renal cortical biopsy was obtained before transplantation after cold storage, and a post-
reperfusion biopsy was collected 45 minutes after reperfusion. Biopsies were immediately 
snap frozen in liquid nitrogen and stored at –70ºC. Total RNA was extracted from renal 
tissues using RNAzol (Campro Scientific, Veenendaal, The Netherlands) and glass beads.17 
The integrity of each RNA sample was examined by Agilent Lab-on-a-chip technology using 
the RNA 6000 Nano LabChip kit and a bioanalyzer 2100 (Agilent Technologies, Amstelveen, 
The Netherlands). RNA preparations were considered suitable for array hybridization only if 
samples showed intact 18S and 28S rRNA bands, and displayed no chromosomal peaks or RNA 
degradation products (RNA Integrity Number >8.0).18 Subsequent microarray analysis was 
performed using Illumina whole-genome gene expression BeadChips (Illumina BeadArray®, 
San Diego, CA, USA) according to instructions of the manufacturer at Service XS (Leiden, 
The Netherlands). IL-9 expression data were obtained from this array. 
Animals and surgical procedures
Male BALB/c Jico mice (Charles River, L’Arbresle, France) of 8 weeks old (20-30 g) were 
divided into the following four groups: (1) I/R pre-treated with anti-IL-9 antibody (Ab) 
(n=12); (2) I/R pre-treated with control Ab (n=12); (3) sham-operated, pre-treated with 
anti-IL-9 Ab (n=4), and (4) sham-operated pre-treated with control Ab (n=4). Monoclonal 
anti-IL-9 Ab (no. 504802, clone D9302C12, BioLegend, San Diego, CA, USA) or isotype control 
IgG (no. 400916, clone HTK888, BioLegend, San Diego, USA) was administered at 1 and 
2 days before surgery. At 2 days before surgery, 2 ug/g body weight anti-IL-9 Ab or its 
equivalent of isotype control Ab was administered by i.p. injection, followed by 4 ug/g 
body weight the day before surgery. This dosage is based on previous research in which a 
significant effect of anti-IL-9 treatment was observed after administration of a similar dose 
of the antibody.19 Mice were anesthetized with isoflurane. Bilateral kidney ischemia was 
induced by clamping the renal artery and vein for 35 minutes, followed by reperfusion. 
In the sham group, identical surgical procedures were used, except that clips were not 










































diagnostics, Almere, The Netherlands) the day before administration of antibodies (day -3), 
day of surgery (day 0), and two consecutive days after surgery (day 1 and 2). Two days after 
surgery, mice were killed and kidneys retrieved. Mice were maintained on standard diet and 
given water ad libitum throughout the whole experimental period. The study was approved 
by the veterinary authorities of our institute. 
Histological evaluation of murine kidney tissue
The mouse kidneys were fixed in formalin for 24 hours and then embedded in paraffin for 
light microscopy. Longitudinal sections of 4 μm were prepared and stained with periodic 
acid-Schiff (PAS). The degree of tissue injury was scored by two blinded observers. Kidney 
injury was scored semi-quantitatively using the amount of proximal tubule necrosis (score 
0–3), band necrosis of the cortex and the medulla (score 0–3) and protein casts in the 
tubules (score 0–3). 
Data collection and statistical analysis
Clinical donor data were retrieved from the Eurotransplant database. Delayed graft function 
was defined as the need for dialysis within the first week after transplantation. Statistical 
analysis was performed using SPSS 16.0 statistical analysis software (SPSS Inc, Chicago, IL, 
USA). Patient characteristics were compared by paired t-test and are expressed as mean 
± standard deviation (SD). Area under the curve (AUC) was calculated for the arterial and 
venous curve of the human plasma measurements for the total of 30 minutes. The delta AUC 
was calculated (venous minus arterial) and the null-hypothesis (delta AUC is 0) was tested 
by a Wilcoxon signed rank test. Urea concentrations were compared using a Mann Whitney 
U-test, Wilcoxon signed rank test or Kruskal-Wallis test where appropriate. Histological 
score was tested by the Mann Whitney U-test. P value < 0.05 was considered significant.
Results
IL-9 is released from deceased donor kidneys during reperfusion
Living donor kidneys released no IL-9 during the first thirty minutes after reperfusion (P = 
0.78, n = 8, Figure 1A). In contrast, deceased donor kidneys, which generally show more 
dysfunction after transplantation, released a vast amount of IL-9 in the first thirty minutes 
after reperfusion (P = 0.006, n = 16, Figure 1B). More specifically, only brain-dead donor 
kidneys showed a significant release of IL-9 (P = 0.04, n = 9). However, cardiac-dead donors 
showed the same trend (P = 0.07, n = 7), and therefore deceased donor data are clustered. 
IL-9 release was specific for I/R, as control measurements over the non ischemic kidney in 












































indicates that IL-9 release is not a consequence of manipulation of the kidney during surgery 
or a reaction to anesthetics. 
Figure 1. Arterial and renal venous plasma concentrations of IL-9 during the first 30 minutes of 
reperfusion. 
(A) No significant release of IL-9 from living donor grafts was observed (P = 0.78, n = 8); (B) IL-9 was 
released significantly from deceased donor grafts (P = 0.006, n = 16). 
Source of human IL-9 release is mainly tubular epithelial cells
The source of IL-9 released from deceased donor kidneys could be local resident cells or 
circulating cells. An immunohistochemical staining of IL-9 was performed on renal biopsy 
tissue from a deceased donor graft, which showed that local stores of IL-9 are present in the 
kidney. IL-9 signals were present predominantly in renal tubular epithelial cells and also in 












































Figure 2. Typical example of IL-9 staining in deceased donor kidney biopsy collected before 
transplantation. 
IL-9 signal was positive in renal tubular epithelial cells, macrophages, and dendritic cells. Original 
magnification x200. 
No change in human renal IL-9 expression after reperfusion
No differences in IL-9 RNA expression were observed between pre- and post-reperfusion 
biopsies in living (P = 0.89, Figure 3A) as well as deceased donor kidneys (P = 0.59, Figure 
3B). In addition, similar baseline expression of IL-9 in living and deceased donor kidneys was 
observed (P = 0.57). 
Figure 3. Interleukin-9 expression in human kidney biopsies. 
IL-9 expression in human pre- and post-transplantation biopsies of (A) living donor kidneys; and (B) 
deceased donor kidneys. There was no difference in IL-9 RNA expression between pre- and post-
reperfusion biopsies in living and deceased donor kidneys (P = 0.89 and P = 0.59, respectively) nor in 













































Anti-IL-9 treatment does not prevent functional and structural kidney I/R injury
Given the dominance of IL-9 release from deceased donor kidneys, we hypothesized that IL-9 
is critical in the initiation of I/R injury. Therefore, mice were treated with anti-IL-9 Ab or 
isotype control Ab before undergoing renal I/R. All mice survived the end of the experiment. 
Baseline urea concentrations were identical in all animals (Figure 4). In both anti-IL-9 Ab 
and isotype control Ab treated mice that underwent renal I/R, urea concentration was 
significantly raised at 1 and 2 days after reperfusion as compared with baseline (all, P = 
0.002). As expected, urea of sham-operated animals, both anti-IL-9 Ab and isotype control 
Ab pre-treated, did not change after surgery as compared with baseline (all, P = NS). Urea 
concentration was similar in anti-IL-9 treated and control Ab treated mice at day 1 (P = 
0.91) and 2 (P = 0.53) after reperfusion (Figure 4). 
Figure 4. Plasma urea levels after murine renal ischemia/reperfusion. 
Plasma urea levels measured at baseline (day -3), at the day of surgery (day 0), and two consecutive 
days after surgery (day 1 and 2). Plasma urea levels were similar in anti-IL-9 Ab treated mice compared 
with isotype control Ab treated mice after I/R at day -3 (P = 0.77), day 0 (P = 0.69), day 1 (P = 0.91), 










































Structural kidney damage was moderate to severe in all kidneys that underwent I/R, 
whereas kidneys of sham-operated mice showed normal histology. Kidney injury was scored 
on several characteristics and then quantified. There was significantly more structural 
damage in kidneys of anti-IL-9 Ab treated mice than in the control Ab treated group after 
I/R. In detail, anti-IL-9 Ab treated mice showed more proximal tubule necrosis (P = 0.02), 













































Figure 5. PAS-staining of murine kidney biopsies. 
Representative PAS-stained kidney sections harvested 2 days after surgery of (A) mice that received anti-
IL-9 Ab before renal I/R; (B) mice that received control Ab before kidney I/R; (C) sham-operated mice 
that received anti-IL-9 or control Ab treatment before operation (no difference). Original magnification 
x200. Mice receiving anti-IL-9 Ab before I/R had evident protein casts and tubule necrosis, more than 
isotype controle Ab treated mice. Sham-operated mice receiving either anti-IL-9 Ab or control Ab had 
no PAS-positive deposits and no structural kidney damage. (D) Semi-quantitative histological damage 
score for the severity of kidney damage is shown. Damage was scored (0-3) on presence of proximal 
tubule necrosis (PTN), band necrosis (BN) and protein casts (PC). Kidneys of all mice that underwent 
kidney I/R showed moderate to severe damage. There were significant differences between anti-IL-9 
Ab-treated and isotype control Ab-treated groups (PTN, P = 0.02; BN, P = 0.01; PC, P = 0.005). Kidneys of 
sham-operated mice scored 0 for all measures. Median and interquartile ranges are plotted. Significant 
differences are indicated by an asterisk. 
Discussion
In this study it is shown that IL-9 is released exclusively from human deceased donor grafts 
directly after reperfusion. Since deceased donor grafts are clinically more affected by 
I/R injury, we hypothesized that IL-9 is a mediator of renal I/R injury. In a subsequent 
mouse experiment, inhibition of IL-9 did not influence kidney function after I/R and even 
aggravated structural kidney injury. 
IL-9 was released instantly after reperfusion from deceased donor grafts and its release 
persisted during the next thirty minutes. The substantial and immediate character of 
this IL-9 release suggests a pre-stored pool, since no change in IL-9 expression in kidney 
tissue upon reperfusion was observed. Pre-transplantation infiltrated cells are probably not 
involved, since baseline biopsies showed no difference between human living and deceased 
donor IL-9 expression, although there was a vast difference in cellular infiltrate before 
transplantation.10 Immunohistochemical staining of IL-9 showed its presence in tubular 
epithelium and resident macrophages and dendritic cells. These cells are likely responsible 










































IL-9 is considered a pro-inflammatory cytokine, although as yet little is known about its 
exact functions. Preclinical studies have shown that IL-9 promotes mast cell growth and 
plays a crucial role in the nephroprotective effects of regulatory T cells.12, 20 In addition, 
a potential role in the stimulation of erythropoiesis has been suggested21, 22, as well as an 
antiapoptotic effect.23 The observation in our study that IL-9 was released exclusively from 
deceased donor kidneys, in which tissue damage is most severe, argues for an active role of 
IL-9 in initiating I/R injury. Therefore, the effect of IL-9 inhibition on kidney I/R injury was 
assessed in a mouse experiment. Remarkably, results showed aggravated structural kidney 
damage after I/R in anti-IL-9 Ab treated animals. When extrapolating these findings, it can 
be suggested that IL-9 plays a regulating role in clinical renal I/R injury or can be an initial 
trigger for salvaging or limiting injury. 
Although no previous data are available regarding the role of IL-9 in I/R injury, the few 
studies on allograft rejection after transplantation are conflicting. An association between 
IL-9 and acute, eosinophil-driven rejection has been suggested by Poulin et al. in mismatched 
heart allografts.24 However, no involvement of IL-9 was observed in rejection on a longer 
term in both mouse islets and human kidney allografts.25 
Our arteriovenous sampling time was limited to thirty minutes after reperfusion, the time 
needed to complete the operative procedure. Deceased donor kidney grafts showed an 
extensive release of IL-9 within the studied timeframe; therefore it is highly unlikely 
that living donor kidney grafts will start releasing IL-9 after the studied period. Finally, 
one might argue that a mouse model of renal I/R injury can only approximate the human 
situation. Nevertheless, the effects of IL-9 inhibition could be accurately assessed in our 
animal experiment and a negative effect of anti-IL-9 treatment was indeed observed. 
In conclusion, this study shows a substantial and exclusive release of IL-9 from deceased 
donor grafts in human kidney transplantation, while living donor kidneys, which generally 
have a more favourable clinical outcome, did not release IL-9 during early reperfusion. The 
source of released IL-9 was its pre-stored pool in renal tubular cells. Experimental inhibition 
of IL-9 in mice aggravated kidney damage after I/R injury. Altogether, these results suggest 
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Donor brain death has profound effects on post-transplantation graft function and survival. 
We hypothesized that changes initiated in the donor influence the graft’s response 
to ischemia and reperfusion. In this study, human brain dead donor kidney grafts were 
compared to living and cardiac dead donor kidney grafts. Pre-transplant biopsies of brain 
dead donor kidneys contained notably more infiltrating T lymphocytes and macrophages. To 
assess whether the different donor conditions result in a different response to reperfusion, 
local cytokine release from the reperfused kidney was studied by measurement of paired 
arterial and renal venous blood samples. Reperfusion of kidneys from brain dead donors was 
associated with the instantaneous release of inflammatory cytokines, such as G-CSF, IL-6, IL-
9, IL-16 and MCP-1. In contrast, kidneys from living and cardiac dead donors showed a more 
modest cytokine response with release of IL-6 and small amounts of MCP-1. In conclusion, 
this study shows that donor brain death initiates an inflammatory state of the graft with T 
lymphocyte and macrophage infiltration and massive inflammatory cytokine release upon 
reperfusion. These observations suggest that brain dead donors require a novel approach 














































Despite better immunological matching, kidney allografts of deceased donors demonstrate 
inferior graft function and survival in comparison with living unrelated donor grafts. This 
can only partially be explained by their longer cold ischemia time.1 It is thus likely that 
donor-specific characteristics influence post-transplantation graft function and explain 
differences in clinical success rate. 
Donor brain death has a significant influence on graft function and survival.2 The 
unphysiological state of brain death is associated with systemic pro-inflammatory changes, 
as illustrated by increased levels of circulating cytokines which reflect an inflammatory 
state in peripheral organs. Indeed, the expression of inflammatory factors in the kidney at 
time of donation is increased in brain dead donors.3-5 
We have previously shown that the graft reperfusion phase is dominated by an inflammatory 
response, and that kidney grafts of living donors release cytokines immediately after 
reperfusion.6 It was thus hypothesized that the inflammatory changes associated with 
brain dead influence the kidney graft and result in a different response to ischemia and 
reperfusion. In this explorative study we first assessed whether there are differences in 
inflammatory cell content between brain dead and living as well as cardiac dead donor 
kidney grafts before transplantation. We subsequently evaluated the inflammatory response 
to reperfusion of the donor kidney through measurement of arteriovenous concentration 
differences over the transplanted organ. Cardiac dead donor grafts were included in this 




Twenty-four patients undergoing renal allograft transplantation were included; 8 patients 
receiving a kidney from a living donor, 9 patients receiving a kidney from a brain dead donor, 
and 7 patients receiving a kidney from a cardiac dead donor (Maastricht category III, table 
1). For technical reasons (renal vein sampling) only patients receiving a left kidney were 
included. The study protocol was approved by the local ethics committee, and informed 











































Kidney transplantations were performed according to local standardized protocol. In living 
donors open nephrectomy was performed and Custodiol® Histidine–tryptophan–ketoglutarate 
solution (HTK) solution (Tramedico, Weesp, The Netherlands) was used for cold perfusion and 
storage of the kidney. Brain dead and cardiac dead donor kidneys were perfused and stored 
with either University of Wisconsin solution (UW) or HTK (table 1). The immunosuppressive 
regimen was based on induction therapy with basiliximab; and tacrolimus or cyclosporine A 
in addition with mycophenolate mofetil and steroids in all groups. 
A renal cortical biopsy was obtained just before transplantation, when the graft was still 
on ice. Biopsy tissue was frozen and cut into 4 mm thick sections in a cryostat. Arterial 
and renal venous blood samples were obtained as described before in detail.6 In short, via 
an umbilical vein catheter placed in the renal vein at 30 sec., 1, 3, 5, 10, 20 and 30 min. 
after reperfusion (i.e., t=0) blood aliquots were sampled. For ethical reasons our study was 
limited to a sample collection time of 30 minutes, which was the timeframe needed to 
anastomose the ureter to the bladder. Paired arterial blood samples were obtained at 0, 3, 
5, 10, 20 and 30 min. after reperfusion. All samples were collected in tubes containing EDTA 
and immediately placed on ice. Blood samples were centrifuged (1,550 g, 20 min, 4ºC) and 
the derived plasma was re-centrifuged (1,550 g, 20 min, 4ºC) to deplete it from leukocytes 
and thrombocytes. Plasma was aliquotted and stored at -70ºC until assayed. 
Validation of the arteriovenous measurements
The method of arteriovenous measurements over the reperfused kidney has been validated 
before.6 Because cholesterol is not secreted, filtered or re-absorbed by the kidney, the plasma 
cholesterol was measured to evaluate potential blood concentrating effect of the kidney. 
Lactate dehydrogenase (LDH) activity was determined as measure of cell lysis. Cholesterol 
and LDH concentrations were measured in a certified facility, using routine laboratory 
assays. There was no evidence for hemoconcentration over the kidney, as cholesterol 
concentrations did not show an arteriovenous difference. LDH was not released into venous 
blood either, excluding cell lysis as source of cytokines. Therefore, all measurements are 
shown as uncorrected values. 
 
Immunohistochemical analysis of biopsies
Cryostat sections were rehydrated and incubated with the primary antibody raised against 
CD3 (1:200, Abcam, Cambridge, MA, USA), CD68 (1:2000, DAKO, Glostrup, Denmark) or 
Myeloperoxidase (MPO) (1:1000, DAKO, Glostrup, Denmark). A standard streptavidin–biotin–
peroxidase complex method was applied to visualize T-lymphocytes, macrophages and 












































Slides were counterstained with Mayer’s haematoxylin. The number of CD3 positive cells 
was counted as a percentage of total cells in at least 5 views at a magnification x20 by 
automated analysis using AxioVision software, version 4.4.1.0 (Carl Zeiss MicroImaging Inc, 
Gottingen, Germany). The numbers of CD68 and MPO positive cells were quantified in each 
specimen (magnification ×20) using a calibrated grid. The number of cells over 5-7 grid areas 
of each kidney biopsy was counted by two independent blinded observers (kappa=0.97).
Plasma measurements
We first performed a pilot measurement in venous and arterial blood samples collected 
30 minutes after reperfusion for both living donor, brain dead donor and cardiac dead 
donor kidney transplantation to identify candidate cytokines and chemokines in the human 
27-plex panel for multiple cytokines (Biorad, Veenendaal, The Netherlands). The panel 
included interleukin (IL)-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, 
IL-15, IL-17, eotaxin, basic fibroblast growth factor (b-FGF), granulocyte colony-stimulating 
factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon 
(IFN)-γ, interferon-inducible protein (IP)-10, monocytes chemoattractant protein (MCP)-
1, macrophage inflammatory protein (MIP)-1α and -1b, platelet-derived growth factor-BB, 
regulated upon activation, normal T cell expressed and secreted (RANTES), tumour necrosis 
factor (TNF)-α, and vascular endothelial growth factor (VEGF). Next, we performed a 
detailed analysis of the targets above the detection threshold and showing a trend towards 
an arteriovenous difference. IL-1ra, IL-6, IL-8, IL-9, IL-16, G-CSF and MCP-1 were measured 
in a custom made multiplex assay in accordance with the manufacturer’s instructions 
(X-plex, Biorad, Veenendaal, The Netherlands) 
 
Data collection and statistical analysis
Clinical donor data were retrieved from Eurotransplant database. Delayed graft function 
(DGF) was defined as the need for dialysis within 1 week after transplantation. Statistical 
analysis was performed using SPSS 16.0 statistical analysis software (SPSS Inc, Chicago, 
Ill). The number of positive cells in the immunohistochemical analysis was compared for 
all three donor types using ANOVA, with post-hoc Bonferroni test to assess the individual 
differences. Area under the curve (AUC) was calculated for the arterial and venous curve 
of the plasma measurements for the total of 30 minutes. The delta AUC was calculated 
(venous minus arterial) and the null-hypothesis (delta AUC is 0) was tested by t-test or non-
parametric test in case of a non-normal distribution. Benjamini-Hochberg correction for 
multiple testing was applied to the cytokine measurements. Graph error bars represent the 












































Transplant and recipient characteristics
Recipient and donor age and gender were similar in living donor, brain dead donor and 
cardiac dead donor groups (table 1). As expected, warm and cold ischemia times differed 
between groups, with shorter cold ischemia times in living donor kidney transplantation 
and a donor warm ischemic period for cardiac dead donor kidney transplantation. The 
immunosuppressive regimen was equal in all recipients. All kidneys were still functioning at 
1 year post transplantation, except for one graft from a cardiac dead donor (the recipient 
was not compliant with immunosuppressive medication). 
Table 1: Transplantation and outcome characteristics in living donor (LD), brain dead donor 
(BDD) and cardiac dead donor (CDD) kidney transplantation. 
LD BDD CDD
n 8 9 7
Donor age: mean (SD) 43.9(10.6) 54.1(17.1) 52.7(15.3)
Donor gender (M:F %) 75:25% 44:56% 43:57%
Duration ICU stay in h. (SD) N/A 126 (211) 107 (139)
Duration of BD in h. (SD) N/A 14.7(9.7) N/A
Preservation fluid HTK (n=8) UW (n=9) UW(n=2)
 HTK (n=5)
WIT1 in min. (SD) N/A N/A 23.1(7.7)
CIT in h. (SD) 3.0(0.3) * ∇ 19.7(6.2) 17.3(2.6)
WIT2 in min. (SD) 34.0(6.3) 33.0(6.1) 34.1(6.4)
Recipient age: mean (SD) 41.1(10.5) 55.1(13.5) 54.0(11.2)
Recipient gender (M:F %) 38:62% 44:56% 71:29%
Creatinine clearance day 30 ml/min 73.3 (20.5) * ∇ 49.3(15.3) ∇ 27.1(10.3)
DGF (%) 0% 56% 86%
DGF: dialysis after transplantation in days (SD) 0 (0) * ∇ 7.0 (5.3) ∇ 17.2 (7.2)
ICU stay: the period the donor was admitted to intensive care unit, BD: the total duration of brain dead 
of the donor, WIT1: first warm ischemia time, CIT: cold ischemia time, WIT2: second warm ischemia 
time, DGF: delayed graft function. 
*p<0.05 compared to BDD, ∇ p<0.05 compared to CDD. 
T lymphocyte and macrophage infiltration in brain dead donor grafts
T lymphocytes and macrophages were found in all pre-transplant biopsies, however the 
amount of T lymphocytes was significantly higher in brain dead donor kidney grafts as 
compared to living and cardiac dead donor grafts (p<0.001, figure 1). Moreover, macrophage 
counts were more than twice as high in brain dead donor kidneys as compared to living 
donor and cardiac dead donor kidneys (p=0.009, figure 2). Neutrophils were only present 
in minimal amounts in grafts of all three donor types and were not significantly different 












































Figure 1: CD3 positive cells in biopsies. Pre-transplantation biopsies of living donor (LD) (A), Brain 
dead donor (BDD) (B) and cardiac dead donor (CDD) (C) were stained for CD3. Representative images 
are shown. Original magnifications were x20. (D) The amount of CD3 positive cells was significantly 
different between brain dead donor (BDD), living donor (LD) and cardiac dead donor (CDD) grafts 
(p<0.001). Post-hoc test showed that BDD and LD (p<0.001) and BDD and CDD (p<0.001) differed 












































Figure 2: CD68 positive cells in biopsies. Pre-transplantation biopsies of living donor (LD) (A), brain 
dead donor (BDD) (B) and cardiac dead donor (CDD) (C) were stained for CD68. Representative images 
are shown. Original magnifications were x20. (D) The amount of CD68 positive cells was significantly 
different between brain dead donor (BDD), living donor (LD) and cardiac dead donor (CDD) grafts 
(p<0.001). Post-hoc test showed that BDD and LD (p=0.001) and BDD and CDD (p=0.009) differed 
significantly, whereas there was no difference between LD and CDD grafts (p=1.00).
Brain dead donor grafts release many inflammatory cytokines
To assess whether infiltrating cells may influence post-transplantation graft characteristics, 
local cytokine release from the kidney was assessed by measuring arteriovenous differences 
over the kidney. To illustrate the method of measurement and analysis, the arterial and 
renal venous concentration of MCP-1 during the first 30 minutes of reperfusion is shown for 
living, brain dead and cardiac dead donor kidney transplantation (figure 3). The difference 
in area under the curve (AUC) of the arterial and venous curve was used as measure of 
total release from the kidney. First, in the explorative study, 27 different cytokines were 
measured in arteriovenous samples collected at 30 minutes after reperfusion. The majority 
of cytokines, i.e. interleukin (IL)-1β, IL-4, IL-5, IL-7, IL-10, IL-12, IL-13, eotaxin, GM-CSF, 
IFN-γ, IP-10, MIP-1b, PDGF-BB, RANTES, TNF-α, and VEGF were not released from the 
kidney. In the measurement of IL-2, IL-15, IL-17, b-FGF and MIP-1a all samples were below 














































Figure 3: Release of MCP-1 from the reperfused kidney. A: Arterial and renal venous plasma 
concentrations of MCP-1 during the first 30 min of reperfusion in living donor (LD) kidney transplantation 
showed no significant MCP-1 release from the graft (p = 0.08, n = 8); B: In cardiac dead donor (CDD) 
kidney transplantation there was a modest, steady MCP-1 release in the first 30 min of reperfusion (p = 
0.002, n = 7); C: In brain dead donor (BDD) kidney transplantation MCP-1 was released in high amounts 
(p = 0.027, n = 9).
Five cytokines changed in concentration over the kidney in at least one of the donor types, 
and figure 4 shows their total release from the kidney in the first 30 minutes of reperfusion. 
Only statistically significant differences are shown. Brain dead donor kidney grafts massively 
released various cytokines, including G-CSF (p=0.011), IL-6 (p=0.011), IL-9 (p=0.029), IL-
16 (p=0.017) and MCP-1 (p=0.012) immediately after transplantation. In contrast, living 
donor and cardiac dead donor kidney grafts show a very modest response with only release 
of IL-6 (p=0.003) and MCP-1 (p=0.002) respectively. No correlation could be established 
between clinical outcome variables (as shown in table 1) and the distribution or magnitude 













































Figure 4: Brain dead donor kidneys show an inflammatory pattern of cytokine release. Delta AUC 
of venous minus arterial release of seven different cytokines for living donor (LD), cardiac dead donor 
(CDD) and brain dead donor (BDD) kidney transplantation. LD and CDD kidney grafts only released 
IL-6 (p=0.003) and MCP-1 (p=0.002) respectively. In contrast, BDD grafts released many different pro-
inflammatory cytokines, such as G-CSF (p=0.011), IL-6 (p=0.011), IL-9 (p=0.029), IL-16 (p=0.017) and 
MCP-1 (p=0.012) in vast amounts. The box runs from the lower to upper quartile, the whiskers indicate 
the 5 to 95 percentile, while the horizontal line is set at the median.
Discussion
Donor brain death is considered an independent risk factor for graft function and survival. 
Yet it is unclear what processes are responsible for the impaired function and survival. We 
hypothesized that the response to ischemia and reperfusion in brain dead donor kidneys is 
different to that of non brain dead donor grafts. This study shows that donor brain death 
predisposes the kidney graft to a pro-inflammatory reaction upon reperfusion. Before 
transplantation, brain dead donor grafts already contain many infiltrated macrophages and T 
lymphocytes. Subsequently, after reperfusion brain dead donor kidneys release various pro-
inflammatory cytokines. This inflammatory response is specific for brain death, as cardiac 
dead donor kidney grafts with equally long periods of cold ischemia do not demonstrate this 














































It is known that brain death leads to a systemic pro-inflammatory state of the donor. 
Circulating levels of TNF-a, IL-2R, IL-6 and IL-8 are many times higher in brain dead donors 
compared to living donors at time of organ procurement.7 Similarly it has been shown that 
brain death induces endothelial cell activation in organs to be recovered as indicated by 
increased expression of adhesion molecules such as E-selectin,4 ICAM-1 and VCAM-1 8 and 
increased presence of leukocytes.5;9 Whether these inflammatory changes persist after 
transplantation and influence the reperfusion response of the graft has been unclear. This 
study not only shows that kidneys of brain dead donors contain certain cellular infiltrates, 
i.e. T lymphocytes and macrophages before transplantation, but also that upon reperfusion 
many inflammatory mediators are released from the graft. This different response of brain 
dead donor kidneys may be explained by changes in the kidney tissue itself; however a 
potentially more likely reason is that these mediators are released from the infiltrated 
T lymphocytes and macrophages. These leukocytes of donor origin may enhance the pro-
inflammatory state of the organ and may increase the immunogenicity of the organ. Many 
of the cytokines that are released upon reperfusion are chemo attractants and may attract 
recipient leukocytes to the kidney, increasing the threat of acute rejection.10;11 Indeed, 
animal experiments demonstrate that brain death increases the rejection rate of allogeneic 
transplants.12;13 
In most previously published studies where the effect of brain death after reperfusion was 
examined, only brain dead donor and living donor kidney transplantation were compared. 
However, in these studies the question remains to what extent results can be explained 
by the great differences in cold ischemia time, as it is known that renal inflammation 
correlates with duration of cold ischemia.14 In this study, cardiac dead donor kidney grafts 
were included in the comparison, as their period of cold ischemia is comparable to that of 
brain dead donor kidney grafts. 
Brain dead donor kidney grafts release the inflammatory cytokines G-CSF, IL-6, IL-9, IL-16 
and MCP-1 immediately after reperfusion. Living donor and cardiac dead donor grafts only 
released IL-6 and MCP-1. IL-6 is released locally from both LD and BDD kidney grafts. The 
role of IL-6 in acute kidney injury is not straightforward, and in the context of I/R IL-6 
can have protective effects as well.6 Of the cytokines that are selectively released in vast 
amounts from brain dead donor grafts, such as IL-16 and MCP-1, the effects are more clear-
cut. These are considered pro-inflammatory cytokines that are harmful and can contribute 
to kidney ischemia/reperfusion (I/R) injury.15;16 However, cytokines can not be classified 
as exclusively pro- or anti-inflammatory and their actions are unpredictable because they 
generally depend on the presence of responsive cells, the combination of cytokines and 










































consequence, it is clear that instead of aiming to inhibit cytokines after reperfusion, a 
more straightforward approach would be to avoid the pro-inflammatory response after 
reperfusion. Pre-treating the brain dead organ donor to prevent changes that cause the 
pro-inflammatory state in the graft may constitute a promising modality to increase graft 
function and survival. Donor pretreatment with steroids has been shown to significantly 
decrease tissue expression and serum concentrations of pro-inflammatory cytokines.17;18 
Moreover, preclinical data indicate that donor pretreatment with steroids increases kidney 
graft survival after transplantation.19 In clinical liver transplantation, donor pretreatment 
with steroids decreased the incidence of acute rejection.18 Other anti-inflammatory acting 
agents may hold promise as well. Statins are known to lower cytokine responses and may 
therefore be an interesting, safe option for future donor pretreatment.20 
Since the goal of this study was to detect differences in the nature of the inflammatory 
response in living and brain dead donor grafts, instead of correlating findings to clinical 
outcome; small patient numbers were sufficient. Indeed, we were able to detect differences 
in patterns of cytokines released from the kidney. By comparing arterial and venous curves, 
the net release from the kidney was assessed and systemic influences or release of cytokines 
from other sites than the kidney did not influence measurements.
In conclusion, this study shows that local inflammatory cell infiltration in brain dead 
donor kidney grafts influences their response to ischemia and reperfusion. Transplanted 
kidneys from brain dead donors release many pro-inflammatory cytokines immediately 
after reperfusion. This cytokine profile is specific for brain death and is not related to 
ischemia time since both cardiac dead and living donor kidney grafts showed a minimal 
response. Therefore, it is suggested that brain dead donors require a more specialized, 
targeted approach for donor pretreatment and graft preservation aimed at reducing the 
inflammatory reaction and thereby improving graft outcome.
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Background. Ischemia/reperfusion injury has a major impact on kidney graft function and 
survival. Animal studies have suggested a role for complement activation in mediating I/R 
injury, however results are not unambiguous. Whether complement activation is involved in 
clinical I/R injury in humans is still unclear. 
Methods. In the present study, we assessed the formation and release of C5b-9 during early 
reperfusion in clinical kidney transplantation in both living, brain dead and cardiac dead 
donor kidney transplantation. By arteriovenous measurements and histological studies, 
local terminal complement activation in the reperfused kidney was assessed. 
Results. There was no release of sC5b-9 from living donor kidneys, nor was there a release 
of C5a. In contrast, instantly after reperfusion, there was a significant but transient venous 
release of soluble C5b-9 from the reperfused kidney graft in brain dead and cardiac dead 
donor kidney transplantation. This short-term activation of the terminal complement cascade 
in deceased donor kidney transplantation was not reflected by renal tissue deposition of 
C5b-9 in biopsies taken 45 minutes after reperfusion. 
Conclusions. This systematic study in human kidney transplantation shows an acute but 
non-sustained sC5b-9 release upon reperfusion in deceased donor kidney transplantation. 
This instantaneous, intravascular terminal complement activation may be induced by 













































Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ transplantation and 
a major determinant of patient and graft survival.1-3 Current therapy is supportive and there 
are no specific therapeutical options yet. The pathophysiology of I/R injury is complex 
and incompletely understood. The innate immune system has been suggested to play an 
important role in potentiating an injurious reaction upon reperfusion since it is prone to 
recognize not only pathogens but also ‘damaged self’.4 
The complement system is one of the fastest responding basal defense mechanisms of the 
innate immune system. Activation of either the classical, alternative, or Mannan-binding 
lectin pathway ultimately leads to the formation of C5b-9, otherwise known as the terminal 
complement complex or membrane attack complex (MAC). Release of soluble (s)C5-9 has 
been described in a variety of renal disorders, such as lupus nephritis, Henöch-Schonlein 
Pupura and aHUS, and has been shown to be a sensitive marker in assessing disease activity.5-8 
Renal I/R affects the endothelial as well as the epithelial compartment and might activate 
the complement cascade leading to deposition of C5b-9 or release of non-lytic sC5b-9.
Animal studies of renal I/R injury generally show that complement inhibition reduces post-
reperfusion damage.9-11 Zhou et al more specifically demonstrated the involvement of 
terminal complement complex C5b-9.12 However, in recent rat experiments by our group, 
inhibition of complement activation did not reduce kidney damage and only 24 hours after 
reperfusion the first signs of complement activation were observed. Moreover, Mannan-
binding lectin itself appears to exert cytotoxic effects on the tubular epithelium early after 
reperfusion, far before first complement deposition was observed.13 These recent findings 
raise questions about the contribution of complement activation as initiator of I/R injury.
Despite the extensive number of animal experiments, studies on the involvement of 
complement in human I/R injury are scarce. Studies in the human heart have suggested 
a role for complement activation in I/R induced tissue damage.14;15 However, the diverse 
studies on experimental anti-complement therapy in human myocardial I/R injury did not 
lead to major improvements yet.16-21 
To address the recent contradictory findings in animals and the lack of evidence for 
involvement of complement in human I/R injury, we investigated the role of complement 
activation in the initiation of clinical renal I/R injury. I/R induced complement activation 
may take place in both the tubular and vascular compartment.10;22;23 Therefore, we 










































kidney transplantation in both the tubular compartment by immunohistochemistry and the 




Twenty-four patients undergoing renal allograft transplantation were included for 
arteriovenous sampling; 8 patients receiving a kidney from a living donor, 9 patients receiving 
a kidney from a brain dead donor and 7 patients receiving a kidney from a cardiac dead 
donor (patient and transplantation characteristics are in table 1), as previously described.24 
Brain dead and cardiac dead donors together were referred to as deceased donors. For 
technical reasons (renal vein sampling) only patients receiving a left kidney were included. 
In another 33 patients (13 living donor, 10 brain dead donor, and 10 cardiac dead donor 
kidney recipients) renal biopsies were collected. The study protocol was approved by the 
local ethics committee, and informed consent was obtained from each patient.
Table 1: Transplantation and outcome characteristics of patients undergoing arteriovenous 
measurements.  
LD BDD CDD
N 8 9 7
Donor age: mean (SD) 43.9(10.6) 54.1(17.1) 52.7(15.3)
Donor gender (M:F %) 75:25% 44:56% 43:57%
Duration ICU stay in h. (SD) N/A 126 (211) 107 (139)
Duration of BD in h. (SD) N/A 14.7(9.7) N/A
Preservation fluid HTK (n=8) UW (n=9) UW(n=2), HTK (n=5)
WIT1 in min. (SD) N/A N/A 23.1(7.7)
CIT in h. (SD) 3.0(0.3) * ∇ 19.7(6.2) 17.3(2.6)
WIT2 in min. (SD) 34.0(6.3) 33.0(6.1) 34.1(6.4)
Recipient age: mean (SD) 41.1(10.5) 55.1(13.5) 54.0(11.2)
Recipient gender (M:F %) 38:62% 44:56% 71:29%
Preemptive transplantation (n) 1 0 0
Creatinine clearance day 30 in ml/min (SD) 73.3 (20.5) * ∇ 49.3(15.3) ∇ 27.1(10.3)
DGF (%) 0% 56% 86%
DGF: dialysis after transplantation in days (SD) 0 (0) * ∇ 7.0 (5.3) ∇ 17.2 (7.2)
Groups undergoing living donor (LD), brain dead donor (BDD) and cardiac dead donor (CDD) kidney 
transplantation were compared. 
Intensive care unit (ICU) stay: the period the donor was admitted to intensive care unit, BD: the total 
duration of brain dead of the donor, WIT1: first warm ischemia time, CIT: cold ischemia time, WIT2: 
second warm ischemia time, DGF: delayed graft function.













































Kidney transplantations were performed according to local standardized protocol. In living 
donors minimally invasive nephrectomy was performed and Custodiol® Histidine–tryptophan–
ketoglutarate solution (HTK) solution (Tramedico, Weesp, The Netherlands) was used for 
cold storage of the kidney. Brain dead and cardiac dead donor kidneys were perfused and 
stored with either University of Wisconsin solution (UW) or HTK. The immunosuppressive 
regimen was based on tacrolimus or cyclosporine A in addition with mycophenolate mofetil 
and steroids in all groups. 
Arterial and renal venous blood samples were obtained as described before in detail.25 A 
schematic drawing of the arteriovenous sampling method is shown in figure 1. In short, via a 
small catheter placed in the renal vein blood aliquots were sampled at 0, 3, 10 and 30 min. 
after reperfusion. Paired arterial blood samples were obtained at 0, 3, 10 and 30 min. after 
reperfusion. All samples were collected in tubes containing EDTA and immediately placed on 
ice. Blood samples were centrifuged (1,550 g, 20 min, 4ºC) and the derived plasma was re-
centrifuged (1,550 g, 20 min, 4ºC) to deplete it from leukocytes and thrombocytes. Material 
was aliquotted and stored at -70ºC until assayed.
Figure 1. Schematic representation of the arteriovenous sampling method over the reperfused kidney 
by simultaneous blood collection from the renal artery and vein. Illustration by Manon Zuurmond© 
(www.manonproject.com)
In another 33 patients (13 living donor, 10 brain dead donor, and 10 cardiac dead donor 
kidney recipients) renal biopsies were collected (table 2). A renal cortical biopsy was 
obtained after cold storage, and a second biopsy of the same kidney was collected 45 










































Table 2: Transplantation and outcome characteristics of patients from which renal biopsies 
were studied.
LD BDD CDD
N 13 10 10
Donor age: mean (SD) 45 (12) 43 (13) 54 (15)
Donor gender (M:F %) 77:23% 20:80% 70:30%
Duration ICU stay in h. (SD) N/A 90 (121) 86 (100)
Duration of BD in h. (SD) N/A 12 (9) N/A
Preservation fluid UW (n=13) UW (n=10) UW (n=10)
WIT1 in min. (SD) N/A N/A 19 (7)
CIT in h. (SD) 132 (40) * ∇ 1131 (369) 1093 (273)
WIT2 in min. (SD) 38 (7) 43 (7) 41 (17)
Recipient age: mean (SD) 42 (16) 55 (14) 53 (12)
Recipient gender (M:F %) 46:54% 40:60% 100:0%
Creatinine clearance day 30 in ml/min (SD) 65 (15) 54 (15) 50 (22)
DGF (%) 8% 20% 100%
Groups undergoing living donor (LD), brain dead donor (BDD) and cardiac dead donor (CDD) kidney 
transplantation were compared. 
Intensive care unit (ICU) stay: the period the donor was admitted to intensive care unit, BD: the total 
duration of brain dead of the donor, WIT1: first warm ischemia time, CIT: cold ischemia time, WIT2: 
second warm ischemia time, DGF: delayed graft function. 
*p<0.05 compared to BDD, ∇ p<0.05 compared to CDD. 
sC5b-9 and C5a plasma measurements
sC5b-9 and C5a levels were assessed by sandwich ELISA. In short, 96-well ELISA plates (Nunc 
Bioscience, Belgium) were coated with a monoclonal antibody (mAb) to a neo-epitope 
on C5b-9 (aE11; Hycult Biotechnology, Uden, Netherlands) or C5a (mAb 2952; Hycult 
Biotechnology). Plasma was incubated in the coated wells and bound sC5b-9 or C5a was 
detected with a biotin-labeled mAb to C6 (9C4; in-house made) or C5a (mAb 561; Hycult 
Biotechnology) respectively, followed by detection with streptavidin–poly-horseradish 
peroxidase (Sanquin, Amsterdam, The Netherlands). Enzyme activity was detected using 
2,2′-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid) (Sigma Chemical Co., St. Louis, MO). 
The optical density was measured at 415 nm using a microplate reader (Model 680; Biorad, 
Philadelphia, USA). The detection limits for C5a and C5b-9 were 1.95 ng/ml and 0.01 U/ml, 
respectively.
Immunohistochemistry
Sections (4 µm) of paraffin embedded, formaldehyde fixed biopsies were deparaffinized and 
treated with 0,1% protease (type XXIV pronase, Sigma) for antigen retrieval. Endogenous 
peroxidase activity was blocked with 0.1% H2O2 and 0.1% NaN3. Consequently, C5b-9 












































followed by anti-mouse peroxidase-conjugated EnVision™ (DAKO, Glostrum, Germany). 
The staining was visualized using Nova RED (Vector Labs, Peterborough, United Kingdom). 
Sections were counterstained with hematoxylin (Merck, Darmstadt, Germany). As a positive 
control, a renal biopsy of a patient with acute graft rejection was used. 
 
Data collection and statistical analysis
Clinical donor data were retrieved from Eurotransplant. Outcome measures were creatinine 
clearance at 30 days after transplantation, presence and duration of delayed graft function 
(DGF) and patient and graft survival. DGF was defined as need for dialysis within 7 days 
post-transplantation. Statistical analysis was performed using SPSS 16.0 statistical analysis 
software (SPSS Inc, Chicago, Ill). Wilcoxon signed ranks test was used for paired non-
parametric data, the Mann-Whitney test for unrelated non-parametric data, i.e. comparison 
of different donor types. Graph points represent the median and error bars represent the 
interquartile range. A p-value of less than 0.05 was considered significant.
Results
Donor and transplant characteristics
Recipient and donor age and gender were similar in living donor, brain dead donor and 
cardiac dead donor groups (Table 1). As expected, warm and cold ischemia times differed 
between the groups, with shorter cold ischemia times in living donor kidney transplantation. 
The immunosuppressive regimen did not differ between groups. A significantly higher rate of 
delayed graft function (DGF) was observed in brain dead donor and cardiac dead donor as 
compared to living donor kidney transplantation. Brain dead donor and cardiac dead donor 
transplantation were equal in occurrence, but not in duration of DGF. All kidneys were still 
functioning at 1 year post-transplantation, except for one kidney from a cardiac dead donor 
(the recipient was not compliant with immunosuppressive medication). 
Early release of soluble complement complex C5b-9 from the kidney into the circulation
Activation of the terminal complement cascade during reperfusion was assessed by measuring 
the release of soluble (s)C5b-9 complex from the kidney by arteriovenous measurements 
(Figure 1). Immediately at reperfusion there was an acute but transient release of sC5b-9 
from deceased donor kidneys, which was not observed from living donor grafts (LD p=0.46, 
BDD p=0.011, CDD p=0.028; Figure 2). There was no release of sC5b-9 at later timepoints, 
at 3 (LD p=0.31, BDD p=0.77, CDD p=0.06), 10 (LD p=0.48, BDD p=0.68, CDD p=0.08) or 
30 minutes (LD p=0.12, BDD p=0.78, CDD p=0.74) after reperfusion. Soluble C5a, as an 










































donor kidneys. In accordance with sC5b-9 measurements, there was no difference in arterial 
and renal venous C5a levels (p=1.00 at 5 minutes, p=0.29 at 30 minutes after reperfusion, 
data not shown). Differences in the net release of sC5b-9 from the kidney for the total of 
30 minutes were assessed by comparing arterial and venous area under the curve. For living 
(p=0.87) and brain dead donor grafts (p=0.26) no net release was observed from the kidney. 
Cardiac dead donor kidneys, however, showed a significant release of C5b-9 from the kidney 
for the total first half hour after reperfusion (p=0.018). Baseline values of sC5b-9 were not 
different between groups (p=NS). 
Figure 2. sC5b-9 concentration in arterial and venous blood samples in living donor (LD), brain dead 
donor (BDD) and cardiac dead donor (CDD) kidney transplantations in the first 30 minutes of reperfusion. 
There was a significant release of sC5b-9 within seconds after reperfusion (first time point) from BDD 
kidney grafts (n=9, p=0.011) and from CDD grafts (n=7, p=0.028), but not from LD grafts (n=8, p=0.46). 
At later time points there was no significant difference anymore. Graphs show median and interquartile 
range. 
No increase in local, tissue-bound complement complex C5b-9 after reperfusion
The acute but transient release of soluble C5b-9 into the circulation might be accompanied 
by local C5b-9 deposition in the kidney, and local deposition could contribute to the 
absence of circulating C5b-9. Therefore, presence and localization of C5b-9 in pre- and 
post-reperfusion kidney biopsies was assessed. Whereas the renal biopsy of acute rejection 
tissue showed extensive C5b-9 positivity, staining for C5b-9 revealed no vascular or tubular 












































Figure 3. Representative sections showing distribution of C5b-9 staining in a pre- and post-
transplantation biopsies of living donor (LD), brain dead donor (BDD) and cardiac dead donor (CDD) 
kidneys. There were no C5b-9 depositions in any of the biopsies (LD n=13, BDD n=10, CDD n=10). In 
contrast, the positive control biopsy of a kidney graft with acute rejection showed massive peritubular 
and tubular C5b-9 depositions. Original magnification, x200. 
Discussion
I/R injury is one of the main causes of delayed graft function in transplantation. Studies 
in mice have suggested a predominant role for complement activation in renal I/R injury. 
However, in our recent study we show that not complement activation, but rather direct 
cytotoxic effects of circulation derived Mannan-binding lectin initiate tissue injury in rat 
renal I/R experiments.26 Studies on timing and role of complement activation in human 
renal I/R injury are scarce and inconclusive. Therefore, we set out to assess the role of 
terminal complement activation in the initiation of renal I/R injury in humans. Our data 
show that there is acute, non-sustained terminal complement activation upon reperfusion 
in deceased donor kidney transplantation. 
We concentrated on measurement of sC5b-9 as it is the common end-point of both the 
classical, alternative and Mannan-binding lectin pathway of the complement cascade. 
Moreover, in mice it is suggested that specifically C5b-9 is essential in the induction of 
tubular damage in renal I/R injury.12 By measuring arteriovenous differences over the 
reperfused organ, we were able to obtain very specific data on local venous release of sC5b-
9 from the human kidney. In a previous study involving living donor kidney transplantations 
only, we found no release of C5b-9, but rather an early and vast release of interleukin-6 
from the kidney.25 In the current study the group is expanded with kidneys from brain dead 
and cardiac dead donors which are more severely affected by I/R. We show that from these 










































of intravascular terminal complement activation. Since C5b-9 is released transiently, 
directly after reperfusion, this may result from a wash out effect. The complement system 
may be triggered upon encounter with intravascular cellular debris accumulated during 
the cold ischemic period or by encounter with hypoxic or injured endothelium.23;27 Studies 
in other human organs, such as the heart confirm complement activation in I/R injury,14;15 
although these observations may be influenced by complement activating effects of the 
cardiopulmonary bypass machine.28 
Besides the intravascular sC5b-9 formation, C5b-9 could be formed locally in the tissue 
without any release into the circulation. To assess this tubular activation, tissue content and 
distribution of C5b-9 was assessed in kidney biopsies collected before and after reperfusion. 
There was no deposition of C5b-9 in the kidney after reperfusion in both living and deceased 
donor kidney transplantation. This is confirmed by a study of Haas et al. where in post 
transplantation biopsies no complement depositions as consequence of reperfusion were 
detected either.29 In contrast, renal tissue of a patient with acute graft rejection showed 
extensive C5b-9 deposition in the tubular compartment. 
Finally, the possibility remained that the complement cascade is activated in living donor 
kidneys as well, without leading to terminal complement activation. Therefore, release of C5a 
from the reperfused kidney was assessed because C5a is more upstream in the complement 
cascade than the terminal complex C5b-9 is. In agreement with C5b-9 measurements, there 
was no C5a release from living donor kidneys. This excludes complement activation after 
reperfusion in living donor kidneys and also excludes early involvement of C5a, which has 
also been ascribed a harmful role in I/R injury.9 
A limitation of our study was the fact that the sampling time was restricted to maximally 
30 minutes following reperfusion. Although complement activation in this study was 
only observed instantly after reperfusion, mouse experiments show membrane attack 
complex elements C6 and C9 later on, at 12 and 24 hours after reperfusion, respectively.30 
Furthermore, one may consider the sample size as a limitation. However, as the goal of this 
study was to assess the basic pathophysiological role of complement activation in I/R injury, 
instead of correlating findings to clinical outcomes, small patient numbers were sufficient. 
Finally, only cortical biopsies could be collected, as deeper puncture holds a high risk of 
bleeding and calycal injury and was considered unsafe. 
In summary, this systematic study in human kidney transplantation shows acute, non-sustained 
intravascular terminal complement activation during early reperfusion of deceased donor 












































or hypoxic endothelium. These results indicate that terminal complement activation may 
play a role in early renal I/R injury in deceased donor kidney grafts.
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Local activation of the complement system has been associated with ischemia/reperfusion 
injury following kidney transplantation and tubular injury under proteinuric conditions. The 
soluble terminal complement complex sC5b-9 is a stable end-product of the complement 
cascade, and as such a promising urinary biomarker. In the early post-transplant period we 
found high urinary levels of sC5b-9, significantly correlating with the degree of proteinuria, 
suggesting activation of filtered complement components at the tubular epithelial surface 
of the kidney. However, when mimicking proteinuria in vitro by exposing serum (or blood) 
to urine (both negative for sC5b-9), we found extensive generation of sC5b-9 in urine. 
This process was inhibited by EDTA, confirming activation of the complement system. In 
conclusion, although sC5b-9 is an attractive urinary biomarker, one should be aware of the 
risk of extra-renal complement activation independent of a renal contribution. This may be 
of special interest when measuring urinary sC5b-9 following kidney transplantation in which 













































Complement activation at the tubular epithelial surface of the kidney, which lacks several 
important complement regulators (CD46, CD55),1 is considered to be a mediator of tubular 
injury in the proteinuric condition. In proteinuaria, complement proteins, which normally 
are retained in circulation, are able to pass the glomerular filter barrier, end up in the 
tubular lumen and are activated by the unprotected epithelial surface of the tubuli.2-4 
To this end, the detection of soluble (s)C5b-9 in urine is widely considered as a clinical 
indicator of tubular complement activation.5-7 
The complement system, a set of circulating proteins of the innate immune system that 
forms a biochemical cascade, is activated by the binding of complement recognition 
molecules (e.g. C1q, MBL or properdin) to their respective target (e.g. pathogens or 
apoptotic cells). Three activation pathways have been recognized, namely the classical, 
lectin and alternative pathway, which all converge at the level of complement component 
C3. Subsequent downstream activation of the complement cascade leads to formation of 
the lytic terminal complement complex C5b-9, which is able to damage and lyse target 
cells. Recently, it was shown that complement activation and deposition of C5b-9 on tubular 
epithelial cells is mediated by binding of properdin, the initiator of the alternative pathway 
of complement.8
Increased glomerular permeability to large plasma proteins (proteinuria) is common in the 
early period following renal transplantation, with a prevalence of 15% to 30% at 1 year post-
transplantation.9 Activation of filtered or locally produced complement components is likely 
to be involved in tubulotoxicity of proteinuria.2,3 Complement activation products indeed 
are detectable in the urine of patients with different proteinuric renal diseases 10,11 and are 
believed to be one of the possible candidates mediating tubular injury in the proteinuric 
condition.2,3 However, in the days after transplantation, not only glomerular damage may be 
responsible for proteinuria, but also a procedure-related (microscopic) hematuria.
In the present study we confirm the relation of urinary sC5b-9 and proteinuria in a renal 
transplantation cohort and we investigated the possibility whether in proteinuric urine 
sC5b-9 can be generated independent of a renal contribution. 
Material and methods
Patient population
Twenty-four patients undergoing a renal allograft transplantation receiving a kidney from 










































were recruited (Table 1). The study protocol was approved by the local ethics committee, 
and informed consent was obtained from each patient. 
Table 1: Donor, recipient and graft characteristics
All (n=24)
Donor age (years) 47 ± 16
Donor gender (% female) 58 %
Recipient age (years) 52 ± 14
Diuresis preTx (number of patients) 17
Cold ischemia time (hours) 17,5 ± 5,0
Warm ischemia time 1 (min) 20,3 ± 6,6
Warm ischemia time 2 (min) 29,0 ± 7,2
Delayed graft function (number of patients)* 17
One-year patient survival (%) 91,7%
One-year graft survival (%)  88,5%
* DGF was defined as cases in which creatinine level increased, remained unchanged, or decreased by 
less than 10% per day immediately after transplantation during 3 consecutive days within the first week. 
Operation and materials
Donor kidney transplantations were performed according to the local protocol. From 
allograft recipients, urine was collected at consecutive days after transplantation. Urine 
samples were centrifuged at 2500g at 4° Celsius for 10 minutes, aliquotted and stored at 
−80° C for later complement measurements.
Urine measurements
Soluble C5b-9 was measured by ELISA using an antibody to a neoepitope on C5b-9 (AE11).12 
Total protein was measured by a colorimetric method. 
Urinary complement activation
Whole blood or serum from 7 healthy volunteers was 1:4 or serially diluted in their 
corresponding urine or PBS, and incubated for 60 minutes at 37°C (mimicking the hematuric 
or proteinuric condition, respectively). Additionally, the process of complement activation 
was prevented by adding 10mM EDTA. To investigate any involvement of remaining renal 
cells or cellular debris, urine from 4 healthy volunteers was filtered with a 0.2 µm filter (GE 
Healthcare, Little Chalfont, UK). Subsequently, corresponding sera were 1:4 diluted in the 
filtered and unfiltered urines and incubated for 60 minutes at 37°C. After incubation, in all 
samples further complement activation was blocked by adding 10mM EDTA. Samples were 













































Correlation analysis between variables was performed by linear regression and the 
significance of differences was calculated by a Mann-Whitney test using GraphPad Prism 
software. Differences with P<0.05 were considered significant.
Results
In a cohort of deceased cardiac dead donors (Table 1), high levels of urinary sC5b-9 were 
detected at day 2 after transplantation, which decreased slowly after 10 and 42 days (Fig 
1A). Although urinary output was still variable at day 2, almost all patients showed normal 
diuresis at day 10. Most patients suffered from proteinuria (Fig 1B), and the degree of 
proteinuria strongly correlated with the urinary sC5b-9 levels (Fig 1C). 
Figure 1. Urine from recipients of a renal allograft were collected at day 2, 10 and 42 after 
transplantation and assessed for sC5b-9 (A) and proteinuria (B). Levels of sC5b-9 at day 2, 10 and 42 (C) 
were correlated to the measured proteinuria. 
To assess whether this observed complement activation may be an extra-renal phenomenon, 
the proteinuric condition was mimicked in vitro. Seven urine samples from healthy 
volunteers, all free of sC5b-9, were incubated with a small amount of freshly drawn blood 
from the corresponding individuals, which strikingly resulted in extensive generation of 
sC5b-9 in urine (Fig 2A). In contrast, levels of sC5b-9 remained low when the same amount 
of blood was added to PBS instead of urine, indicating that complement can be activated in 
urine ex vivo, independent of any renal contribution. To assess whether this effect was due 
to the presence of blood cells 13 (e.g. in hematuric conditions), similar dilutions of human 
serum in urine were tested. This also resulted in an extensive generation of sC5b-9 (Fig 2B), 










































The active process of complement activation in the urine samples in vitro was confirmed 
by the complete abolishment of complement activation when EDTA was added before 
incubation (Fig 2C). Since EDTA chelates calcium and magnesium needed for complement 
activation, measured urinary sC5b-9 must be formed by active complement activation in 
vitro in urine. 
Figure 2. Blood (A) or serum (B, C) from seven healthy volunteers was 1:4 diluted in the corresponding 
urines or PBS and incubated for 60 minutes at 37°C followed by assessment of sC5b-9. Additionally, 
10mM EDTA was added to the serum/urine to block complement activation (C). ** P < 0.01; *** P<0.001.
The urinary protein content in the transplantation patients varied from 0 to 10 mg/ml (Fig 
1C). In an additional experiment, this range was approached by serially diluting serum 
(normal serum protein content is 60-80 mg/ml) 4 to 32 times (Fig 3A). Even when serum was 
32 times diluted in urine (reflecting a urinary protein content of 1.8-2.5 mg/ml), significant 
levels of sC5b-9 could be detected. This indicates that also in less severe proteinuric 
conditions, sC5b-9 can be generated without any renal contribution. 
Urine, even from healthy subjects, often contains viable or apoptotic renal cells and cellular 
debris,14,15 as turnover or injury to epithelial cells lining the urinary tract results in shedding 
of these cells into urine which potentially could lead to activation of complement proteins 
present in proteinuric urines.16,17 To investigate such an involvement, the urine was filtered 
with a 0.2 µm filter to remove cells and cellular particles which possibly remained after 
centrifugation. Next, the corresponding serum was added to the filtered or unfiltered urine 
to allow sC5b-9 generation (Fig 3B). Removal of remaining cells and cellular debris reduced 
the sC5b-9 generation in the urine by half, suggesting that sC5b-9 generation in proteinuric 
urine is partially caused by cellular debris and apoptotic epithelial cells. The remaining 
complement activation observed after filtration, may be explained by high urinary levels 













































Figure 3. Serum from a healthy volunteer was serially diluted in the corresponding urine and 
incubated for 60 minutes at 37°C followed by assessment of sC5b-9. Represented data are true sC5b-
9 concentrations, uncorrected for dilution. sC5b-9 levels in the diluted serum were compared to 
undiluted serum. * P < 0.05; ** P < 0.01; *** P<0.001 (A).
Urine from 4 healthy volunteers was filtered with a 0.2 µm filter to remove any remaining cells or 
cellular debris. Subsequently, corresponding sera were 1:4 diluted in the filtered and unfiltered urine 
for 60 minutes after which sC5b-9 generation was assessed. ** P < 0.01 (B).
Discussion
After renal transplantation, proteinuria is a common event, with a prevalence of 15% 
to 30% at 1 year after transplantation.9 Here, we show that after renal transplantation, 
urinary sC5b-9 can be detected in the majority of renal allograft recipients and significantly 
correlates with the degree of proteinuria. This would classically be interpreted as activation 
of complement by the tubular epithelial surface.8,20 However, in this study we show that, 
independent of a renal contribution, presence of blood or serum constituents in urine form 
healthy subject could lead to complement activation and generation of sC5b-9 in vitro. This 
implies that following transplantation, proteinuria and procedure-related (microscopic) 
hematuria may cause urinary complement activation resulting in high urinary sC5b-9 levels. 
Centrifugation or filtration following collection of patient urines would not prevent this, 
since urinary complement activation most probably occurs in the urinary tract.
We would like to conclude that urinary sC5b-9 measurement is troubled by extra-renal or 
even ex vivo complement activation in case of hematuric or proteinuric conditions, rendering 
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Apart from their primary function in haemostasis, platelets serve as modulators of 
inflammation. Although in preclinical studies activated platelets have been implicated 
in the inflammatory response after reperfusion, their role in clinical renal ischemia/
reperfusion (I/R) injury is unknown. In this study, the role of platelets in living, brain dead 
and cardiac dead donor kidney transplantation was assessed by our unique method of 
arteriovenous measurements over the reperfused kidney. Markers of platelet activation and 
degranulation, i.e. b-thromboglobulin, soluble glycoprotein Ib and platelet derived growth 
factor did not show an arteriovenous concentration difference over the reperfused kidney. 
The solitary RANTES release from brain dead donor kidneys presumably reflects leukocytic 
release. Since no overt platelet activation was observed, more subtle changes in excitability 
of platelets were measured. Remarkably, platelets in renal venous blood were less easily 
and less intensely excitable than platelets in arterial blood. In conclusion, results of this 
study unequivocally deny platelet activation in early reperfusion in both living and deceased 
donor kidney transplantation. Platelet excitability was even inhibited in the reperfused 













































Ischemia/reperfusion (I/R) is an important clinical problem and an inevitable component 
of organ transplantation. I/R injury is characterized by inflammation,1-6 but the mechanism 
that initiates this inflammatory reaction is unknown. At present no effective therapy is 
available. A role of platelets in the etiology of I/R injury has been suggested but is not fully 
sustained or understood.7 Upon activation, platelets release granules containing growth 
factors, cytokines, chemokines and leukotrienes into the circulation by exocytosis.8 As such, 
platelets serve as inflammatory mediators that can initiate recruitment and activation of 
leukocytes and thereby significantly aggravate tissue injury.9
Increasing experimental evidence suggests that platelet activation orchestrates an 
inflammatory response upon reperfusion.10, 11 However, clinical studies on the mechanism 
and timing of platelet activation in I/R injury are scarce. In myocardial infarction, platelets 
mediate thrombotic occlusion and increase damage by causing micro vascular occlusions 
and no-reflow phenomenon.12 Administration of anti-platelet agents is routine therapy in 
acute coronary syndrome.13 Whether platelet activation, apart from its role in infarction 
and thrombosis, is involved in the initiation of inflammation in clinical I/R injury in humans 
is not clear yet. 
In this study, kidney transplantation was used as model of human I/R injury. Since peripheral 
blood measurements are influenced by many systemical influences, and factors of interest 
are diluted in the total intravascular volume, we instead applied selective arteriovenous 
measurements over the reperfused graft to specifically assess local release of mediators. 
The role of platelet activation and excitability was systematically investigated using these 
arteriovenous measurements over the reperfused kidney. We show that there is no platelet 
activation in both living, brain dead and cardiac dead donor kidney transplantation in the 
immediate period following reperfusion. In fact, platelet excitability is even repressed in the 
reperfused kidney, indicating that regulatory mechanisms prevent post-reperfusion platelet 
activation and subsequent thrombus formation. It is therefore unlikely that platelets are an 
initiator of the inflammatory response leading to I/R injury. 
Patients and Methods
Patient population
Thirty-four patients undergoing renal allograft transplantation were included for 










































patients received a kidney from a brain dead donor, and 7 patients received a kidney from 
a cardiac dead donor. Brain dead and cardiac dead donors together are referred to as 
deceased donors. Ten other patients that received a kidney from a living donor were included 
for direct arteriovenous measurements of platelet excitability, and biopsy collection for 
immunohistochemical anlysis. Patient characteristics are shown in Table 1. For technical 
reasons (renal vein sampling), only patients receiving a left kidney were included. The study 
protocol was approved by the local ethics committee, and informed consent was obtained 
from each patient.
Table 1: Transplantation and outcome characteristics in living donor (LD), brain dead donor 




n 10 8 9 7
Donor age: mean (SD) 53.1(10.0) 43.9(10.6) 54.1(17.1) 52.7(15.3)
Donor gender (M:F %) 30:70% 75:25% 44:56% 43:57%
Preservation fluid HTK (n=10) HTK (n=8) UW (n=9) UW(n=2)
 HTK (n=5)
WIT1 in min. (SD) N/A N/A N/A 23.1(7.7)
CIT in h. (SD) 2.8(0.4) * ∇ 3.0(0.3) * ∇ 19.7(6.2) 17.3(2.6)
WIT2 in min. (SD) 30.9(8.1) 34.0(6.3) 33.0(6.1) 34.1(6.4)
Recipient age: mean (SD) 47.8(16.1) 41.1(10.5) 55.1(13.5) 54.0(11.2)
Recipient gender (M:F %) 70:30% 38:62% 44:56% 71:29%
Creatinine clearance day 30 (ml/min) 49.8(6.1) ∇ 73.3 (20.5) * ∇ 49.3(15.3) ∇ 27.1(10.3)
DGF (%) 0% 0% 56% 86%
DGF: dialysis after transplantation 
in days (SD)
0 (0) * ∇ 0 (0) * ∇ 7.0 (5.3) ∇ 17.2 (7.2)
LD procedures that were exclusively sampled for platelet excitability assay (PEA) and biopsy collection 
(IHC) are presented in a separate column. WIT1: first warm ischemia time, CIT: cold ischemia time, 
WIT2: second warm ischemia time, DGF: delayed graft function. * P <.05 compared to BDD, ∇ P <.05 
compared to CDD.
Operation and materials
Kidney transplantations were performed according to local standardized protocol. In living 
donors minimally invasive nephrectomy was performed. For cold perfusion and storage of the 
kidney, Custodiol® Histidine–tryptophan–ketoglutarate solution (HTK) solution (Tramedico, 
Weesp, The Netherlands) was used. Deceased donor kidneys were perfused and stored with 
University of Wisconsin solution (UW) or HTK (Table 1). The immunosuppressive regimen 
was based on induction therapy with an interleukin-2 receptor blocker and maintenance 
treatment with tacrolimus or cyclosporine A, in addition to mycophenolate mofetil and 












































aggregation were administered. Donors, not recipients, were routinely administered a daily 
prophylactic dose of low molecular weight heparin. 
Arterial and renal venous blood samples were obtained as described before in detail.14 In 
short, via a small catheter placed in the renal vein, 10 ml blood aliquots were sampled 
at 30 seconds, 1, 3, 5, 10, 20 and 30 minutes after reperfusion (i.e., t=0). Paired arterial 
blood samples were obtained at 0, 3, 5, 10, 20 and 30 minutes after reperfusion (Figure 1). 
All samples were collected in tubes containing EDTA and immediately placed on ice. Blood 
samples were centrifuged (1,550 g, 20 min, 4ºC) and the derived plasma was subsequently 
centrifuged to deplete it from leukocytes and platelets (1,550 g, 20 min, 4ºC). Plasma was 
aliquotted and stored at -70°C until assayed. A renal cortical biopsy was obtained after cold 
storage, and a second biopsy of the same kidney was collected 45 minutes after reperfusion. 
Figure 1. Schematic representation of the arteriovenous sampling method over the reperfused kidney 
by simultaneous blood collection from the renal artery and vein. Illustration by Manon Zuurmond© 
(www.manonproject.com).
Plasma measurements
Platelet activation was assessed by measuring the local renal release of platelet granule 
contents into the circulation. Platelets contain three main types of secretory granules: the 
α-granules (the most prominent population in size and number), the dense granules and the 
lysosomal granules. Beta-thromboglobulin (β-TG) is abundant in α-granules and is a specific 
marker for platelet activation. Levels of b-TG and soluble GPIb (sGPIb) were determined 
in plasma using semi-automated ELISA on a TECAN Freedom EVO 150. Each antigen was 
measured on a separate Nunc maxisorb 384 well ELISA plate (Thermofischer Scientific, 
Roskilde, Denmark). The capture antibodies, MAB393 (1 µg/mL) and mouse anti-GP1b (clone 










































removed by washing five times using phosphate-buffered saline (PBS)/0.5% Tween. Plasma 
samples were diluted 1/80 for NAP-2 and 1/25 for sGPIb measurements and added to the 
plate with the corresponding capture antibody. Each plate contained four calibration curves 
consisting of standard serum sample with known b-TG and sGPIb concentrations. Dilutions 
were made in PBS/1% BSA and incubated for 2 hours on the capture antibodies. Unbound 
antigens were removed by washing five times with PBS/0.5% Tween. The detection antibodies 
BAF393 (50 ng/mL) and biotinylated M1852 (0.25 µg/mL, Sanquin Amsterdam) were added 
to the corresponding plates. Unbound detection antibody was removed by three wash steps 
with PBS/0.5% Tween, after which streptavidin/horseradish peroxidase (HRP) was added for 
2 hours to bind the biotin on the detection antibody. Bound antigen was quantified using 
Supersignal West Pico Chemiluminescent Substrate (#34080, Thermoscientific, Rockford USA) 
on a Spectramax Luminescence Microplate Reader (Molecular Devices, Sunnyvale, USA). 
The chemokine ‘Regulated on Activation, Normal T Cell Expressed and Secreted’ (RANTES) 
and platelet-derived growth factor (PDGF)-BB can be released from platelet α-granules 
upon activation. Both RANTES and PDGF-BB were measured in a custom made multiplex 
assay in accordance with the manufacturer’s instructions (X-plex, Biorad, Veenendaal, the 
Netherlands). 
Platelet excitability assay (PEA)
In the absence of platelet activation, more subtle changes in excitability of platelets were 
explored, using a renewed, bedside applicable assay for platelet excitability. For this purpose, 
arterial and renal venous samples from another 10 patients undergoing living donor kidney 
transplantation were collected in citrate coated tubes at 5 and 30 minutes after reperfusion. 
Whole blood was added to tubes containing either platelet agonist adenosine diphosphate 
(ADP), collagen-related peptide (C-RP) or thrombin related activatable peptide (TRAP) in 
eight increasing concentrations. Fluorescent anti-P-selectin and anti-GP1b antibody were 
co-incubated for subsequent flow cytometry analysis. Final concentrations in the tubes were 
0.01, 0.03, 0.12, 0.49, 1.95, 7.81, 31.25, 125.00 μM ADP; 0.2, 0.6, 2.4, 9.8, 39.1, 156.3, 
625 and 2500 ng/ml C-RP; and 0.04, 0.15, 0.61, 2.44, 9.77, 39.06, 156.25, 625.00 μM TRAP. 
After 20 minutes of incubation, the reaction was stopped by adding 0.5% formaldehyde in 
heparin buffered saline. FACS-Calibur flow cytometer adjusted in a standard configuration 
(Cytomics FC 500 flow cytometer, Beckman and Coulter, Krefeld, Germany) was used to 
assess the activation state and excitability of platelets. Samples were analyzed on GP1b 
positivity (all platelets) and P-selectin positivity (activated platelets). A typical example 
of the flow cytometry result of a low and high percentage of activated platelets is shown 
in Figure 2A and 2B. Analysis involved assessment of the maximum percentage of activated 
platelets (% P-selectin positive) and their intensity of activation (mean fluorescence index; 
MFI). The percentage activated platelets increased with concentration of the agonist in a 












































Figure 2. Typical examples of flow cytometry results after stimulation with low (A) and high (B) 
concentration agonist, i.e. thrombin related activatable peptide (TRAP). The corresponding P-selectin 
positive percentage of platelets was 0.1% and 96.6%, respectively. The eight results of a stimulation 
series are depicted in sigmoid shaped curves were arterial □ and renal venous ■ percentages of 
P-selectin positive platelets can be compared (C). 
Platelet staining 
Pre-transplant and reperfusion (45 min. post reperfusion) cortical biopsies were collected 
from living donor kidneys. Biopsies were snap frozen and cryostat sections (5 µm) were fixed 
in acetone for 10 min. Endogenous peroxidase activity was blocked with 0.1% H2O2. Slides 
were incubated with primary antibody biotin labeled CD41 antibody (ab30434, Abcam, 
Cambridge, United Kingdom), followed by ABC complex (Vectastain, Vector laborotories, 
Peterborough, United Kingdom). The staining was visualized using DAB (DAKO, Glostrup, 
Denmark). Sections were counterstained with hematoxylin (Merck, Darmstadt, Germany). 
Analysis
Clinical donor data were retrieved from Eurotransplant Foundation (Leiden, The 
Netherlands). Delayed graft function (DGF) was defined as the need for dialysis within one 
week after transplantation. Statistical analysis was performed using SPSS 16.0 statistical 
analysis software (SPSS Inc, Chicago, Ill). The area under the curve (AUC) was calculated for 
the arterial and venous curve of the plasma measurements for the total of 30 minutes. The 
delta AUC was calculated (venous minus arterial) and the null-hypothesis (delta AUC is 0) 
was tested by t-test or non-parametric test in case of a non-normal distribution. Wilcoxon 
test was applied to test for differences between arterial and venous outcome per agonist 
and per time-point in the analysis of the PEA. Graph error bars represent the standard error 











































Donor and transplant characteristics
Recipient and donor age and gender were similar in all three donor groups (Table 1). As 
expected, the warm and cold ischemia duration differed between the groups, with a shorter 
duration of cold ischemia in living donor kidney transplantation. The immunosuppressive 
regimen was similar in the three groups. A significantly higher rate of DGF was observed in 
brain dead and cardiac dead donor groups as compared to living donor kidney transplantation. 
Although incidence of DGF was similar in brain dead donor and cardiac dead donor kidney 
transplantations, DGF was more prolonged in the cardiac dead donor group. With the 
exception of one kidney from a cardiac dead donor in which the recipient was not compliant 
with immunosuppressive medication, all kidneys were still functioning at one year after 
transplantation. There were no complications because of local or deep venous thrombosis 
or any (re-)bleeding problems. 
No platelet activation in the reperfused kidney
Platelet activation leading to degranulation was assessed by comparing plasma concentrations 
of granule contents, i.e. RANTES, PDGF-BB, β-TG and GP1b between arterial and renal 
venous samples, i.e. net change over the kidney. RANTES was not released from the kidneys 
of living or cardiac dead donors (P=0.11, P=0.34 respectively). Kidneys of brain dead donors 
however, showed a significant RANTES release during the first 30 minutes of reperfusion 
(P=0.03, Figure 3). PDGF-BB was not released from living, brain dead, or cardiac dead donor 
kidneys (P=0.28, P=0.51, P=0.14, respectively). Similarly, β-TG and GP1b were not released 
from the kidney in any of the three donor groups (P=0.68, 0.72, 0.17 for β-TG, and P=0.08, 
0.64, 0.51 for GP1b in LD, BDD and CDD respectively).
Inhibition of platelet excitability in the reperfused kidney
Although direct arteriovenous measurements over the kidney did not indicate platelet 
activation and degranulation in the reperfused kidney, more subtle changes in platelet 
excitability may be induced when platelets pass through the graft. Maximum platelet 
excitability was measured by an established platelet activation assay, now optimized 
for bedside use. Before stimulating the samples, there was no arteriovenous difference 
in percentage of spontaneously P-selectin positive platelets at 5 minutes (arterial 0.24%, 
venous 0.22%; P=0.36) or 30 minutes after reperfusion (arterial 0.25%, venous 0.23%; 
P=0.21). After in vitro stimulation of arterial or renal venous blood with platelet activation 
agonists ADP, C-RP and TRAP, the maximum total percentage of activated platelets and 
the mean fluorescence index (MFI) of activated platelets were measured. There was a 












































C-RP (P=0.01) and TRAP (P=0.005) at 5 minutes after reperfusion. At 30 minutes after 
reperfusion this venous decrease in activation was not significant anymore (Figure 4). The 
MFI of activated platelets was significantly lower in renal venous blood compared to arterial 
blood at 5 minutes after reperfusion for both C-RP (P=0.047) and TRAP (P=0.009). After 30 
minutes, only ADP activated platelets showed a significant decrease in MFI (P=0.013, Figure 
5). Overall results of the platelet excitability assay indicate that platelets are less easily and 
less intensely excitable after they passed the reperfused kidney. 
Figure 3. Arterial □ and venous ■ concentrations of (A) RANTES, (B) PDGF, (C) β-TG and (D) GP1b are 
shown for the first 30 minutes of reperfusion of brain dead donor kidney grafts. RANTES was significantly 
released (P=0.03), however other platelet degranulation markers were not released from the kidney. 










































Figure 4. Maximum percentage activated platelets after stimulation with agonists adenosine 
diphosphate (ADP), collagen-related peptide (C-RP) or thrombin related activatable peptide (TRAP). 
Five minutes after reperfusion there was a significant decrease in maximum percentage activated 
platelets over the kidney for both C-RP (P=0.013) and TRAP (P=0.005). After 30 minutes of reperfusion 
changes were not statistically different anymore. Graph error bars represent the standard error of the 
mean (SEM).
Figure 5. Maximum intensity of activated platelets after stimulation with agonists adenosine diphosphate 
(ADP), collagen-related peptide (C-RP) or thrombin related activatable peptide (TRAP). Five minutes 
after reperfusion there was a significant decrease in maximum intensity over the kidney for both C-RP 
(P=0.047) and TRAP (P=0.009). After 30 minutes of reperfusion only ADP activated platelets showed a 
significant decrease in intensity (P=0.013). Graph error bars represent the standard error of the mean 
(SEM).
No platelet retention in the kidney
The difference between arterial and venous platelet excitability could be explained by 
retention of a subpopulation of (activated) platelets in the kidney. To evaluate platelet 
retention, arterial and renal venous platelet concentrations were measured 5 and 30 minutes 
after reperfusion. There was no difference between arterial and renal venous concentration 
of platelets at 5 minutes after reperfusion (mean arterial 148.6 x 109/l, renal venous 145.1 x 
109/l, P=0.08) and at 30 minutes after reperfusion (mean arterial 147.6 x 109/l, renal venous 












































substantiate the lack of platelet infiltration in the reperfused kidney, immunohistochemical 
analysis of renal biopsies collected before and 45 minutes after reperfusion was executed 
as well. CD41 staining showed occasional clusters of platelets, mostly in glomeruli (Figure 
6). Pre- and post-reperfusion patterns were highly similar, and thereby substantial platelet 
retention after reperfusion could be excluded. 
  2

 Representative sections showing CD41 staining in living donor renal biopsy tissue 
collected (A) pre, and (B) postreperfusion. Occasional CD41 positive cells were detected, mostly 
in glomeruli (arrows). Original magnification 200x.  
 
Figure 6. Representative sections showing CD41 staining in living donor renal biopsy tissue collected 
(A) pre, and (B) post-reperfusion. Occasional CD41 positive cells were detected, mostly in glomeruli 
(arrows). Original magnification 200x. 
Discussion
Platelets have been suggested to be involved in experimental I/R injury. However, their 
potential role in human I/R injury and the opportunities of anti-platelet agents in clinical 
I/R injury are unclear. In this study, we show there is no platelet activation in early I/R 
injury in human kidney transplantation. Moreover, platelet activation is even repressed in 
renal venous blood, suggesting a platelet inhibitory effect of the reperfused kidney.
It is well-established that platelets, aside from their thrombotic role, are contributors to 
the inflammatory response through release of cytokines, chemokines and growth factors 
from their granules.15 Platelets have been suggested to be involved in the inflammatory 
response of I/R injury in various organs. In mouse gut, platelets roll and adhere to post-
reperfusion endothelium in a P-selectin dependent mechanism.16 Furthermore, I/R injury of 
the liver results in platelet adhesion to the sinusoidal endothelium.17-21 The first activated 
platelets are present in mouse myocardial tissue within two minutes after reperfusion,22 
and then accumulate in the infarcted myocardium.23 In the mouse renal vascular bed, 
platelet accumulation has been shown early after reperfusion as well.24 However, the role 
of platelet activation in the initiation of human clinical I/R injury in general is unclear. In 
kidney biopsies potential infiltration of P-selectin positive platelets after reperfusion was 










































infarction show beneficial effects, however it is difficult to discern the effects of diminished 
(microvascular) thrombosis from potential anti-inflammatory effects.
In this study, platelet activation upon reperfusion was examined in living and deceased 
donor kidney transplantation. Since deceased donor kidneys have more clinical organ 
damage, platelet activation was expected to be more pronounced in these kidneys. In the 
arteriovenous measurements, renal release of various platelet degranulation products into 
the circulation was assessed. Among all of the measured factors, only RANTES was found to 
be minimally released from the reperfused kidney of brain dead donors. Since none of the 
other platelet degranulation markers were released from the reperfused kidney, it is more 
likely that RANTES is released from another source. Increased T-lymphocyte and macrophage 
content is found in kidneys from brain dead donor grafts already before transplantation, 
and both cell types can be a source of RANTES.1 Moreover, RANTES is constitutively 
released during the first 30 minutes of reperfusion, while a peak after reperfusion could 
be expected should the source of this RANTES be degranulating platelets. Since none of 
the other platelet activation markers were released in any of the groups, platelet granule 
release upon reperfusion is probably minimal and as such there is no evidence for platelet 
activation upon reperfusion. 
Although platelet activation leading to degranulation was not observed in the reperfused 
kidney, more delicate changes in the excitability of platelets could potentially be sufficient 
to change platelet homeostasis. We used a novel and sensitive bedside test to determine 
platelet excitability. Results showed that platelet excitability decreased when blood 
passed through the reperfused graft. This inhibitory effect on platelets passing through 
the reperfused kidney may be explained very well by an endothelial regulatory release 
of short-acting inhibitors of platelet activation, such as nitric oxide and prostacyclin.26-28 
Release of these factors unfortunately is difficult to confirm due to their short half-life. The 
difference is probably not mediated by adherence of platelets in the kidney, since platelet 
concentration was equal in arterial and venous blood, and immunohistochemical analysis 
did not reveal renal platelet deposits after reperfusion. Moreover, one would then expect a 
measurable release of platelet activation markers as well.
A limitation of our study was the fact that the sampling time was restricted to a maximum 
of 30 minutes following reperfusion. Although platelet activation is considered to be a short-
term process, thought to occur during the first contact between recipient blood and the 
graft, we cannot exclude that platelet activation commences after this time period. Hence, 
apart from their potential role at later time points, platelets do not appear to be involved 












































the goal of this study was to assess the basic pathophysiological role of platelet activation 
in I/R injury, instead of correlating findings to clinical outcomes, small patient numbers 
were sufficient. 
In conclusion, we unequivocally show absence of platelet activation in early reperfusion 
injury in both living and deceased donor kidney transplantation. In fact, platelets display 
inhibited excitability upon passing the reperfused kidney. This indicates that platelets do 
not initiate the inflammatory response of I/R injury and other factors are more important in 
regulating the immune response. 
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Background: Recent insights suggest that endothelial cell (EC) activation plays a major 
role in renal ischemia/reperfusion (I/R) injury. Interactions between ECs and pericytes via 
signaling molecules, including angiopoietins, are involved in maintenance of the vascular 
integrity. Experimental data have shown that enhancement of Angiopoietin (Ang)-1 signaling 
might be beneficial in renal I/R injury. However, little is known about the role of angiopoietins 
in human renal I/R injury.
Methods: In this study, EC activation and changes in angiopoeitins are assessed in human 
living and deceased donor kidney transplantation. Local release of angiopoietins was 
measured by unique, dynamic arteriovenous measurements over the reperfused kidney.
Results: Renal I/R is associated with acute EC activation shown by a vast Ang-2 release from 
both living and deceased donors shortly after reperfusion. Its counterpart Ang-1 was not 
released. Histological analysis of kidney biopsies showed EC loss after reperfusion. Baseline 
protein and mRNA Ang-1 expression was significantly reduced in deceased compared to 
living donors and declined further after reperfusion.
Conclusions: Human renal I/R injury induces EC activation after reperfusion reflected by 
Ang-2 release from the kidney. Interventions aimed at maintenance of vascular integrity by 













































Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ transplantation and 
a major determinant of patient and graft survival.1;2 The pathophysiology of renal I/R injury 
is complex and incompletely understood. Although the role of tubular cell injury in post-
transplantation graft dysfunction is widely acknowledged, microvascular endothelial cell 
(EC) damage is considered increasingly important.3 ECs line the lumen of all blood vessels 
within the kidney graft and in this unique position they form the interface between the 
recipient blood and the allograft tissue. ECs are very susceptible to damage, including I/R 
injury.4 The repetitive insults during transplantation may induce loss of the microvasculature, 
on the long term resulting in impaired delivery of oxygen and nutrients to renal tubular 
epithelial cells, chronic ischemia and cell death.4-8 
  
The molecular mechanisms that lead to microvascular graft injury are largely unknown. 
Endothelial homeostasis is regulated by the angiopoietin system and pericytes.9 Pericytes 
are the basic supportive cells of the endothelium, connected to the vessel’s basement 
membrane.10 Angiopoietin-1 (Ang-1) and -2 (Ang-2) are both ligands for the Tie2 receptor, 
but have opposite effects. Ang-1 is produced by pericytes and is responsible for suppressing 
vascular leakage, maintaining EC survival and inhibiting vascular inflammation. Ang-2 acts as 
an antagonist of Ang-1 and thereby destabilizes quiescent endothelium.11-14 Ang-2 promotes 
pericyte loss, leading to loosening contacts between ECs and pericytes, subsequent vessel 
destabilization and abnormal microvascular remodeling.15-18 ECs store Ang-2 in Weibel–Palade 
bodies from where it can be released quickly following stimulation, and Ang-2 expression 
can be upregulated manifold following endothelial activation.19 A few experimental studies 
have focused on the functional role of angiopoietins in endothelial damage in the kidney. 
The relation between a disbalance in angiopoietins and EC loss was demonstrated in a 
mouse model of anti-glomerular basement membrane glomerulonephritis, where glomerular 
capillary loss was associated with reduced Ang-1 and increased Ang-2 expression.20 Similarly, 
Ang-1 expression decreased after renal I/R injury in mice.21 Moreover, Ang-1 overexpression 
even significantly improved renal function and renal tissue blood flow after renal I/R in mice 
and decreases inflammatory cells and renal interstitial fibrosis.22 
Although these experimental data suggest a functional role of angiopoietins in renal I/R 
injury, their involvement in human renal I/R injury had not been investigated yet. In 
addition, their involvement in living and deceased donor kidney transplantation had not 
been compared. In our recent studies on renal I/R, we exploited selective arteriovenous 
measurements over the kidney as a reliable method to study inflammatory processes after 
reperfusion.23;24 In this study, local renal angiopoietin expression and release during renal 












































Eighteen patients undergoing renal allograft transplantation were included for arteriovenous 
sampling, 6 living donor (LD), 6 brain dead donor (BDD), and 6 cardiac dead donor (CDD) 
kidney recipients. BDD and CDD together are referred to as deceased donors (DD). Twenty-
three other patients receiving a kidney from a LD (n=10), a BDD (n=7) or a CDD (n=6) 
were included for mRNA isolation from renal biopsies. Immunohistochemical analyses were 
performed on biopsies of 10 LD, BDD and CDD kidney graft recipients. Patient characteristics 
are shown in Table 1. All kidneys were still functioning at 1 year after transplantation, 
except for one patient in the arteriovenous sampling cohort who received a kidney from 
a CDD (the recipient was not compliant with immunosuppressive medication) and one 
patient in the PCR cohort, that received a BDD kidney transplant and died 6 months after 
transplantation (because of veno-occlusive disease ultimately causing hepatic failure). For 
technical reasons (renal vein sampling) only patients receiving a left kidney were included 
in the arteriovenous group. The reason for including different cohorts was to minimize 
patient burden by collecting one type of material per patient, i.e. either blood or a single 
renal biopsy. The study protocol was approved by the local ethics committee, and informed 
consent was obtained from each patient.
Operation and materials
Kidney transplantations were performed according to local standardized protocol. In LD 
minimally invasive nephrectomy was performed. For cold perfusion and storage of the 
kidney, Custodiol® Histidine–tryptophan–ketoglutarate solution (HTK) solution (Tramedico, 
Weesp, The Netherlands) was used. DD kidneys were perfused and stored with University 
of Wisconsin solution (UW) or HTK. The immunosuppressive regimen was based on 
induction therapy with an interleukin-2 receptor blocker (basiliximab, day 0 and day 4) and 
maintenance treatment with tacrolimus or cyclosporine A, in addition to mycophenolate 
mofetil and steroids in all groups. 
Arterial and renal venous blood samples were obtained as described before in detail 23. In 
short, via a small catheter placed in the renal vein, blood aliquots were sampled at 3, and 
30 minutes after reperfusion. Paired arterial blood samples were obtained simultaneously. 
All samples were collected in tubes containing EDTA and immediately placed on ice. Blood 
samples were centrifuged (1,550 g, 20 min, 4ºC) and the derived plasma was subsequently 
centrifuged to deplete it from leukocytes and platelets (1,550 g, 20 min, 4ºC). Plasma was 












































Table 1: Transplantation and outcome characteristics of the three different patient cohorts 
that were included. In each cohort material was collected from living donor (LD), brain dead 
donor (BDD) and cardiac dead donor (CDD) grafts during kidney transplantation. 
AV IHC PCR
LD BDD CDD LD BDD CDD LD BDD CDD
N 6 6 6 10 10 10 10 7 6
Donor age: mean (SD) 42(11) 51(21) 52(16) 57(10) 48(16) 41(10) 52(8) 45(21) 41(13)
Donor gender (M:F) 5:1 2:4 3:3 5:5 5:5 6:4 2:8 3:4 4:2
WIT1 in min. (SD) N/A N/A 23(8) N/A N/A 18(5) N/A N/A 18(6)
CIT in h. (SD) 2.9(0.3) 21.3(7.1) 17.1(2.9) 2.8(0.5) 18.6(9.6) 17.8(3.4) 3.0(0.4) 17.4(7.6) 15.6(3.9)
WIT2 in min. (SD) 33(7) 31(6) 34(7) 29(8) 28(4) 28(8) 29(7) 34(3) 28(5)
Recipient age: mean (SD) 41(11) 57(13) 52(10) 54(16) 51(13) 45(15) 49(16) 53(14) 54(9)
Recipient gender (M:F) 3:3 2:4 5:1 4:6 7:3 7:3 6:4 4:3 3:3
CrCl day 30 (ml/min) 73(19) 64(13) 35(12) 45(11) 63(30) 48(21) 56(17) 47(14) 50(8)
DGF 0/6 3/6 5/6 0/10 3/10 7/10 0/10 3/7 4/6
DGF duration in days (SD) 0 5(6) 13(10) 0 5(2) 13(6) 0 3(4) 7(6)
Acute rejection n (%) 1(17%) 0(0%) 1(17%) 0(0%) 2(20%) 1(10%) 1(10%) 0(0%) 0(0%)
AV: cohort of patients included for arteriovenous sampling over the kidney. 
IHC: cohort of patients in which renal biopsies were used for immunohistochemical analysis. PCR: 
cohort of patients from which renal biopsies were used for PCR analysis. 
WIT1: first warm ischemia time. 
CIT: cold ischemia time. 
WIT2: second warm ischemia time.
DGF: delayed graft function.
DGF duration: dialysis after transplantation in days (SD).
CrCl: Creatinine clearance.
Immunohistochemical analysis
A renal cortical biopsy was obtained after cold storage from LD, BDD and CDD kidney graft 
recipients. For logistical reasons, only in the LD group a second biopsy 45 minutes after 
reperfusion was collected as well. Immunohistochemical analyses were performed on 4 
µm cryostat kidney tissue sections fixed in acetone. Slides were washed and incubated 
with peroxidase blocking solution and blocked with PBS containing 5% normal human serum 
(NHS) and 1% BSA. Then slides were incubated with the following primary antibodies: Ang-1 
mouse monoclonal IgG, 1:800 (R&D systems), Ang-2 mouse monoclonal IgG, 1:100 (Novus 
Biologicals), ECs (CD34) mouse polyclonal IgG, 1:3200 (Dako), vWf, rabbit polyclonal, 1:2500 
(Dako). Next, the following peroxidase-conjugated secondary antibodies were applied: goat 
anti-rabbit IgG, 1:200 (Dako); goat anti-mouse IgG, 1:200 (Dako); or rabbit anti-goat IgG, 
1:200 (Dako), followed by sequential fluorescein isothiocyanate (FITC, amplification reagent) 
and anti-fluorescein-HRP. Staining was completed by incubation with 3,3’ diaminobenzidine 
tetrahydrochloride (DAB)/ hydrogen peroxide and counterstained with Mayer’s Hematoxylin 
Solution (Merck, Darmstadt, Germany). At 100 × magnification, 10 microscopic fields of each 










































Plasma measurements of endothelial cell activation
Activation of the endothelium was assessed by measuring the local release of endothelial 
activation markers from the kidney. Release of Ang-1 and Ang-2 from the kidney was assessed 
by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. The 
paired arteriovenous samples were also analyzed on more classical markers of endothelial 
activation; von Willebrand factor (vWf) and vWf propeptide. The propeptide has a shorter 
circulating half-time (2–3 h), compared with vWf itself (>12 h), and may therefore be a more 
sensitive marker of acute endothelial activation. Plasma levels of vWf and vWf propeptide 
were determined using a semi-automated ELISA. Plates were coated overnight with coating 
buffer, consisting of sodium carbonate, sodium bicarbonate and NaN3. Commercial antibody 
duo sets, optimized for ELISA, were used (rabbit anti-human vWf and peroxidise-conjugated 
rabbit anti-human vWf, A00082 and P0226, Dako, Glostrup, Denmark). vWf propeptide, 
rabbit-anti-propeptide, and rabbit-anti-propeptide-biotine were used for the analysis of 
vWf propeptide as described previously.25 
mRNA expression in human kidney biopsies
A renal cortical biopsy was obtained after cold storage from LD, BDD and CDD kidneys, 
and a second biopsy was collected 45 minutes after reperfusion from LD kidneys. Biopsies 
were immediately snap frozen in liquid nitrogen and stored at -70ºC. Total RNA was 
extracted from renal tissues using RNAzol (Campro Scientific, Veenendaal, The Netherlands) 
and glass beads.26 The integrity of each RNA sample was examined by Agilent Lab-on-a-
chip technology using the RNA 6000 Nano LabChip kit and a bioanalyzer 2100 (Agilent 
Technologies, Amstelveen, The Netherlands). RNA preparations were considered suitable 
for further processing if samples showed intact 18S and 28S rRNA bands, and displayed 
no chromosomal peaks or RNA degradation products (RNA Integrity Number >8.0).27 cDNA 
was synthesized from 1 µg total RNA, using an oligo dT primer, RNase-OUT, M-MLV reverse 
transcriptase, 0.1 M-DTT and buffers in a volume of 20 µL (all purchased from Invitrogen, 
Breda, The Netherlands). Quantitative real-time PCR was performed in duplicate by using 
iQ SYBR Green Supermix on iCycler Real-Time Detection System (BioRad). The amplification 
reaction volume was 20 µL, consisting of 10 µL iQ SYBR Green PCR mastermix, 1 µL primers, 
1 µL cDNA, and 8 µL water. Data were analyzed using Gene Expression Analysis for iCycler 
Real-Time PCR Detection System (BioRad). Expression of each gene was normalized against 













































Table 2: Primer sequences used for quantitative real-time polymerase chain reaction.
Gene Forward primer 5’->3’ Reverse primer 5’->3’ Supplier
GAPDH TTCCAGGAGCGAGATCCCT CACCCATGACGAACATGGG Biolegio
Ang-1 GCAACTGGAGCTGATGGACACA CATCTGCACAGTCTCTAAATGGT Biolegio
Ang-2 TGGGATTTGGTAACCCTTCA GTAAGCCTCATTCCCTTCCC Biolegio
Tie-2 GTATGGACTCTTTAGCCGGCTT TTCGCCCATTCTCTGGTCAC Biolegio
Analysis
Clinical donor data were retrieved from Eurotransplant Foundation (Leiden, The 
Netherlands). Delayed graft function (DGF) was defined as the need for dialysis within 
one week after transplantation. Acute rejection was defined as biopsy proven rejection 
within 60 days after transplantation. Statistical analysis was performed using SPSS 17.0 
statistical analysis software (SPSS Inc, Chicago, Ill). Paired, non-parametric test (Wilcoxon) 
was applied to assess differences between arterial and venous concentration, and between 
pre- and post-reperfusion samples. Graph error bars represent the standard error of the 
mean (SEM), unless otherwise stated. A P-value of less than 0.05 was considered significant.
Results
Integrity of the renal microvasculature is disturbed after reperfusion
To assess endothelial structure and viability, staining for ECs was quantified in both living 
and deceased donor kidney tissue. Both CD34 and vWf staining showed a characteristic 
positive pattern of peritubular and glomerular ECs. Pre-reperfusion biopsies did not show 
a difference between living and deceased donor kidneys in either CD34 (p=0.76) or vWf 
(p=0.07; Figure 1). Next, pre- and post-reperfusion biopsies of LD kidneys were compared. 
There was a trend towards a decrease in CD34 positive cells after reperfusion (p=0.08, data 
not shown), whereas vWf staining of ECs showed a significant decrease in expression after 










































Figure 1: vWf staining decreased after reperfusion. Staining for vWf showed a characteristic positive 
endothelial pattern. Typical example of vWf staining in A a pre-reperfusion biopsy, B a post-reperfusion 
biopsy of a LD kidney. C Quantification of vWf staining showed no differences in intensity between groups 
before transplantation (p=0.07). D After reperfusion, vWf signal showed a vast decrease (p<0.005) in LD 
kidneys. The boxes run from the lower to upper quartile, the whiskers indicate the 5 to 95 percentile, 
while the horizontal line is set at the median. 
Ang-2 is released from the reperfused kidney
Arteriovenous differences for Ang-1 and Ang-2 were assessed over the kidney during 
reperfusion. Ang-1 levels did not change significantly over the reperfused kidney in LD, BDD 
and CDD kidney transplantation, making it unlikely that anti-inflammatory Ang-1 is released 
from the kidney after reperfusion (Figure 2A-C). In contrast Ang-2, a marker for endothelial 
activation, was released from the kidney both early and late after reperfusion (Figure 2D-
F). Ang-2 release was statistically significant in LD kidneys early after reperfusion (3 min., 
p=0,005; 30 min. p=0.064), in BDD kidneys only late after reperfusion (3 min. p=0.15; 30 
min., p=0.036) and in CDD kidneys both early and late after reperfusion (3 min., p<0.001; 
30 min., p=0.017). In the total group of deceased donor kidney transplantations, both early 
and late Ang-2 release was statistically significant (3 min., p=0.024; 30 min., p=0.001). The 
Ang-1/Ang-2 ratio was consistently higher in the arterial compared to renal venous samples 












































(data not shown). There was no early or late release of vWf or its more dynamic propeptide 
(Figure 3). 
Figure 2: Ang-2 is released from the kidney during reperfusion. Ang-1 was not released from the 
kidney either 3 or 30 minutes after reperfusion in A LD (3 min. p=0.18; 30 min. p=0.59); B BDD (3 min. 
p=0.29, 30 min. p=1.0); C CDD (3 min. p=0.47; 30 min. p=1.0). Ang-2 was significantly released from 
the kidney in D LD kidneys early after reperfusion (3 min. p=0,005; 30 min. p=0.064), E in BDD kidneys 
only later after reperfusion (3 min. p=0.15; 30 min. p=0.036) and F in CDD kidneys both early and late 
after reperfusion (3 min. p<0.001; 30 min. p=0.017). N=6 in each group. Bars represent mean and error 










































Figure 3: No vWf or vWf propeptide release from the reperfused kidney. vWf was not released from 
the reperfused graft both early (3 min.) and later (30 min.) after reperfusion in kidney transplantation 
with A LD (p=0.89, p=0.78), B BDD (p=0.89, p=0.33) and C CDD (p=0.40, p=0.18) respectively. The 
shorter lived and more dynamic vWf propeptide, was not released either from the kidney in D LD 
(p=0.78, p=0.62), E BDD (p=0.19, p=0.89) and F CDD (p=0.35, p=0.74) kidney transplantation. Bars 
represent mean and error bars represent SEM.
Ang-1 protein and mRNA expression are significantly higher in LD kidneys and are 
reduced after reperfusion       
Protein and mRNA expression of angiopoietins was assessed in the three donor groups. Ang-1 
protein was expressed in glomeruli and capillary walls (Figure 4A, B). The protein expression 
was already reduced before transplantation in CDD kidneys (p=0.003), not BDD kidneys 
(p=0.17) compared to LD kidneys (Figure 4C, D). Consistently, Ang-1 mRNA expression before 
transplantation was significantly higher in LD kidneys compared to CDD kidneys (p=0.006) 
(Figure 4E). In LD kidney biopsies collected before and 45 minutes after reperfusion, there 
was a significant reduction in both Ang-1 mRNA (p=0.007) and protein expression after 
reperfusion (p=0.001; Figure 4D, F).
Ang-2 protein and RNA expression levels are similar between LD and deceased donors
Ang-2 immunostaining of kidney sections revealed expression in interstitial vessels and 
negative staining in the glomeruli (Figure 5A, B). There were no differences in Ang-2 protein 
and mRNA expression between LD, BDD and CDD kidneys (p=0.69, p=0.73, respectively; 












































after reperfusion in LD kidneys (p=0.006, Figure 5D). However, mRNA expression of Ang-2 
did not change after reperfusion in LD kidney transplantation (p=0.72, Figure 5F). The mRNA 
expression of the angiopoietin receptor Tie-2 was similar between the different donor types 
(p=0.48) and not upregulated after reperfusion in LD grafts (p=0.32) (data not shown). 
Figure 4: Ang-1 protein and mRNA expression decreased after reperfusion. Ang-1 staining was positive 
in glomeruli and peritubular capillaries. Typical example of Ang-1 staining in A a pre-reperfusion biopsy 
and B a post reperfusion biopsy of a LD kidney. C Quantification of Ang-1 in pre-transplantation kidney 
biopsies showed a significantly decrease in CDD (p=0.003) compared to LD grafts. D Ang-1 in LD kidney 
biopsies taken before (pre) and after (post) reperfusion showed a significant decrease in Ang-1 protein 
expression (p=0.001). The boxes run from the lower to upper quartile, the whiskers indicate the 5 to 95 
percentile, while the horizontal line is set at the median. In kidney biopsies mRNA expression of Ang-1 
was assessed. E pre-transplantation Ang-1 mRNA expression was significantly reduced in CDD kidneys 
compared to LD kidneys (p=0.006). F when comparing biopsies collected before (pre) and after (post) 











































Figure 5: Ang-2 protein and mRNA levels are similar between living and deceased donors. 
Ang-2 staining was positive in interstitial vessels and peritubular capillaries. Typical example of Ang-2 
staining in A a pre-reperfusion biopsy and B a post-reperfusion biopsy of a LD kidney. C There were 
no differences in Ang-2 protein expression between groups before transplantation (p=0.69). D After 
reperfusion, there was a decrease in Ang-2 protein expression (p=0.006), consistent with degranulation 
of ECs and loss of Ang-2. The boxes run from the lower to upper quartile, the whiskers indicate the 5 to 
95 percentile, while the horizontal line is set at the median. mRNA expression of Ang-2 was assessed in 
kidney biopsies. E Ang-2 expression was similar before reperfusion in all groups (p=0.73). F In LD kidney 













































Previous studies, primarily exploiting animal models, have revealed that EC activation plays 
a major role in I/R injury and that the angiopoietin balance may be critical in maintaining 
vascular integrity. Enhancement of Ang-1 signaling has been demonstrated to be beneficial 
in renal I/R injury.28 However, thus far, no study has reported on the role of angiopoietins 
in human renal I/R injury or local release of angiopoeitins from the kidney. In this study, 
the local response of the reperfused kidney was assessed by arteriovenous concentration 
differences of angiopoietins during the first 30 minutes after reperfusion in living and 
deceased donor kidney transplantation. Results demonstrate that renal I/R is associated 
with acute EC activation shown by a vast Ang-2 release from both living and deceased donor 
kidneys shortly after reperfusion. 
In the present study, a reduction in CD34 and vWf protein expression was observed in tissue 
biopsies after reperfusion, consistent with either EC death or endothelial injury that induces 
loss of their characteristic epitopes. These findings are consistent with experimental models 
of acute ischemic renal endothelial injury after reperfusion,7;29;30 and recently observed in 
humans as well.31-34 EC activation represents a switch from a quiescent phenotype toward 
one that is involved in the host defense response. This process will result in expression 
of chemokines, cytokines, angiogenic factors and adhesion molecules designed to interact 
with leukocytes and platelets and target inflammation. In our previous study in human 
living donor kidney transplantation no evidence for EC activation was found by absence of 
local release of ICAM-1, P-selectin and vWf.23 However, the angiopoietins and endothelial/
pericyte interactions were not studied. 
Angiopoietins have been shown to play a critical role in the maintenance of the 
microvasculature.15 This study focused on the release of these factors from both living and 
deceased donor kidneys. Results show that Ang-1 was not released from the kidney during 
reperfusion in any of the three groups, consistent with the theory that Ang-1 is constitutively 
expressed and dynamic changes in Tie-2 signaling are mediated via Ang-2. Consistent with 
previous reports, Ang-1 protein was found in glomeruli and capillary walls.35 Interestingly, 
we show that Ang-1 mRNA and protein expression decreased after reperfusion in human 
renal I/R injury. In contrast, in rodents Ang-1 expression has been shown to increase after 
chemical or ischemic kidney injury.36;37 However, these observations in experimental animals 
were done days after the injury, in contrast to the immediate changes observed in our 
patients. The loss of Ang-1 signal may indicate loss of vital pericytes, since pericytes are 
the main Ang-1 producing cells. However, decreased Ang-1 protein in renal tissue may also 










































identity, the storage and release of Ang-1 may have the same mechanism as that of Ang-2.38 
Loss of Ang-1 signaling appears important in many disease processes, and enhancement of 
Ang-1 signaling was beneficial in sepsis and renal I/R injury.28;39 
High Ang-2 levels have repeatedly been shown in pathological conditions, such as in diabetes 
mellitus, renal failure and in myocardial I/R injury.40-42 Ang-2 triggers an inflammatory 
response by inducing permeability of the vascular lining,43 possibly mediated by the Ang-2 
induced loss of pericytes.44 Results of this study show a vast Ang-2 release from both living 
and deceased donor kidneys shortly after reperfusion. This indicates injury to ECs, which 
can release Ang-2 from Weibel-Palade bodies upon activation.45 Since expression of Ang-2 
did not change upon reperfusion, the arteriovenous difference may reflect Ang-2 release 
from Weibel-Palade bodies upon stress. This was confirmed by decreased endothelial Ang-
2 tissue biopsy staining after reperfusion, consistent with exocytosis of Ang-2 containing 
granulae. In contrast to Ang-1, there was no expression of Ang-2 in the glomeruli, and 
positive signal was mainly seen on peritubular capillaries.35 The Ang-2 release from the 
kidney may induce continuing endothelial damage, ultimately leading to pericyte dropout, 
loosening contacts between endothelial and perivascular cells, with subsequent vessel 
destabilization and fibrosis. 
In our arteriovenous measurements directly over the reperfused graft no release of vWf itself 
or its propeptide was observed, while Ang-2, another constituent of Weibel-Palade bodies 
was released. Possible explanations include that Ang-2 may be more easily detectable by 
arteriovenous measurements due to a shorter half-life, or that Ang-2 release from Weibel-
Palade bodies is regulated independent from vWf release.46 Moreover, when vWf multimers 
are secreted from stimulated ECs they may remain anchored to the endothelial surface.47 
This early retention of vWf to endothelium may provide a further explanation for the lack 
of a detectable release of vWf into the renal vein. 
A limitation of our study was the fact that sampling time was restricted to maximally 45 
minutes following reperfusion. Although endothelial damage is considered to be initiated 
during cold ischemia and expected to be vast around reperfusion, we cannot exclude 
continuing damage after 45 minutes. Another limitation is that we had to include different 
patient cohorts for arteriovenous measurements and collection of biopsies. Since for 
ethical reasons from every patient only one biopsy could be obtained, either DNA isolation 
or immunohistochemistry was done. Although one cohort for all sampling may have been 
preferable, our sampling is not expected to have influenced the conclusions from this study, 
since no correlations with patient characteristics are made. The aim of this study was to 












































future studies correlations between patient characteristics and angiopoietin release will be 
made.
In conclusion, human renal I/R injury induces EC activation after reperfusion which leads to 
Ang-2 release from the kidney in both living and deceased donor kidney transplantation. This 
is accompanied by loss of ECs and diminished Ang-1 protein and mRNA expression. Moreover, 
compared to living donors expression of Ang-1 was significantly reduced in deceased donors. 
Interventions aimed at maintenance of vascular integrity by modulation of angiopoietin 
signaling may provide new therapeutical insights for I/R injury in human clinical kidney 
transplantation.
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Changes in adenosine generating enzymes 
CD39 and CD73 upon reperfusion in 
clinical kidney transplantation
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Ischemia reperfusion (I/R) injury is an inevitable consequence of organ transplantation. 
Its pathophysiology is complex and treatment is primarily supportive. Recent animal 
experiments suggest that extracellular adenosine may be a critical mediator in protection 
from renal I/R injury. However, information on adenosine production in human kidney 
transplantation is lacking. In this study changes in protein and mRNA expression of adenosine 
generating enzymes CD39 and CD73 in transplanted human kidneys are assessed. Results 
show that more CD39 protein is present in living compared to deceased donor kidneys before 
transplantation. CD39 mRNA expression was not different between groups and did not change 
upon reperfusion. However, CD73 mRNA expression was significantly downregulated after 
reperfusion, while its tissue protein expression did not change. Altogether, results show 
that living donor kidneys may be protected by higher pre-transplantation CD39 expression. 
Yet, this effect may be counteracted by the decrease in CD73 expression after reperfusion. 
Further studies will need to focus on the consequences of these enzyme changes for renal 













































Ischemia reperfusion (I/R) injury is an inevitable consequence of organ transplantation, and 
a major determinant of patient and graft survival.1-3 The pathophysiology of I/R injury is 
complex and incompletely understood, and effective treatment is currently lacking. Recent 
animal experiments suggest that adenosine may be a critical mediator in protection from 
renal I/R injury.4;5
Adenosine is a nucleoside, acting as a signaling molecule when present in the extracellular 
space. Extracellular adenosine can be generated by metabolization of adenosine triphosphate 
(ATP) and adenosine diphosphate (ADP) to adenosine through an enzymatic reaction initiated 
by ectonucleoside-triphosphate-diphosphohydrolase-1 (CD39) and completed by the enzyme 
ecto-5’-nucleotidase (CD73) (Figure 1). Hypoxia and ischemia are known to induce CD39 and 
CD73.6;7 Animals genetically modified by CD39 or CD73 deletion experience lower adenosine 
levels during ischemia and a vast increase in I/R induced inflammation and subsequent 
tissue damage in many organs.6-9 Consequently, CD39 overexpression has beneficial effects 
in mouse renal I/R injury.10
Altogether, animal models provide clear evidence for the protective role of CD39 and CD73 
activity in renal I/R injury. In this study, we report on changes in adenosine generation by 
CD39 and CD73 in human clinical renal I/R injury. 
Figure 1: Schematic representation of extracellular adenosine generation from ADP and ATP by the 












































Twenty-three patients receiving a kidney from a living donor (n=10), a brain dead donor 
(n=7) or a cardiac dead donor (n=6) were included for mRNA isolation from renal biopsies 
and subsequent expression analysis. From a different cohort of 10 living, 10 brain dead 
donor and 10 cardiac dead donor kidney graft recipients, renal biopsies were collected 
and processed for immunohistochemical analysis. Patient characteristics are shown in 
Supplemental Table 1. All kidneys were still functioning at 1 year after transplantation, but 
one patient in the mRNA cohort, that received a BDD kidney transplant died 6 months after 
transplantation (because of veno-occlusive disease ultimately causing hepatic failure). The 
study protocol was approved by the local ethics committee, and informed consent was 
obtained from each patient.
Table 1: Transplantation and outcome characteristics of the three different patient cohorts 
that were included. In each cohort material was collected from living donor (LD), brain dead 
donor (BDD) and cardiac dead donor (CDD) grafts during kidney transplantation. 
IHC PCR
LD BDD CDD LD BDD CDD
N 10 10 10 10 7 6
Donor age: mean (SD) 57(10) 48(16) 41(10) 52(8) 45(21) 41(13)
Donor gender (M:F) 5:5 5:5 6:4 2:8 3:4 4:2
WIT1 in min. (SD) N/A N/A 18(5) N/A N/A 18(6)
CIT in h. (SD) 2.8(0.5) 18.6(9.6) 17.8(3.4) 3.0(0.4) 17.4(7.6) 15.6(3.9)
WIT2 in min. (SD) 29(8) 28(4) 28(8) 29(7) 34(3) 28(5)
Recipient age: mean (SD) 54(16) 51(13) 45(15) 49(16) 53(14) 54(9)
Recipient gender (M:F) 4:6 7:3 7:3 6:4 4:3 3:3
CrCl day 30 (ml/min) 45(11) 63(30) 48(21) 56(17) 47(14) 50(8)
DGF 0/10 3/10 7/10 0/10 3/7 4/6
DGF duration in days (SD) 0 5(2) 13(6) 0 3(4) 7(6)
IHC: cohort of patients in which renal biopsies were used for immunohistochemical analysis. 
PCR: cohort of patients from which renal biopsies were used for PCR analysis. 
WIT1: first warm ischemia time. 
CIT: cold ischemia time. 
WIT2: second warm ischemia time.
DGF: delayed graft function.
DGF duration: dialysis after transplantation in days (SD).
CrCl: Creatinine clearance.
Operation and materials
Kidney transplantations were performed according to local standardized protocol. In living 












































kidney, Custodiol® Histidine–tryptophan–ketoglutarate solution (HTK) solution (Tramedico, 
Weesp, The Netherlands) was used. Deceased donor kidneys were perfused and stored with 
University of Wisconsin solution (UW) or HTK. The immunosuppressive regimen was based on 
induction therapy with an interleukin-2 receptor blocker (basiliximab, day 0 and day 4) and 
maintenance treatment with tacrolimus or cyclosporine A, in addition to mycophenolate 
mofetil and steroids in all groups. 
Immunohistochemical analysis
To assess presence of CD39 and CD73, a renal cortical biopsy was obtained after cold storage 
from living, brain dead and cardiac dead donor kidney grafts. Only in the LD group, a second 
cortical biopsy was collected as well at 45 minutes after reperfusion. Immunohistochemical 
analyses were performed on 4 µm cryostat kidney tissue sections. Frozen sections were 
fixed in acetone for 10 min. Slides were washed and incubated with peroxidase blocking 
solution for 30 minutes and blocked with PBS containing 5% normal human serum (NHS) and 
1% BSA for 45 minutes at room temperature. Then slides were incubated overnight at room 
temperature with the following primary antibodies: CD39 mouse monoclonal IgG1, 1:50 
(eBioscience, Vienna, Austria); CD73 mouse monoclonal IgG1, 1:3200 (Hycult Biotechnology, 
Uden, Netherlands). Next, a peroxidase-conjugated goat anti-mouse IgG (1:200) secondary 
antibody was applied (DAKO, Glostrum, Germany), followed by sequential fluorescein 
isothiocyanate (FITC, amplification reagent, NENTM Life Science Products, Boston, MA, 
USA) and anti-fluorescein-HRP (DAKO, Glostrum, Germany). Staining was completed by 
incubation with 3,3’ diaminobenzidine tetrahydrochloride (DAB)/ hydrogen peroxide 
(Sigma, St Louis, MO, USA) and counterstained with Mayer’s Hematoxylin Solution (Merck, 
Darmstadt, Germany). At 100× magnification, 10 microscopic fields of each kidney section 
were quantified using computerized image analysis (ImageJ). 
mRNA expression in human kidney biopsies
A renal cortical biopsy was obtained after cold storage, before transplantation, from living, 
brain dead and cardiac dead donor kidneys. A second, post-reperfusion biopsy was collected 
45 minutes after reperfusion from living donor kidneys only. Biopsies were immediately 
snap frozen in liquid nitrogen and stored at -70ºC. Total RNA was extracted from renal 
tissues using RNAzol (Campro Scientific, Veenendaal, The Netherlands) and glass beads.11 
The integrity of each RNA sample was examined by Agilent Lab-on-a-chip technology using 
the RNA 6000 Nano LabChip kit and a bioanalyzer 2100 (Agilent Technologies, Amstelveen, 
The Netherlands). RNA preparations were considered suitable for further processing if 
samples showed intact 18S and 28S rRNA bands, and displayed no chromosomal peaks or 
RNA degradation products (RNA Integrity Number >8.0).12 cDNA was synthesized from 1 µg 










































and buffers in a volume of 20 µL (all purchased from Invitrogen, Breda, The Netherlands). 
Quantitative real-time PCR was performed in duplicate by using iQ SYBR Green Supermix on 
iCycler Real-Time Detection System (BioRad). The amplification reaction volume was 20 µL, 
consisting of 10 µL iQ SYBR Green PCR mastermix, 1 µL primers, 1 µL cDNA, and 8 µL water. 
Data were analyzed using Gene Expression Analysis for iCycler Real-Time PCR Detection 
System (BioRad). Expression of each gene was normalized against mRNA expression of the 
housekeeping gene GAPDH. The primer sequences are shown in Supplemental Table 2.
Table 2: Primer sequences used for quantitative real-time polymerase chain reaction
Gene Forward primer 5’->3’ Reverse primer 5’->3’ Supplier
CD39 AGCAGCTGAAATATGCTGGC GAGACAGTATCTGCCGAAGTCC Biolegio
CD73 GCAGACATTAACAAATGGAGG CATCCGTGTGTCTCAGGTTG Biolegio
Analysis
Clinical donor data were retrieved from Eurotransplant Foundation (Leiden, The 
Netherlands). Delayed graft function (DGF) was defined as the need for dialysis within one 
week after transplantation. Statistical analysis was performed using SPSS 17.0 statistical 
analysis software (SPSS Inc, Chicago, Ill). Graph error bars represent the standard error 




CD39 staining was positive in peritubular capillaries and in glomeruli. Already before 
transplantation, living donor kidneys had a significantly higher CD39 tissue expression as 
compared to both brain dead (p=0.004), and cardiac dead (p<0.0001) donor kidneys (Figure 
2). After reperfusion, CD39 tissue expression did not change in living donor kidneys (p=0.16). 
CD39 mRNA expression was similar in grafts of all three donor types before transplantation 
(p=0.27). Upon reperfusion CD39 mRNA expression did not change (p=0.49). 
CD73
CD73 signal was positive in endothelial cells and to a lesser extent in tubular epithelial cells. 
Before transplantation, CD73 protein and mRNA expression was equal in renal biopsies of the 
three different donor types (p=0.52, p=0.13, respectively, Figure 3). After reperfusion, CD73 
tissue expression did not change (p=0.20). However, CD73 mRNA expression was significantly 












































Figure 2: CD39 protein levels are higher in living than deceased donor kidneys. 
CD39 staining was positive in peritubular capillaries and in glomeruli. Typical example of CD39 staining 
in A a pre-reperfusion biopsy and B a post-reperfusion biopsy of a LD kidney. C Before transplantation, 
CD39 tissue expression was significantly higher in LD kidneys as compared to BDD (p=0.004) or CDD 
kidneys ( p<0.0001). D Upon reperfusion, there was no change in CD39 protein expression in living 
donor kidneys (p=0.16). The boxes run from the lower to upper quartile, the whiskers indicate the 5 to 
95 percentile, while the horizontal line is set at the median. mRNA expression of CD39 was assessed in 
kidney biopsies. E CD39 mRNA expression was similar before reperfusion in all groups (p=0.27). Similar 
to protein expression, CD39 mRNA expression did not change upon reperfusion in LD, BDD and CDD 










































Figure 3: CD73 mRNA levels decrease after reperfusion.
CD73 staining was positive in endothelial and tubular epithelial cells. Typical example of CD73 staining 
in A a pre-reperfusion biopsy and B a post-reperfusion biopsy of a LD kidney. C Before transplantation, 
CD73 tissue expression was similar in kidneys of all three donor types (p=0.52). D 45 minutes after 
reperfusion, CD73 protein expression had not changed in living donor kidneys (p=0.20). The boxes run 
from the lower to upper quartile, the whiskers indicate the 5 to 95 percentile, while the horizontal 
line is set at the median. mRNA expression of CD39 was assessed in kidney biopsies. E CD73 mRNA 
expression was similar before reperfusion in kidneys of all three donor groups (p=0.13). While CD73 
mRNA expression was massively down regulated after reperfusion (p=0.002) in LD kidneys, BDD kidneys 
showed no significant changes in expression although mean CD73 showed a trend towards decrease 













































I/R injury is a compulsory component of kidney transplantation, and its pathophysiology is 
still unclear. Although animal experiments have suggested protection from renal I/R injury 
by extracellular adenosine, data on adenosine generation in human renal I/R have been 
missing. In this study we show changes in adenosine generation by the enzymes CD39 and 
CD73 in transplanted human kidneys. 
CD39 mediates the first step in the extracellular hydrolysis of ATP and ADP towards 
adenosine. Animal experiments show critical involvement of CD39 in renal I/R injury.10;13 In 
human renal I/R injury, we found no changes in CD39 expression after reperfusion in kidney 
transplantation. However, before transplantation CD39 tissue expression was significantly 
higher in living compared to deceased donor kidneys. This may suggest a protective effect 
of CD39 in living donor kidneys, and a potential beneficial effect of CD39 over expression 
in humans as well. 
CD73 is the enzyme that generates adenosine from AMP in the extracellular space. In contrast 
to CD39, results on the exact role of CD73 in renal I/R injury are conflicting. Although its 
essential role in ischemic preconditioning has been shown,14 others report on a protective 
effect of CD73 deletion mediated by AMP accumulation or by nonenzymatic functions of 
CD73.15-17 Here, we show a vast decrease in CD73 mRNA expression after reperfusion in 
both living and deceased donor kidneys. Since these are the first human data describing 
expression of these enzymes in renal I/R injury, we can only relate our results to previous 
experimental studies. These quite unambiguously show the in vitro upregulation of CD73 
after hypoxia 6 and an increase in CD73 activity after ischemic preconditioning in mice.14 
Although in this study CD39 and CD73 are central, when extrapolating results, it may 
be suggested that extracellular adenosine are involved in human renal I/R injury. In the 
transplantation setting, it is of interest that adenosine has been added to UW preservation 
solution. Although this adenosine appears critical in the beneficial effects of UW solution,18 
the effect of enhanced adenosine generation is probably many times larger, since the in vivo 
effect of adenosine lasts only minutes.19 
In conclusion, we show that expression of adenosine generating enzymes CD39 and CD73 is 
different between living and deceased donor kidneys and changes after reperfusion. Further 
studies are needed to assess the consequences of these enzyme changes for renal adenosine 
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Background: Ischemia/reperfusion (I/R) injury is a common clinical problem. Although 
the pathophysiological mechanisms underlying I/R injury are unclear, oxidative damage is 
considered a key factor in the initiation of I/R injury. Findings from preclinical studies 
consistently show that quenching reactive oxygen and nitrogen species (RONS), thus limiting 
oxidative damage, alleviates I/R injury. Results from clinical intervention studies on the 
other hand are largely inconclusive. In this study, we systematically evaluated the release 
of established biomarkers of oxidative and nitrosative damage during planned I/R of kidney 
and heart in a wide range of clinical conditions.
Results: Sequential arteriovenous concentration differences allowed specific measurements 
over the reperfused organ in time. None of the biomarkers of oxidative and nitrosative 
damage (that is, malondialdehyde, 15(S)-8-iso-prostaglandin F2α, nitrite, nitrate and 
nitrotyrosine) were released upon reperfusion. Cumulative urinary measurements confirmed 
plasma findings. As of these negative findings, we tested for oxidative stress during I/R and 
found activation of the nuclear factor erythroid 2-related factor 2, the master regulator of 
oxidative stress signaling. 
Innovation: This comprehensive, clinical study evaluates the role of RONS in I/R injury in 
two different human organs (kidney and heart). Results show oxidative stress, but do not 
provide evidence for oxidative damage during early reperfusion, thereby challenging the 
prevailing paradigm on RONS-mediated I/R injury. 
Conclusions: Findings from this study suggest that the contribution of oxidative damage 
to human I/R may be less than commonly thought and propose a re-evaluation of the 













































Ischemia/reperfusion injury (I/R) is the paradoxical increase of tissue damage upon 
reperfusion of ischemic tissue. I/R is considered a major contributor to tissue damage in 
multiple clinical situations such as myocardial infarction, stroke and organ transplantation. 
The pathophysiology of I/R injury is complex and incompletely understood, and effective 
treatment is currently lacking. 
Reactive oxygen and nitrogen species (RONS) are considered key initiators of I/R injury. 
Ischemia-related metabolic adaptations and dysregulated mitochondrial homeostasis are 
thought to result in substantial RONS release upon reintroduction of oxygen. This RONS 
overload can overwhelm the endogenous antioxidant system, resulting in oxidative damage. 
This may trigger secondary processes such as a pro-inflammatory response.1-4 
It has long been supposed that antioxidant therapy mitigates I/R injury. The validity of 
this concept has been proven in numerous animal studies, which all clearly demonstrate 
that antioxidant therapy ameliorates I/R injury.5-7 Despite these findings, studies in humans 
consistently fail to show any clinically relevant effect.5, 8-11 The basis for this discrepancy 
between human and animal studies is still unclear, yet it may suggest that the contribution 
of RONS to I/R injury in humans may be less than commonly thought.
In this study, a double approach was used to evaluate the role of RONS in clinical I/R injury. 
First, release of established biomarkers of oxidative damage from the human kidney and 
heart was assessed during planned I/R. By cannulation of the efferent vein, that is, the 
renal vein during kidney transplantation and the coronary sinus during cardiac valve surgery, 
sensitive and organ-specific measurements of net changes in oxidative damage biomarkers 
over the organ were conducted. Next, as none of the biomarkers were released during the 
reperfusion phase, we tested for presence of oxidative stress during early reperfusion, 
which did show activation of nuclear factor erythroid 2-related factor 2 (Nrf2), a critical 
transcription factor in oxidative stress signaling. All together, results from these studies, 
comprising different organs, clinical settings and durations of ischemia, are highly consistent 
and do indicate oxidative stress, but no RONS-related damage during the acute reperfusion 
phase in humans, suggesting that the endogenous antioxidant system is able to cope with 











































Patients and surgical procedures
This prospective observational study involved patients undergoing renal I/R during kidney 
transplantation with living donor (LD) and deceased donor (DD) grafts, and patients 
undergoing myocardial I/R (that is, during cardiac valve surgery) with and without 
preexisting heart failure. The study protocols were approved by the local Ethics Committee, 
and written informed consent was obtained from each patient. 
Kidney transplantation
Twenty-four patients undergoing renal allograft transplantation were included: eight 
patients receiving a kidney from a LD and 16 patients receiving a kidney from a DD (nine 
brain-dead donors and seven cardiac-dead donors). LD and DD kidney transplantations were 
separately analyzed and compared because of large differences in ischemia times, pre-
transplantation graft handling, and clinical outcome between these groups. Within groups 
variability of patient and graft characteristics was small for both donor types, rendering the 
comparison more reliable. LD kidney transplantations allowed for measurements in urine 
produced by the graft directly after reperfusion, providing a more cumulative measure than 
the arteriovenous measurements. 
Kidney transplantations were performed according to the local standardized protocol. For 
technical reasons (renal vein sampling), only patients receiving a left kidney were included. 
In LDs a minimally invasive open nephrectomy was performed. The immunosuppressive 
regimen was based on induction therapy with basiliximab followed by maintenance therapy 
with tacrolimus or cyclosporine A in addition to mycophenolate mofetil and steroids. 
Cardiac valve surgery
Myocardial I/R was studied in patients undergoing cardiac valve surgery with aortic cross-
clamping (that is, cessation of blood flow in the coronary arteries). Twenty-four patients 
scheduled for elective mitral valve annuloplasty with use of cardiopulmonary bypass were 
included: 12 patients with preexisting heart failure and 12 patients without heart failure. 
Heart failure was defined as an inadequate pump function with an echocardiographically 
estimated ejection fraction biplane below 35%12 and the presence of one or more clinical 
symptoms of heart failure (New York Heart Association classification).13 Exclusion criteria 
were perioperative corticosteroid therapy, minimal invasive surgical procedures, emergency 












































Cardiac surgery was performed according to the local standardized protocol. All surgical 
procedures were performed via a midline sternotomy under normothermic cardiopulmonary 
bypass (Jostra Maquet, Maquet, Hirrlingen, Germany) with intermittent potassium-enriched 
antegrade warm-blood cardioplegia. This solution was administered every 15 to 20 minutes 
throughout the entire ischemic period. The cardiopulmonary bypass system was coated 
with a heparin softline coating. No antioxidants or other preservational or therapeutical 
substances were added. 
During cardioplegia-induced cardiac arrest (myocardial ischemia), valve surgery was 
executed. Eventually, the aortic cross-clamp was removed to restore the blood flow through 
the heart (start of reperfusion). 
Arteriovenous measurements
Arterial and venous blood samples were collected directly over the reperfused organ, that 
is, from the afferent and efferent blood vessel. Comparison of multiple biomarkers in 
these samples allowed for accurate and specific assessment of locally ongoing processes in 
the reperfusion phase.14 This method was used to determine the release of biomarkers of 
oxidative damage in both kidney and heart I/R. 
Kidney transplantation
Arterial and renal venous blood samples were obtained as described before.14 Via an 
umbilical vein catheter placed in the renal vein, blood aliquots were sampled at 30 seconds, 
3, 10 and 30 minutes after reperfusion. Paired arterial blood samples were simultaneously 
obtained via the iliac artery at 0, 3, 10 and 30 minutes after reperfusion (Figure 1A). The 
endpoint of sampling was reached 30 minutes after reperfusion by closing the abdominal 
wall. The initial urine produced by the graft in the first 10 minutes after reperfusion was 
collected directly from the graft’s ureter. Control urine was collected from the urethral 
catheter of LDs during the nephrectomy procedure before kidney ischemia was induced. 
All samples were collected in pre-cooled tubes containing ethylenediaminetetraacetic acid 
(EDTA) (BD Vacutainer, Plymouth, UK) and placed on melting ice immediately. Blood and 
urine samples were centrifuged (1.550 g, 20 min, 4ºC) within one hour after collection and 
the derived plasma or supernatant was re-centrifuged (1.550 g, 20 min, 4ºC) to deplete it 
from remaining leukocytes and platelets. Material was aliquoted and stored at -70ºC until 
analysis. 
Cardiac valve surgery
A 5 French indwelling jugular vein catheter (PICC, Arrow International Inc., REF PS-










































cardiac surgery (Figure 1B). As all patients underwent mitral valve surgery using a vertical 
transseptal incision, the coronary sinus could easily be cannulated during the surgical 
procedure. An arterial catheter was routinely placed in the radial artery. Arterial and paired 
myocardial venous blood (coronary sinus) samples were obtained at 0, 15, 30 and 60 minutes 
after reperfusion as described recently.15 All samples were collected in pre-cooled tubes 
containing EDTA (BD Vacutainer, Plymouth, UK) and placed on melting ice immediately. 
Blood samples were centrifuged (1.550 g, 10 min, 4ºC) within one hour after collection 
and the derived plasma was re-centrifuged (10.000 g, 4 min, 4ºC) to obtain leukocyte and 
platelet poor plasma. Aliquots were stored at -70ºC until analysis. 
Figure 1. Schematic representation of the arteriovenous measurements of the kidney and heart. 
The figure shows the position of the arterial and renal venous catheter in the kidney (A), and the 
coronary sinus catheter in the heart (B). 
Biopsy collection
A pre-transplantation renal cortical biopsy was obtained just before transplantation, when 
the graft was still on ice. A paired needle biopsy of the same kidney was collected 45 
minutes after reperfusion. Myocardial biopsies were collected at start of cardioplegia-
induced cardiac arrest and a paired, second biopsy was obtained at the end of the 
ischemic period, just before reperfusion of the heart. Because of technical reasons, a post-
reperfusion biopsy could not be collected since most of the included heart failure patients 
were hemodynamically instable in the early reperfusion phase. Lifting the heart, to take 
a post reperfusion biopsy, was considered unsafe. All biopsies were snap-frozen in liquid 














































To validate the method of arteriovenous measurements and to assess whether there is 
oxygen consumption by the reperfused organ, the oxygen saturation level was assessed in 
arterial as well as venous blood samples of a LD by means of a routinely used validated blood 
gas analyzer. The extent of RONS-mediated damage was evaluated by measuring different 
well established biomarkers of oxidative and nitrosative damage by state of the art stable 
isotope dilution gas chromatography-mass spectrometry (GC-MS) and gas chromatography-
tandem mass spectrometry (GC-MS/MS) methods. Malondialdehyde (MDA) and 15(S)-8-iso-
PGF2α are widely recognized biomarkers of lipid peroxidation.16 In humans, nitrite and 
nitrate are reliable indicators of nitric oxide synthesis and frequently measured breakdown 
products of RONS.16-18 
MDA and total 15(S)-8-iso-prostaglandin F2α (15(S)-8-iso-PGF2α), that is, free and esterified 
15(S)-8-iso-PGF2α, were assessed with an extensively validated GC-MS/MS method as 
described previously.19, 20 In parallel, the thiobarbituric acid-reactive substances (TBARS) 
method was used to detect MDA in plasma as well as in urine samples.21 Free 15(S)-8-
iso-PGF2α in urine was measured by GC-MS/MS.20 Nitrite and nitrate were measured 
simultaneously by GC-MS in plasma and urine aliquots as described elsewhere in detail.19, 
22 The prostaglandin E2 (PGE2) concentration in urine was measured by GC-MS/MS after 
immunoaffinity column chromatography extraction.20 Urinary parameters were corrected 
for creatinine excretion.23 Study samples were analyzed alongside quality control (QC) 
samples as described previously.19, 22, 23 The MDA plasma concentration in the QC samples was 
determined to be 57.3 ± 7.8 nmol/L (mean ± standard deviation (SD), n = 25) corresponding 
to an imprecision (relative SD) of 13.7 %. The total 15(S)-8-iso-PGF2α plasma concentration 
in the QC samples was determined to be 157 ± 6.4 pmol/L (mean ± SD, n = 10) corresponding 
to an imprecision of 4.1%. In the QC samples for plasma nitrite and nitrate (n = 30), 
accuracy and imprecision were 90% to 112% and below 6%, respectively. 3-Nitrotyrosine in 
proteins, a biomarker of nitrosative damage, was measured by ELISA in accordance with 
the manufacturer’s instructions (Biotech nitrotyrosine EIA, Oxis, Portland, Oregon, USA).16
Nrf2/ARE pathway
Nrf2 activation was assessed in whole-cell lysate. Snap-frozen renal biopsies were 
homogenized and whole-cell extracts were prepared according to the manufacturers’ 
instructions (Nuclear extract kit, Active Motif, Carlsbad, CA, USA). Next, activated Nrf2 in 
cell lysates was quantified by DNA-binding ELISA according to the manufacturers’ instructions 
(TransAM Nrf2, Active Motif, Carlsbad, CA, USA). Total RNA was extracted from renal or 
myocardial tissues as described earlier, using glyceraldehyde phosphate dehydrogenase 










































was examined by Agilent Lab-on-a-chip technology using the RNA 6000 Nano LabChip kit and 
a bioanalyzer 2100 (Agilent Technologies, Amstelveen, The Netherlands). RNA preparations 
were considered suitable for array hybridization only if samples showed intact 18S and 
28S rRNA bands, and displayed no chromosomal peaks or RNA degradation products (RNA 
Integrity Number >8.0).25 Subsequent microarray analysis was performed using Illumina 
whole-genome gene expression BeadChips (Illumina BeadArray®, San Diego, CA, USA) 
according to instructions of the manufacturer at Service XS (Leiden, The Netherlands). 
Selected probes from the canonical Nrf2 pathway were used as an input for pathway analysis 
through the Ingenuity Pathway Analysis suite (http://www.ingenuity.com). Hierarchical 
clustering and heatmap visualization were carried out using Hierarchical Clustering Viewer 
and Heatmap Viewer modules within the GenePattern analysis suite.26-28
Histological analyses
In kidney biopsies collected before and after reperfusion, presence of various antioxidant 
enzymes and RONS generation by xanthine oxidase (XO) was assessed. Antioxidant enzymes 
superoxide dismutase (SOD) and peroxidases (catalase and glutathione peroxidase) were 
measured by histochemical methods as described previously in detail.29 The XO activity was 
measured in renal tissue, based on the generation of superoxide anions from hypoxanthine, 
as described earlier.30 Specificity of the assay was demonstrated by inhibition of XO by 
allopurinol. Rat liver tissue was included as positive control. 
Statistical analysis
Statistical analysis was performed with the Statistical Package for the Social Sciences 16.0 
(SPSS Inc., Chicago, IL, USA). All data in the text and tables are expressed as mean ± SD. 
Patient characteristics were compared by paired t-test. The area under the curve (AUC) 
was calculated for the arterial and venous curve. AUC’s and urinary measurements were 
compared by using the Wilcoxon signed rank test. Differential expression of probes was 
assessed using unpaired moderated t-test (LIMMA) through the Remote Analysis Computation 
for gene Expression data (RACE) suite at http://race.unil.ch.31 A P value less than 0.05 was 
considered significant. Graph error bars indicate the standard error of the mean (SEM).
Results
Patient characteristics and outcome
Patient characteristics for kidney transplantation and cardiac valve surgery are summarized 
in Tables 1 and 2, respectively. One-year patient and graft survival was 100% for the patients 
who underwent kidney transplantation. One-year survival was also 100% for all patients who 












































Table 1. Transplantation and outcome characteristics in living donor and deceased donor 
kidney transplantations
LD DD P value
n 8 16
Recipient age (years) mean ± SD 41.1 ± 10.5 54.6 ± 12.2 0.02


























Donor age (years) mean ± SD 43.9 ± 10.6 53.5 ± 16.1 0.14
Donor gender (% male) 75 (n = 6) 44 (n = 7) 0.15














Preservation fluids HTK (n = 8) UW (n = 11)
HTK (n = 5)
0.001
CIT (min) mean ± SD 179.1 ± 18.6 1117.7 ± 299.1 < 0.001
WIT (min) mean ± SD 34.0 ± 6.3 33.5 ± 6.1 0.85
Abbreviations: ADPKD, Autosomal Dominant Polycystic Kidney Disease; BDD, Brain-Dead Donor; BM, 
Basement Membrane; CDD, Cardiac-Dead Donor; CIT, Cold Ischemia Time; DD, Deceased Donor; FSG, 
Focal Segmental Glomerulosclerosis; HTK, Histidine–Tryptophan–Ketoglutarate; LD, Living Donor; MPG, 
Membranous Glomerulonephritis; SAH, Subarachnoid Hemorrhage; UW, University of Wisconsin; WIT, 
Warm Ischemia Time. 
Table 2. Characteristics of patients with and without preexisting heart failure undergoing 
cardiac surgery
Heart failure No heart failure P value
n 12 12
Gender 
     (% male)
75 (n = 9) 42 (n = 5) 0.11
Age (years)
     Mean ± SD
66.75 ± 8.91 62.68 ± 11.65 0.20
Ischemia time (min) 
     Mean ± SD
128.25 ± 50.66 127.00 ± 32.62 0.89
Duration ICU stay (h)*
     Mean ± SD 
62.50 ± 40.75 31.58 ± 23.90 0.02










































Validation of arteriovenous measurements
The methodology of the arteriovenous sampling is schematically shown in Figure 1. The 
principle of the method is illustrated by arterial and venous oxygen saturation levels 
measured during early reperfusion, showing an effective and consistent consumption of 
oxygen (Figure 2).
Figure 2. A typical example of arteriovenous oxygen saturation differences during reperfusion of 
the kidney. 
Arterial and renal venous oxygen saturation was measured during the first 30 minutes of reperfusion. 
The consistently lower venous oxygen saturation level indicates the uptake of oxygen by the reperfused 
kidney, demonstrating its immediate metabolic activity.   
Biomarkers of oxidative damage 
Renal I/R is not associated with oxidative damage 
MDA and 15(S)-8-iso-PGF2α were measured as established biomarkers of RONS-mediated 
damage. Arteriovenous measurements of MDA did not indicate its release from the kidney 
during the first 30 minutes of reperfusion of LD kidneys by either GC-MS (P = 0.17; Figure 
3) or TBARS method (P = 0.06). Urinary MDA levels (TBARS method) were also assessed in 
the first urine produced immediately after reperfusion (LDs only) as an aggregate measure 
of total MDA formation in the kidney. The MDA levels in this first urine collected after 
reperfusion were similar to the control urine, that is, urine produced by the kidney before 












































Figure 3. Arterial and venous plasma concentrations of MDA.
(A) Arterial and renal venous plasma MDA concentrations during the first 30 minutes of reperfusion in 
living donor kidney transplantation as determined by GC-MS/MS showed no MDA release (p = 0.17); (B) 
No MDA release was observed when determined by TBARS method either (p = 0.06); (C) Arterial and 
myocardial venous plasma MDA concentrations during the first 60 minutes of reperfusion in patients 
with preexisting heart failure showed no release from the myocardium (p = 0.05). In fact, venous MDA 
levels tended to be lower than the arterial levels in patients with preexisting heart failure; (D) In 
patients without preexisting heart failure MDA was not released either (p = 0.43).
Minimal release was observed for 15(S)-8-iso-PGF2α from reperfused LD kidney grafts (P = 
0.03). However, clinically more vulnerable DD kidneys did not show any 15(S)-8-iso-PGF2α 
release upon reperfusion (P = 0.16; Figure 4). Arteriovenous measurements over the non-
ischemic kidney in LDs, that is, before donor nephrectomy, revealed no release of 15(S)-
8-iso-PGF2α (P = 0.69), demonstrating that its post-reperfusion release is specific for I/R. 
Urinary 15(S)-8-iso-PGF2α levels were not influenced by reperfusion (P = 0.35; Table 3). 
Urinary PGE2 was measured as marker of cyclooxygenase-2 (COX-2) activity. PGE2 levels in 
the first urine collected after reperfusion were higher than those of the control urine, that 
is, urine produced by the kidney prior to its removal from the donor (P = 0.02; Figure 5). 
This shows that in contrast to the absence of apparent oxidative damage, oxidative stress 










































Figure 4. Arterial and venous plasma concentrations of 15(S)-8-iso-prostaglandin F2α.
(A) Arterial and renal venous plasma 15(S)-8-iso-PGF2α concentrations during the first 30 minutes of 
reperfusion in living donor (LD) kidney transplantation showed a small, but significant release from 
the kidney (P = 0.03); (B) In deceased donor (DD) kidney transplantation, 15(S)-8-iso-PGF2α was not 
released from the reperfused kidney during the first 30 minutes of reperfusion (P = 0.16); (C) Arterial and 
myocardial venous plasma 15(S)-8-iso-PGF2α concentrations during the first 60 minutes of reperfusion 
in patients with preexisting heart failure showed a small, but significant release from the myocardium 
(P = 0.02); (D) In patients without preexisting heart failure, 15(S)-8-iso-PGF2α was not released from 












































Table 3. AUC venous minus AUC arterial (delta AUC) of the measured plasma biomarkers for 
oxidative and nitrosative damage during the early reperfusion phase.
Kidney transplantation Cardiac valve surgery

























Nitrosative stress and damage
Nitrite (nmol/L×min)































* Delta AUC: AUC venous minus AUC arterial (P value) of the measured plasma markers during the early 
reperfusion phase. A positive number indicates a release from the reperfused organ, whereas a negative 
number indicates an uptake of the biomarker. 
† Results in urine indicate P values of the difference of the pre- and post reperfusion measure. 
‡ Significant venous release (P < 0.05).
Abbreviation: AUC, area under the curve.
Figure 5. Prostaglandin E2 excretion in urine. 
Creatinine-corrected levels of prostaglandin E2 (PGE2) in the first urine collected after reperfusion 
(post) were higher than those of control urine (pre), that is, urine produced by the kidney before its 










































Myocardial I/R is not associated with oxidative damage
Results of myocardial I/R resembled those of the kidney. There was no myocardial MDA 
release during the first hour after reperfusion in both patients with and without heart 
failure (P = 0.05 and P = 0.43, respectively; Table 3, Figure 3). In fact, venous MDA levels 
tended to be lower than arterial levels in patients with preexisting heart failure. 15(S)-8-
iso-PGF2α showed a small local release early after reperfusion in patients with preexisting 
heart failure (P = 0.02; Figure 3). In contrast, arteriovenous measurements of 15(S)-8-iso-
PGF2α in patients without preexisting heart failure did not indicate a local release during 
the first hour after reperfusion (P = 0.18; Table 3).
Figure 6. Arterial and venous plasma concentrations of nitrite.
(A) Arterial and renal venous plasma nitrite concentrations during the first 30 minutes of reperfusion 
in living donor kidney transplantation showed no release from the kidney (p = 0.50); (B) In deceased 
donor kidney transplantation nitrite was not released either during the first 30 minutes of reperfusion 
(p = 0.87); (C) Arterial and myocardial venous plasma nitrite concentrations during the first 60 minutes 
of reperfusion in patients with preexisting heart failure showed no myocardial release. However, a 
myocardial uptake was observed (p = 0.002); (D) Similarly, in patients without preexisting heart failure 












































Biomarkers of nitrosative damage
No evidence for nitrosative damage in human kidney transplantation
Nitrite concentrations were equal in renal arterial and venous blood samples (LDs P = 0.50, 
DDs P = 0.87; Figure 6). Likewise, nitrate was not released from the reperfused graft either 
(LDs P = 0.50, DDs P = 0.98; Figure 7). These findings were confirmed by the additional 
measurement of plasma nitrotyrosine in LD kidney grafts, indicating no such release (P = 
0.93, Figure 8). The integral urinary measurement of nitrite and nitrate remained similar 
after reperfusion in LD kidney transplantations (P = 0.06, P = 0.69 respectively; Table 3). 
Figure 7. Arterial and venous plasma concentrations of nitrate.
(A) Arterial and renal venous plasma nitrate concentrations during the first 30 minutes of reperfusion 
in living donor kidney transplantation showed no release from the kidney (p = 0.50); (B) In deceased 
donor kidney transplantation nitrate was not released either during the first 30 minutes of reperfusion 
(p = 0.98); (C) Arterial and myocardial venous plasma nitrate concentrations during the first 60 minutes 
of reperfusion in patients with preexisting heart failure showed no myocardial release (p = 0.53); (D) 











































Figure 8. Arterial and venous plasma concentrations of nitrotyrosine.
These was no release of nitrotyrosine from living donor kidney grafts during early reperfusion (p = 0.93).
No evidence for nitrosative damage after reperfusion of the myocardium
Arterial nitrite concentrations were higher than venous concentrations in both patient 
groups during the early reperfusion phase (P = 0.002 preexisting heart failure, P = 0.03 no 
preexisting heart failure; Figure 6), excluding myocardial nitrite release. Nitrate did not 
change over the reperfused myocardium in both patient groups (P = 0.53 preexisting heart 
failure, P = 0.81 no preexisting heart failure; Table 3, Figure 7).
Oxidative stress
Kidney
Since the above-mentioned results indicated no extracellular evidence for RONS-mediated 
damage, we tested for the occurrence of oxidative stress during I/R by assessing activation 
of Nrf2, the master regulator of the antioxidant stress response. Activation of Nrf2 was 
quantified, as well as the upregulation of Nrf2 responsive genes, heme oxygenase-1 (HMOX-
1), NAD(P)H quinone oxidoreductase (NQO1), and glutathione S-transferase A2 (GSTA2) 
in pre- and post biopsies collected from both kidney and heart (Figure 9). Using a DNA 
binding ELISA for activated Nrf2, we found clear activation of this transcription factor upon 
reperfusion (P = 0.01; Figure 10), while Nrf2 gene expression increased as well in both LD 
and DD kidney grafts (P = 0.03, P = 0.04 respectively; Figure 11). Pathway-based analysis 
of Nrf2 downstream genes (Ingenuity Pathway Analysis suite, Figure 12) showed highly 
significant (P = 7.06*10-12) upregulation of the cannonical antioxidant responsive element 












































Figure 9. Schematic representation of the nuclear factor erythroid 2-related factor 2 / antioxidant 
responsive element pathway and antioxidant responsive element induced gene expression. 
Environmental stress exerts oxidative stress on cells through production of reactive oxygen and 
nitrogen species (RONS). The oxidative stress response is largely coordinated by a transcription factor, 
nuclear factor erythroid 2-related factor 2 (Nrf2). Under homeostatic conditions, there is only an 
inactive minimal basal level of Nrf2-directed gene expression under tight control of protein Keap 1. 
RONS lead to the activation of mitogen-activated protein kinases (such as MAPK, ERK, p38), protein 
kinase C (PKC), phosphatidylinositol 3 kinase (PI3K), and others, which phosphorylate Keap1 and Nrf2. 
The Keap1-Nrf2 complex is then disrupted and the transcriptionally active Nrf2 is translocated to the 
nucleus where it binds to antioxidant responsive elements (AREs) in association with Maf proteins. This 
results in an increase of the transcriptional expression of Nrf2-inducible genes such as those encoding 
heme oxygenase-1 (HMOX1), NAD(P)H quinone oxidoreductase (NQO1), and glutathione S-transferase 
A2 (GSTA2). Together, these proteins scavenge RONS and limit oxidative damage. 
Figure 10. Nuclear factor erythroid 2-related factor 2 activation upon renal reperfusion.
Nuclear factor erythroid 2-related factor 2 (Nrf2) in renal tissue was significantly converted to its 










































Figure 11. Changes in renal expression of nuclear factor erythroid 2-related factor 2 gene.
Renal expression of nuclear factor erythroid 2-related factor 2 (Nrf2) gene in biopsies collected before 
(pre) and 45 minutes after (post) reperfusion during living donor (LD) and deceased donor (DD) kidney 
transplantation. Y-axis shows the relative change in gene expression as calculated by log(1/2ddCt), where 
the dCt is the Ct of studied gene minus the Ct of GAPDH, and ddCt is dCt of post-biopsy minus dCt of 
pre-biopsy. A positive number indicates an increase in expression after reperfusion, whereas a negative 
number indicates a downregulation after reperfusion. Expression of the transcription factor Nrf2 gene 
NFE2L2 was significantly upregulated after reperfusion in both LD (P = 0.03) and DD (P = 0.04) kidney 
grafts. 
Conversion of xanthine reductase to XO and accumulation of hypoxanthine during ischemia 
has been proposed as a major source of oxygen radicals during I/R injury. Histochemical 
analysis of kidney biopsies collected before and after reperfusion did not indicate the 
XO activity in renal tissue, whereas ample XO activity and abundant hypoxanthine were 












































Figure 12. Nrf2 downstream genes.
Pathway-based analysis of Nrf2 downstream genes showed highly significant upregulation of the 










































Figure 13. Xanthine oxidase activity.
Histochemical analysis showing minimal xanthine oxidase activity in pre and post perfusion kidney 
biopsies. Liver biopsies showing xanthine oxidase activity in the presence (left) and absence of 
hypoxanthine (middle) are included as a positive control. Staining in the absence of hypoxanthine 
implies endogenous hypoxanthine. Specificity of the analysis is shown by including the xanthine oxidase 
inhibitor allopurinol (right). 
Antioxidant enzyme activities
SOD and peroxidase activities (catalase and glutathione peroxidase) were evaluated by 
histochemical analyses of kidney biopsies taken before and 45 minutes after reperfusion. 
Results of this analysis show abundant and similar antioxidant activities before and after 












































Figure 14. Endogenous antioxidant enzymes. 
Histochemical analysis showing the endogenous antioxidant enzyme systems superoxide dismutase, and 
peroxidases (catalase and gluthathione peroxidase) are active in pre and post perfusion kidney biopsies.
Discussion
Oxidative damage is long considered a key factor in the initiation of I/R injury. Although 
animal studies repeatedly showed the involvement of free radicals in I/R injury, studies 
in humans are scarce, and results of clinical intervention studies using antioxidants are 
inconclusive. Our study shows minimal release of markers of oxidative and nitrosative 
damage, and did not indicate upregulation of the classical oxidative response genes in both 
heart and kidney I/R. Results of our study are highly consistent and suggest that the role 
of oxidative and nitrosative damage in the initiation of clinical I/R injury may be less than 
commonly thought. 
RONS have long been held responsible for the initiation and propagation of I/R injury in 
many different tissue types, including the kidney, liver, and heart.32 Initial studies date 










































reperfusion of rat kidneys.33 Since then, further animal studies have supported a role for 
oxidative damage in I/R.34-36 In contrast, studies in humans are scarce and findings are 
inconclusive. In a clinical study of Grech et al, it was confirmed that RONS are formed after 
I/R.37 By using direct spin trapping methods, they demonstrated an immediate free radical 
production during the first four hours after myocardial reperfusion. However, whether RONS 
actually lead to tissue damage was not studied. Further studies on oxidative damage in 
I/R injury in humans show conflicting results. Zahmatkesh et al. showed that after kidney 
transplantation circulating lipid peroxidation biomarkers rise in peripheral blood.38 Whether 
this can be attributed to oxidative damage in the kidney itself or in any other part of the body 
can not be distinguished by peripheral measurements. Some studies involving myocardial 
I/R used more specific methods, that is, arteriovenous measurements over the reperfused 
heart, after percutaneous transluminal coronary angioplasty (PTCA). F2-isoprostanes were 
released from the reperfused myocardium after PTCA.39, 40 However, results on MDA release 
were contradictory, showing no myocardial release after PTCA 41 and low extent MDA release 
during coronary artery bypass grafting.42 
Although available antioxidant intervention studies are limited and results are inconclusive, 
antioxidant treatment appears a potential therapy to study in humans. Somehow, only 
few trials using antioxidants in human I/R injury are known, and it seems reasonable that 
a certain amount of publication bias has been introduced. El-Hamamsy et al. showed 
that administration of the antioxidant N-acetylcysteine around human coronary artery 
bypass surgery did not lead to improvement in clinical endpoints or decreased release 
of biochemical markers.10 Administration of tirilazad mesylate, a nonglucocorticoid 
21-aminosteroid inhibiting lipid peroxidation, to patients with acute ischemic stroke even 
increased the end-point of death instead of having beneficial effects.8 In kidney I/R only 
two clinical trials have been published using antioxidants in renal transplantation. Pollak et 
al. administered SOD intravenously before and one hour after reperfusion, but no beneficial 
effects were observed with respect to early graft function.43 One year later, Land et al. 
administered a single, higher intravenous dose of SOD, immediately before reperfusion. The 
results demonstrated a significant reduction in first acute rejection.44 However, up to now, 
none of both observations have been confirmed in other studies or have led to application 
in daily practice. 
Thus, despite encouraging results of antioxidant I/R therapy in animals, published clinical 
studies lack an appreciable, clinically relevant effect thus far.5, 8-11 Let alone minor differences 
in clinical set up, there appears to be a mechanistic disparity in the role of oxidative 
damage and endogenous antioxidant capacity in I/R injury between animals and humans. 












































with large mass-specific metabolic rate, such as mice, have a relative high RONS production 
and a weak capacity to maintain homeostasis compared with humans.45 This difference in 
homeostatic capacity may explain differences in the role of oxidative damage between 
species as well. Thus, it can be suggested that endogenous antioxidant systems in humans 
are sufficiently equipped to handle the excess RONS load during clinical reperfusion, thus 
preventing damage. A finding that is supported by abundant SOD and peroxidases activities 
before and after I/R. 
Whether oxidative damage is indeed prevented in human I/R injury was assessed in this 
study. RONS have a transient nature and are difficult to assess in vitro and in vivo.22 
Consequently, we measured more stable oxidation products caused by RONS to determine 
the extent of oxidative damage in I/R injury. By combining multiple biomarkers, a footprint 
of oxidative and nitrosative damage could be reconstructed. Arteriovenous concentration 
differences of various established oxidative and nitrosative damage biomarkers were 
sequentially measured during reperfusion in kidney transplantation. To exclude organ- and 
procedure-specific findings, kidney results were compared with a different clinical setting, 
that is, myocardial I/R. 
Arteriovenous measurements did not indicate release of oxidative or nitrosative damage 
biomarkers upon reperfusion of both the kidney and heart with the sole exception of a 
minimal and transient release of 15(S)-8-iso-PGF2α in a selection of patients. Although 
the arteriovenous measurements provide important information on local processes in the 
reperfused organ, sensitivity may be restricted by dilution of released biomarkers because 
of high flow rates. Therefore, accumulation of oxidative damage markers was measured 
in urine produced by the transplanted kidney (LD) during the first minutes of reperfusion. 
Urinary measurements were in accordance to plasma findings, showing no release of 
oxidative or nitrosative damage biomarkers, including 15(S)-8-iso-PGF2α. 
In the absence of other markers, it can be questioned whether venous 15(S)-8-iso-PGF2α 
release observed in subgroups of patients in this study reflects oxidative damage or 
alternatively reflects activation of inflammatory pathways. Since all other markers refute 
oxidative damage, it is highly unlikely that 15(S)-8-iso-PGF2α is the sole reflection of 
oxidative damage. Altogether, the multiple biomarkers of oxidative and nitrosative damage 
showed no consistent release upon reperfusion, denying RONS-mediated tissue damage. 
Absence of venous release of oxidative and nitrosative damage markers may suggest that 
oxidative and nitrosative stress during I/R is less pronounced than commonly thought or may 










































defense pathways, in a DNA-binding ELISA that exclusively measures the activated form 
of this transcription factor. Moreover, the activation of the conical downstream pathway 
of Nrf2 was evaluated through pathway analysis. Clear increases in Nrf2 activation and its 
downstream pathway show that oxidative stress does occur during I/R. 
Evaluation of the XO activity, an often referred source of oxygen radicals in I/R injury, did 
not indicate XO activity in human kidney, although abundant XO was found in rat liver. 
These observations are in line with previous reports showing abundant XO activities in 
rodent tissue but not in human tissue.46 XO therefore appears not to be a prominent source 
of RONS generation in human tissue. 
Limitations 
This is a clinical study, and as such, procedures and timing were dictated by the operative 
procedures. We did include two clinically distinct situations of I/R to identify universal 
mechanisms of free radical-mediated damage after reperfusion. In human kidney 
transplantation, I/R included extremes in both short and long cold ischemia duration, the 
use of antioxidant preservation fluids, corticosteroids, and other immunosuppressive drugs. 
In cardiac surgery, I/R involved a normothermic ischemic period, and no antioxidants, 
corticosteroids, or other immunosuppressive drugs were administered. Throughout this 
whole spectrum of clinical conditions, independent of antioxidant use or immunosuppression, 
results unequivocally showed no dominant role of oxidative and nitrosative damage in 
human I/R injury. 
Sampling in our study was restricted to less than an hour post-reperfusion. This time window 
should be adequate as it is generally assumed that I/R injury is an acute process, initiated 
directly after reperfusion.18 This notion is supported by spin trap experiments indicating 
free radical formation within 15 minutes after reperfusion.37 Yet, we can not exclude that 
I/R injury is less acute than commonly thought and that oxidative damage occurs after an 
hour of reperfusion. 
A second limitation of the study is that it largely relies on repetitive measurement of 
arteriovenous concentration differences. Although this methodology has the advantage of 
specificity, and has been proven effective in elaborating the inflammatory response after 
I/R.14, 47 the high flow rates over the organs may compromise the sensitivity. To compensate 
for this limitation, we considered an evaluation of the first urine produced after I/R and 












































In conclusion, the findings from this study do not indicate a dominant role for RONS-induced 
damage in the pathophysiology of early I/R injury. The production of RONS during I/R is 
explicitly not questioned by our findings. In fact, Nrf2 activation and the higher PGE2 levels in 
post-transplantation urine indicate increased COX activity after reperfusion, suggesting that 
oxidative stress does occur during early reperfusion. Yet, the generated RONS apparently do 
not induce tissue damage in human I/R. These observations suggest an efficient antioxidant 
system, providing an explanation for the limited efficacy of antioxidant therapy in human 
I/R. Altogether, this study challenges the prevailing paradigm of prominent involvement of 
oxidative damage in the initiation of human I/R injury. 
Innovation
I/R injury is a common clinical problem, complicating myocardial infarction, cardiovascular 
surgery, and organ transplantation. As such, it is of great importance to unravel the exact 
pathophysiological mechanisms leading to I/R injury. This comprehensive clinical study 
systematically assessed the putative role of oxidative stress in human I/R injury in two 
diverse clinical settings. Findings for all biomarkers studied were highly consistent and 
did not indicate release of markers of oxidative damage from the reperfused organs nor 
did we observe upregulation of redox-response genes. As such, this study questions the 
involvement of RONS in the pathophysiology of I/R injury in humans.
Acknowledgements
We thank Lars Verschuren for his help with the pathway analysis. Manon Zuurmond and 
Gerrit Kracht are gratefully acknowledged for providing, respectively, the image in Figure 1 
and Figure 4. Frank-Mathias Gutzki is thanked for performing GC-MS and GC-MS/MS analyses. 











































 1.  Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur 
M, Telser J. Free radicals and antioxidants 
in normal physiological functions and human 
disease. Int J Biochem Cell Biol 2007;39:44-84.
 2.  Misra MK, Sarwat M, Bhakuni P, Tuteja R, Tuteja 
N. Oxidative stress and ischemic myocardial 
syndromes. Med Sci Monit 2009;15:209-219.
 3.  Gourdin MJ, Bree B, De Kock M. The impact of 
ischaemia-reperfusion on the blood vessel. Eur 
J Anaesthesiol 2009;26:537-547.
 4.  Crimi E, Sica V, Williams-Ignarro S, Zhang H, 
Slutsky AS, Ignarro LJ, Napoli C. The role of 
oxidative stress in adult critical care. Free 
Radic Biol Med 2006;40:398-406.
 5.  Yellon DM, Hausenloy DJ. Mechanisms of 
disease: Myocardial reperfusion injury. N Engl J 
Med;357:1121-1135.
 6.  Lakhan SE, Kirchgessner A, Hofer M. 
Inflammatory mechanisms in ischemic 
stroke: therapeutic approaches. J Transl Med 
2009;7:97-107.
 7.  Ambrosio G, Flaherty JT, Duilio C, Tritto I, 
Santoro G, Elia PP, Condorelli M, Chiariello 
M. et al. Oxygen radicals generated at reflow 
induce peroxidation of membrane lipids in 
reperfused hearts. J Clin Invest 1991;87:2056-
2066.
 8.  Bath PM, Iddenden R, Bath FJ, Orgogozo JM. 
Tirilazad for acute ischaemic stroke. Cochrane 
Database Syst Rev 2001;4:CD002087.
 9.  Suzuki K. Anti-oxidants for therapeutic use: 
why are only a few drugs in clinical use? Adv 
Drug Deliv Rev 2009;61:287-289.
 10.  El-Hamamsy I, Stevens LM, Carrier M, 
Pellerin M, Bouchard D, Demers P, Cartier 
R, Page P, Perrault LP. Effect of intravenous 
N-acetylcysteine on outcomes after coronary 
artery bypass surgery: a randomized, double-
blind, placebo-controlled clinical trial. J Thorac 
Cardiovasc Surg 2007;133:7-12.
 11.  Land W, Zweler JL. Prevention of reperfusion-
induced, free radical-mediated acute 
endothelial injury by superoxide dismutase as 
an effective tool to delay/prevent chronic renal 
allograft failure: a review. Transplant Proc 
1997;29:2567-2568.
 12.  Hoffmann R, von Bardeleben S, ten Cate F, 
Borges AC, Kasprzak J, Firschke C, Lafitte S, 
Al-Saadi N, Kuntz-Hehner S, Engelhardt M, 
Becher H, Vanoverschelde JL. Assessment of 
systolic left ventricular function: a multi-centre 
comparison of cineventriculography, cardiac 
magnetic resonance imaging, unenhanced and 
contrast-enhanced echocardiography. Eur Heart 
J 2005;26:607-616.
 13.  Dickstein K, Cohen-Solal A, Filippatos G, 
McMurray JJ, Ponikowski P, Poole-Wilson 
PA, Stromberg A, van Veldhuisen DJ, Atar D, 
Hoes AW, Keren A, Mebazaa A, Nieminen M, 
Priori SG, Swedberg K. ESC guidelines for the 
diagnosis and treatment of acute and chronic 
heart failure 2008: the Task Force for the 
diagnosis and treatment of acute and chronic 
heart failure 2008 of the European Society of 
Cardiology. Developed in collaboration with the 
Heart Failure Association of the ESC (HFA) and 
endorsed by the European Society of Intensive 
Care Medicine (ESICM). Eur J Heart Fail 
2008;10:933-989.
 14.  de Vries DK, Lindeman JH, Tsikas D, de Heer 
E, Roos A, de Fijter JW, Baranski AG, van Pelt 
J, Schaapherder AF. Early renal ischemia-
reperfusion injury in humans is dominated by 
IL-6 release from the allograft. Am J Transplant 
2009;9:1574-1584.
 15.  Kortekaas KA, Lindeman JH, Versteegh MI, 
van Beelen E, Kleemann R, Klautz RJ. Heart 
failure determines the myocardial inflammatory 
response to injury. Eur J Heart Fail 2012; doi: 
10.1093/eurjhf/hfs183.
 16.  Giustarini D, le-Donne I, Tsikas D, Rossi 
R. Oxidative stress and human diseases: 
Origin, link, measurement, mechanisms, and 
biomarkers. Crit Rev Clin Lab Sci 2009;46:241-
281.
 17.  Tsikas D. A critical review and discussion of 
analytical methods in the L-arginine/nitric 
oxide area of basic and clinical research. Anal 
Biochem 2008;379:139-163.
 18.  Halliwell B and Gutteridge JMC. Free radicals 
in biology and medicine. 3rd Edition ed. Oxford 
Science Publications; 2004, pp. 645-661.
 19.  Tsikas D. Simultaneous derivatization and 
quantification of the nitric oxide metabolites 












































chromatography/mass spectrometry. Anal Chem 
2000;72:4064-4072.
 20.  Tsikas D, Schwedhelm E, Suchy MT, Niemann 
J, Gutzki FM, Erpenbeck VJ, Hohlfeld JM, 
Surdacki A, Frolich JC. Divergence in urinary 
8-iso-PGF(2alpha) (iPF(2alpha)-III, 15-F(2t)-
IsoP) levels from gas chromatography-tandem 
mass spectrometry quantification after thin-
layer chromatography and immunoaffinity 
column chromatography reveals heterogeneity 
of 8-iso-PGF(2alpha). Possible methodological, 
mechanistic and clinical implications. J 
Chromatogr B Analyt Technol Biomed Life Sci 
2003;794:237-255.
 21.  Londero D, Lo GP. Automated high-
performance liquid chromatographic separation 
with spectrofluorometric detection of a 
malondialdehyde-thiobarbituric acid adduct in 
plasma. J Chromatogr A 1996;729:207-210.
 22.  Dreissigacker U, Suchy MT, Maassen N, 
Tsikas D. Human plasma concentrations of 
malondialdehyde (MDA) and the F2-isoprostane 
15(S)-8-iso-PGF(2alpha) may be markedly 
compromised by hemolysis: evidence by GC-
MS/MS and potential analytical and biological 
ramifications. Clin Biochem 2010;43:159-167.
 23.  Tsikas D, Wolf A, Mitschke A, Gutzki FM, Will W, 
Bader M. GC-MS determination of creatinine in 
human biological fluids as pentafluorobenzyl 
derivative in clinical studies and biomonitoring: 
Inter-laboratory comparison in urine with Jaffe, 
HPLC and enzymatic assays. J Chromatogr B 
Analyt Technol Biomed Life Sci 2010;878:2582-
2592.
 24.  Abdul-Hussien H, Soekhoe RG, Weber E, Von der 
Thusen JH, Kleemann R, Mulder A, Van Bockel 
JH, Hanemaaijer R, Lindeman JH. Collagen 
degradation in the abdominal aneurysm: 
a conspiracy of matrix metalloproteinase 
and cysteine collagenases. Am J Pathol 
2007;170:809-817.
 25.  Kleemann R, Verschuren L, van Erk MJ, 
Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, 
Hendriks HF, Zadelaar S, Smith GJ, Kaznacheev 
V, Nikolskaya T, Melnikov A, Hurt-Camejo E, 
van der Greef J, van Ommen B, Kooistra T. 
Atherosclerosis and liver inflammation induced 
by increased dietary cholesterol intake: a 
combined transcriptomics and metabolomics 
analysis. Genome Biol 2007;8:200-216.
 26.  de Hoon MJ, Imoto S, Nolan J, Miyano S. Open 
source clustering software. Bioinformatics 
2004;20:1453-1454.
 27.  Eisen MB, Spellman PT, Brown PO, Botstein D. 
Cluster analysis and display of genome-wide 
expression patterns. Proc Natl Acad Sci U S A 
1998;95:14863-14868.
 28.  Reich M, Liefeld T, Gould J, Lerner J, Tamayo 
P, Mesirov JP. GenePattern 2.0. Nat Genet 
2006;38:500-501.
 29.  Frederiks WM, Bosch KS. Localization of 
superoxide dismutase activity in rat tissues. 
Free Radic Biol Med 1997;22:241-248.
 30.  Kooij A, Frederiks WM, Gossrau R, Van Noorden 
CJ. Localization of xanthine oxidoreductase 
activity using the tissue protectant polyvinyl 
alcohol and final electron acceptor Tetranitro 
BT. J Histochem Cytochem 1991;39:87-93.
 31.  Psarros M, Heber S, Sick M, Thoppae G, 
Harshman K, Sick B. RACE: Remote Analysis 
Computation for gene Expression data. Nucleic 
Acids Res 2005;33:638-643.
 32.  McCord JM. Oxygen-derived free radicals 
in postischemic tissue injury. N Engl J Med 
1985;312:159-163.
 33.  Paller MS, Hoidal JR, Ferris TF. Oxygen free 
radicals in ischemic acute renal failure in the 
rat. J Clin Invest 1984;74:1156-1164.
 34.  Schneider MP, Sullivan JC, Wach PF, Boesen 
EI, Yamamoto T, Fukai T, Harrison DG, Pollock 
DM, Pollock JS. Protective role of extracellular 
superoxide dismutase in renal ischemia/
reperfusion injury. Kidney Int 2010;78:374-381.
 35.  Nath KA, Paller MS. Dietary deficiency of 
antioxidants exacerbates ischemic injury in the 
rat kidney. Kidney Int 1990;38:1109-1117.
 36.  Weight SC, Furness PN, Nicholson ML. Nitric 
oxide generation is increased in experimental 
renal warm ischaemia-reperfusion injury. Br J 
Surg 1998;85:1663-1668.
 37.  Grech ED, Dodd NJ, Jackson MJ, Morrison 
WL, Faragher EB, Ramsdale DR. Evidence 
for free radical generation after primary 
percutaneous transluminal coronary angioplasty 
recanalization in acute myocardial infarction. 
Am J Cardiol 1996;77:122-127.
 38.  Zahmatkesh M, Kadkhodaee M, Mahdavi-
Mazdeh M, Ghaznavi R, Hemati M, Seifi B, 
Golab F, Hasani K, Lessan-Pezeshki M, Einollahi 
B. Oxidative stress status in renal transplant 










































 39.  Iuliano L, Pratico D, Greco C, Mangieri E, 
Scibilia G, FitzGerald GA, Violi F. Angioplasty 
increases coronary sinus F2-isoprostane 
formation: evidence for in vivo oxidative stress 
during PTCA. J Am Coll Cardiol 2001;37:76-80.
 40.  Berg K, Jynge P, Bjerve K, Skarra S, Basu S, 
Wiseth R. Oxidative stress and inflammatory 
response during and following coronary 
interventions for acute myocardial infarction. 
Free Radic Res 2005;39:629-636.
 41.  Cedro K, Marczak E, Czerwosz L, Herbaczynska-
Cedro K, Ruzyllo W. Elective coronary 
angioplasty with 60 s balloon inflation does 
not cause peroxidative injury. Eur J Clin Invest 
2002;32:148-152.
 42.  Lazzarino G, Raatikainen P, Nuutinen M, 
Nissinen J, Tavazzi B, Di Pierro D, Giardina 
B, Peuhkurinen K. Myocardial release of 
malondialdehyde and purine compounds 
during coronary bypass surgery. Circulation 
1994;90:291-297.
 43.  Pollak R, Andrisevic JH, Maddux MS, Gruber 
SA, Paller MS. A randomized double-blind 
trial of the use of human recombinant 
superoxide dismutase in renal transplantation. 
Transplantation 1993;55:57-60.
 44.  Land W, Schneeberger H, Schleibner S, Illner 
WD, Abendroth D, Rutili G, Arfors KE, Messmer 
K. The beneficial effect of human recombinant 
superoxide dismutase on acute and chronic 
rejection events in recipients of cadaveric 
renal transplants. Transplantation 1994;57:211-
217.
 45.  Demetrius L. Of mice and men. When it comes 
to studying ageing and the means to slow it 
down, mice are not just small humans. EMBO 
Rep 2005;6:39-44.
 46.  Bianciardi P, Scorza R, Ghilardi G, Samaja M. 
Xanthine oxido-reductase activity in ischemic 
human and rat intestine. Free Radic Res 
2004;38:919-925.
 47. de Vries DK, Lindeman JH, Ringers J, Reinders 
ME, Rabelink TJ, Schaapherder AF. Donor brain 
death predisposes human kidney grafts to a 
proinflammatory reaction after transplantation. 
Am J Transplant 2011;11:1064-1070.
10
Exploring human renal ischemia/reperfusion injury: 
a gene array-based bioinformatics approach
D.K. de Vries, L.G.M. Wijermars, T. Kooistra, L. Verschuren, A.F.M. Schaapherder, 
M. Radonjic, L.J.C. van Loon, J.H.N. Lindeman











































Ischemia/reperfusion (I/R) injury impairs short and long term graft function and survival. 
Its pathophysiology is still largely unresolved. Proposed mechanisms underlying I/R injury 
include oxidative damage, complement activation, and inflammation. While targeting of 
these mechanisms effectively alleviated I/R injury in preclinical models, results from clinical 
interventions remained disappointing. Therefore, in this study a whole genome expression 
array was conducted, enabling the comparison of expression profiles in kidney biopsies 
taken before and after reperfusion. Ingenuity pathway analysis was used to assess the effect 
of reperfusion, mapping genes in functional categories and canonical pathways. Results 
show that the majority of metabolism related pathways were exclusively upregulated after 
reperfusion in grafts of living donors, while they remained unchanged or were downregulated 
in deceased donor grafts. In conclusion, results from this systematic study show there is no 
upregulation of metabolism related genes after reperfusion in kidneys of deceased donors. 
Therefore it has been hypothesized that I/R injury is instigated by metabolic exhaustion, 













































Kidney transplantation is the only curative treatment for end-stage renal disease. A 
persistent donor shortage has led to extension of donor criteria, and use of organs with a 
less favourable profile. These kidneys are more likely to experience delayed graft function 
(DGF), which is characterized by a slow functional recovery and impaired long term graft 
survival. The mechanisms underlying delayed graft function are thought to involve both 
ischemic damage as well as ischemia/reperfusion (I/R) injury.1 Although graft procurement 
methods aimed at reducing ischemic damage have greatly improved in the last decade, 
currently there is no established therapy that ameliorates I/R injury. This sharply contrasts 
with an abundance of preclinical studies showing that pharmaceutical interventions reduce 
I/R injury.2-7 This contrast between preclinical and clinical studies points towards poor 
translatability of preclinical models and an incomplete understanding of clinical (renal) I/R 
injury.
In a series of studies performed during human kidney transplantation we systematically 
evaluated factors that have been generally mentioned in the pathophysiology of I/R injury. 
These studies did not identify oxidative damage, neutrophil or thrombocyte activation 
as major triggers for I/R injury; whereas indications were found that the emergent post-
reperfusion inflammatory response is protective.8-11 As such, these observations suggest that 
human renal I/R injury is (in part) driven by factors beyond those commonly implicated in 
the process. From this perspective, we considered an unbiased evaluation of the processes 
involved in the early phase of reperfusion through gene-expression profiling relevant. A 
comparison between living, brain dead and cardiac dead donor grafts was specifically 
chosen as kidneys from living donors exhibit outstanding short and long term function and 
survival, and as such can be considered the primary comparator. 
Results of this analysis show that while early reperfusion of kidneys from living donors 
is characterized by the broad upregulation of metabolism-related pathways, and the 
pronounced upregulation of the NRF-2 redox-response pathway; kidneys from deceased 
donors are largely unresponsive and only exhibit a weak upregulation of the redox response 
pathway. The comprehensive upregulation of metabolic pathways in living donors kidneys 
and the generic inertness of cadaveric donors imply that metabolic impotence is a driving 












































Twenty-five patients undergoing renal allograft transplantation were included; of these, ten 
patients received a kidney from a living donor (LD), 8 from a brain dead donor (BDD) and 7 of 
a cardiac dead donor (CDD). Kidney transplantations were performed according to the local 
standardized protocol.8 In living donors open nephrectomy was performed and Custodiol® 
Histidine–tryptophan–ketoglutarate solution (Tramedico, Weesp, The Netherlands) was 
used for cold perfusion and storage of the kidney. Brain dead and cardiac dead donor 
kidneys were perfused and stored with either University of Wisconsin solution or Custodiol® 
Histidine–tryptophan–ketoglutarate solution. The immunosuppressive regimen was based on 
induction therapy with basiliximab on day 0 and day 4; and tacrolimus or cyclosporine A in 
addition with mycophenolate mofetil and steroids. Postoperative course was uneventful in 
all patients. One-year patient and graft survival was 100%. The study protocol was approved 
by the local ethics committee, and informed consent was obtained from each patient.
Renal Transcriptone Analysis
A renal cortical biopsy was obtained before transplantation at the end of the cold storage 
phase, and a post-reperfusion biopsy was collected 45 minutes after reperfusion. Biopsies 
were immediately snap frozen in liquid nitrogen and stored at -70ºC. Total RNA was 
extracted from renal tissues using RNAzol (Campro Scientific, Veenendaal, The Netherlands) 
and glass beads.12 The integrity of each RNA sample was examined by Agilent Lab-on-a-
chip technology using the RNA 6000 Nano LabChip kit and a bioanalyzer 2100 (Agilent 
Technologies, Amstelveen, The Netherlands). RNA preparations were considered suitable for 
array hybridization only if samples showed intact 18S and 28S rRNA bands, and displayed no 
chromosomal peaks or RNA degradation products (RNA Integrity Number >8.0).13 Subsequent 
microarray analysis was performed using Illumina whole-genome gene expression BeadChips 
(Illumina BeadArray®, San Diego, USA) according to instructions of the manufacturer at 
Service XS (Leiden, The Netherlands).
Results were analyzed by biostatistic methods using average replicate values for each of 
the groups of samples. Log2 ratios were computed and one value per gene was calculated 
for the average expression of probes with same Entrez ID, resulting in 15093 unique gene 
profiles. ToxProfiler was used to compute pathway/geneset scores using KEGG pathways. 













































Three different groups were compared in this study: living, brain dead and cardiac dead 
donor kidneys. Living donor kidney transplantations served as primary comparator, while 
deceased donor kidneys from brain dead and cardiac dead donors were studied separately. 
Clinical donor and graft characteristics are provided in table 1.
Table 1: Transplantation and outcome characteristics.  
LD BDD CDD
N 10 8 7
Donor age: mean (SD) 52(8) 47(22) 45(18)
Donor gender (M:F) 3:7 4:4 4:3
CIT in h. (SD) 3.6(0.5) 17.2(10) 15.1(4)
Recipient age: mean (SD) 51(16) 56(16) 58(7)
Recipient gender (M:F) 7:3 3:5 4:3
DGF 0/10 3/8 6/7
LD: Living donor. 
BDD: brain dead donor. 
CDD: cardiac dead donor.
Principle component analysis was performed on the pre and post reperfusion biopsy samples. 
This analysis revealed a clear linear separation between the pre and post reperfusion 
samples, as well as a separation between the different donor types, thus indicating clear 
biological differences.
After determining the quantitative gene expression upon reperfusion, the expressed genes 
were analyzed in clusters or pathways. We first mapped genes in pre-fitted KEGG pathways. 
This approach revealed a comprehensive upregulation of multiple metabolic pathways upon 
reperfusion of living donor kidneys. Such an upregulation was not observed in kidney of 
deceased donors, in fact we only observed upregulation of immunity related pathways such 
as asthma, cellular antigens and complement in kidneys of brain dead donors, whereas 
cardiac dead donor kidneys appeared largely unresponsive.
We further explored the array data through the ingenuity database. This pathway based 
platform identified an unequivocal upregulation of the NRF-2 response pathway as the 
dominant response in early reperfusion, both in kidneys of living and deceased donors. 
The ingenuity-based analysis further confirmed conclusions from the KEGG-based pathway 
analysis. These analyses all point towards a comprehensive upregulation of metabolic 










































Figure 1: KEGG pathway analysis demonstrates the rapid upregulation of metabolism-related pathways 
after reperfusion in living donor (LD) kidney transplantation, while in brain dead donor (BDD) and 
cardiac dead donor (CDD) kidneys expression did not change. Blue color indicates upregulation at 45 














































Ischemia reperfusion is the inevitable consequence of kidney transplantation. Despite decades 
of research its pathophysiology has not been unraveled yet. Although many experimental 
strategies proved successful in preclinical studies, none of them made an appreciable impact 
on clinical I/R injury. This contrast points to a poor translatability of preclinical models, 
and an incomplete understanding of I/R injury in humans. We systematically evaluated 
mechanisms implied in human I/R in clinical kidney transplantation. Findings from this 
series of studies were highly consistent and did not identify oxidative damage, neutrophil or 
thrombocyte activation as major triggers for I/R injury.8-11 There was an immediate release 
of IL-6 and IL-9 upon reperfusion, yet evaluation of these inflammatory mediators in an 
animal model of renal I/R injury suggested a protective or modulating role for these factors. 
Overall, these observations challenge the current paradigms of I/R injury.
In an effort to find new clues of processes involved in human renal I/R injury, we performed 
an evaluation of the changes in gene expression during the early phase of reperfusion. 
We used living donor kidney transplantation as the comparator. Results from the array 
analysis were evaluated by two bio-informatics platforms: KEGG pathways and the ingenuity 
database, a functional analysis. Results from the ingenuity based analysis showed that the 
early reperfusion phase was dominated by upregulation of the NRF-2 pathway: a quickly 
responsive tissue protective pathway that is activated by redox-stress. Both the ingenuity 
data base and KEGG pathways also indicated a broad upregulation of metabolism related 
pathways in living donor kidneys. Kidneys from brain dead and in particular cardiac dead 
donors exhibited a highly mitigated response with moderate activation of the NRF-2 pathway. 
Brain dead donor kidneys showed an activation of immune related pathways (KEGG: asthma, 
rejection) after reperfusion instead. An effect that may reflect activation of infiltrating 
lymphocytes which are less abundant in living and cardiac dead donor kidneys compared to 
brain dead donor kidneys.9
Results from living donor kidneys showed a clear response to the redox stress during early 
reperfusion but also a comprehensive upregulation of metabolism related pathways. 
Deceased donor kidneys on the other hand only showed suppressed upregulation of the NRF-
2 pathway and no upregulation of metabolic pathways. This provides a hypothesis in which 
an adequate response to ischemia and reperfusion in living donor kidneys is characterized 
by upregulation of a tissue protective network and restoration of metabolic pathways. The 
suppressed NRF-2 response and absent upregulation of other gene pathways in deceased 
donor kidneys may reflect a metabolic inadequacy with insufficient energy supply to sustain 










































injury, in which metabolic failure persists despite adequate oxygen supply. We therefore 
hypothesize that preservation of an adequate metabolic reserve may ameliorate I/R injury 
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The ultimate aim of all studies on the pathophysiology of I/R injury would be to gain insight 
into the processes which directly cause I/R injury in patients. When the sequence of events 
and mechanisms involved in I/R injury become more clear, a specific, more targeted therapy 
may be within reach. However, current treatment is still supportive and simultaneous with 
mechanistic studies, others focus on experimental therapies that alleviate I/R injury. 
The first moment of intervention is already prior to transplantation. Before the actual 
transplantation the graft has already been exposed to various noxious events, including 
potential donor brain death and cold preservation. These non-immunological factors such 
as donor health and the duration of the ischemic period probably have substantial impact 
on short and long term graft function. Consequently, interventions in the donor aimed at 
minimizing pre-transplantation graft injury, may potentially have large effects in preventing 
acute and long term graft dysfunction. In chapter 11.1 the successes of donor pretreatment 
are discussed. 
Next, during transplantation, I/R injury may be limited by modulation of the inflammatory 
response. Various anti-inflammatory drugs have been tested in animal experiments and 
human trials. Unfortunately they generally had more side-effects than wanted effects on 
I/R injury. From this perspective, mesenchymal stromal cells (MSCs) are under extensive 
investigation, since MSCs are able to exert immune regulatory and reparative effects. These 
versatile cells have been shown to migrate to sites of injury and to enhance repair by 
paracrine mechanisms instead of by differentiating and replacing the injured cells. In chapter 
11.2 various preclinical studies and the first clinical study are discussed demonstrating the 
beneficial effects of MSC’s. 

11.1
Donor pretreatment in clinical kidney transplantation:
a critical appraisal
D.K. de Vries, L.G.M. Wijermars, M.E.J. Reinders, J.H.N. Lindeman, A.F.M. Schaapherder











































Kidney transplantation represents one of the medical achievements of the 20th century. 
Its continued success, however, is limited by the increasing shortage of donor grafts. As a 
result more kidney grafts from marginal donors are being considered for transplantation, 
with concomitantly more initial graft injury and limited organ and patient survival. This 
has led to an increased need for interventions aiming to optimize and preserve graft 
quality. Interventions within the donor may protect against ischemia/reperfusion injury and 
therefore donor pretreatment is a promising strategy to increase graft function and survival. 
During the last decade, diverse donor pretreatment interventions have been explored in 
animal studies. Moreover, the first human trials concerning donor pretreatment in kidney 
transplantation have provided encouraging results. Unfortunately, it remains difficult to 
determine how and where to intervene in the multifactorial and complex processes that 
affect the donor kidney. Moreover, ethical matters play a critical role in donor interventions, 
and pretreatment should principally not have any potentially unfavorable effects on other 
organs to be transplanted or on the living donor. This review provides an overview of 
promising therapeutical strategies for donor pretreatment in kidney transplantation and 













































Kidney transplantation is the preferred treatment of patients with end-stage renal disease.1-3 
The previous decade has been characterized by a steady increase in the number of kidney 
transplantations. This increase largely reflects improved medical therapy for renal failure. 
Besides the fact that more patients are being considered eligible for kidney transplantation, 
improved patient survival rate after transplantation led to the emergence of patients 
requiring re-transplantation, because of progressive loss of graft function in the long run.4-6 
The augmented demands for kidney transplantation resulted in organ shortage and as a 
consequence, waiting lists for kidney transplantation are ever increasing. As of June 2012 
more than 99,000 American citizens were on the waiting list for a kidney transplantation.7-9 
Kidney grafts can be derived from living or deceased donors. For the deceased donors, 
more kidneys are recovered by donation after brain death than from donation after cardiac 
death. The current organ shortage, however, necessitates expansion of the donor pool 
by the increased use of marginal donor kidneys. Since these marginal donor kidneys have 
worse long term outcome, it has been proposed that these may benefit most from pre-
transplantation interventions that preserve or even improve graft quality.10
Before and during the process of transplantation the graft is exposed to various noxious 
events, including donor brain death, cold preservation and ischemia/reperfusion (I/R) 
injury; potentially all contributing to the functional deterioration of the graft. The 
importance of these harmful mechanisms is illustrated by the superior results of living 
donor transplantation. Despite generally more accepted HLA mismatches, living donor 
transplantation is associated with minimal delayed graft function and improved long term 
outcomes. This observation suggests that non-HLA-specific factors such as donor health and 
duration of the ischemic period before transplantation have substantial impact on short and 
long term graft function.11-13 
Consequently, interventions in the donor, aimed at minimizing pre-transplantation 
graft injury, may potentially have large effects in preventing acute and long term graft 
dysfunction. This review will focus on the prevention of harmful processes that initiate 
graft damage in the donor. Various intervention strategies for donor pretreatment that have 
been tested in clinical kidney transplantation or in animal experiments involving kidney 
transplantation will be discussed. 
Processes in brain death
To date, the majority of deceased kidney grafts are derived from donation after brain 










































as compared to living donor kidneys. Brain death leads to dysregulation of the autonomic 
nerve system, inducing many pathophysiological processes in the human body. Brain death is 
usually provoked by a period of increased intracranial pressure exceeding the mean arterial 
pressure and thereby blocking brain perfusion. The physiological responses to this increased 
pressure and brain damage can have effects on multiple organ systems. The most prevalent 
derangements are cardiovascular. With increasing intracranial pressure, a compensatory 
arterial hypertension is induced, sometimes with bradycardia. The catecholamine storm sets 
in next, with sympathetic stimulation, vasoconstriction, raised systemic vascular resistance, 
and tachycardia. After the catecholamine storm, there is a loss of sympathetic tone and 
peripheral vasodilatation. Next, brain death results in severe hemodynamic instability and 
the resulting hypotension, if untreated, leads to hypoperfusion of all organs. This phase is 
well-known for the damage it can inflict in organs to be transplanted. Other common clinical 
problems associated with donor brain death may include diabetes insipidus, disseminated 
intravascular coagulation, arrhythmias and pulmonary edema. Injury to the hypothalamus 
and the pituitary gland causes disturbances of hormonal homeostasis and thermoregulation. 
On the microvascular level, brain death is associated with the induction of adhesion 
molecule expression and endothelial cell activation.14 The hemodynamic, neurogenic, 
hormonal and microvascular disturbances lead to a generalized inflammatory response in 
the donor. This is characterized by the release of cytokines into the circulation which can 
trigger an inflammatory response in all organs 15,16 with tissue infiltration by granulocytes,16 
monocytes and lymphocytes.17 All these physiological derangements should be limited as far 
as possible to maintain optimal graft condition before donation. Donor management is the 
primary approach to do so. 
Donor management
After the diagnosis of brain death, there is a change from curative patient care to optimizing 
organ function for subsequent transplantation. This donor management is the active care of 
the donor from the time of diagnosis of brain death until procurement of organs and involves 
correction of the widespread physiological changes that occur during brain death. Early 
recognition of the potential organ donor and aggressive correction of the non-physiological 
state, even before consent to organ donation, are crucial to optimize post-transplantation 
graft function. 
In order to standardize management, donor goals have been developed. These aim to 
maintain physiology close to normal values and were based on measurements performed 
routinely in patients in the intensive care unit. They include objectives to maintain body 












































and adequate urine output. Indeed, in a prospective study, the application of a standardized 
donor management protocol increased the number of retrieved and transplanted organs per 
donor substantially.18
One part of donor management is providing cardiovascular support. This support 
principally includes stabilization of hemodynamics in the donor. Treatment of hypertension 
associated with the catecholamine storm may significantly increase graft availability for 
transplantation.19 In the consecutive hypotensive period, the first priority is to maintain 
an adequate intravascular volume. Fluid therapy should, however, be carefully titrated. 
Recent studies recommend restrictive fluid management, since this restriction increases the 
number of transplantable lungs without influencing kidney graft function or survival after 
transplantation.20, 21
Hormone replacement can aid by correcting the loss of pituitary function after brain death, 
as a method of stabilizing the donor. Posterior pituitary function is lost very commonly, 
leading to diabetes insipidus with associated fluid and electrolyte changes. Anterior pituitary 
function may be preserved or only partially affected. Most hormone replacement therapies 
use a combination of methylprednisolone, vasopressin and thyroid hormone. The fraction of 
donors that received replacement therapy with these three hormones had an increase in the 
number of procured organs by 22,5%, as demonstrated by a retrospective study.22
Aggressive donor management increases the number of organs available for transplantation 
and has minimized loss of potential donors due to cardiovascular collapse in the process 
of brain death. Most studies, however, deny a major effect on graft quality and survival of 
donor management. Grafts may therefore benefit from additional interventions that more 
specifically prevent organ damage before procurement. This donor pretreatment aiming 
to further maximize organ quality is an evolving field that constitutes the next step in 
optimizing kidney graft survival.
Donor pretreatment
Donor pretreatment is the active treatment of the donor in order to improve organ quality 
before and after transplantation. It distinguishes itself from donor management by the 
fact that donor management concentrates on stabilizing the donor to normal physiological 
ranges, while pretreatment aims to inhibit potentially harmful processes. Many therapies 
used as donor pretreatment have been investigated for their ability to reduce or prevent 
renal I/R injury in animal experiments. Few interventions have been studied in clinical 
trials, which are summarized in Table 1. Here we discuss the most frequently applied and 










































Table 1: Human clinical trials of donor pretreatment and result on outcome in kidney 
transplantation.
Intervention Design n Main result Reference
Dopamine Single blind 
RCT
264 brain dead 
donors
Dopamine pretreatment decreased 
the incidence of dialysis post-
transplantation. No change in acute 
rejection or patient or graft survival 
after 3 years.
Schnuelle et al., 
2009 42
Steroids Double blind 
RCT
306 brain dead 
donors
Donor pretreatment with 
corticosteroids did not reduce the 
incidence or duration of DGF.






PUVA pretreated grafts had a 
significantly lower number of 
rejection episodes, other outcome 
parameters were not different. 
Oesterwitz et 
al., 1987 70
Hyperoxia Double blind 
RCT
60 living donors Donor oxygen pre-treatment the day 
before transplantation improved 
kidney function at 10 days after 
transplantation. 
Montazeri et al., 
2011 79
RCT: randomized controlled trial
DGF: delayed graft function
PUVA: psoralen plus ultraviolet A
Ischemic preconditioning
Over the past decades several studies were performed, exposing an organ to brief periods 
of ischemia to protect against subsequent periods of ischemia and reperfusion. This 
phenomenon of ischemic preconditioning has been first described in 1986 in the heart.23 
Many animal studies, mainly in rats, have reported beneficial effects of donor renal ischemic 
preconditioning before kidney transplantation since then.24-27 Our present understanding of 
the molecular mechanisms causing these effects is still largely incomplete. Experimental 
studies have shown that the protective effects of renal ischemic preconditioning are mediated 
by adenosine28, nitric oxide 29, 30 and subsequent activation of signal networks involving 
protein kinases and transcription factors. More complex mechanisms have been proposed 
recently as well, including cellular actions of regulatory T cells and endothelial progenitor 
cells.31, 32 It is generally acknowledged that the mechanism of ischemic preconditioning 
may differ between species and organs and it still remains controversial whether ischemic 
preconditioning is beneficial in large animals as well. Studies on kidney transplantation in 
dogs and renal I/R injury in pigs in fact both failed to confirm beneficial effects of renal 
ischemic preconditioning. Although the first description of ischemic preconditioning dates 
from almost thirty years ago, the technique has not yet been successfully translated into 












































More recent studies demonstrated that remote ischemic preconditioning confers protection 
to I/R injury by preceding ischemia and reperfusion of another organ or tissue. In animal 
experiments, the donor kidney can be protected after transplantation by remote ischemic 
preconditioning of the hindlimb.35 Remote ischemic preconditioning suggests the involvement 
of humoral mediators and consequently protection is both dialyzable, transferable, and 
receptor-mediated.36 Remote ischemic preconditioning has the advantage that it is more 
easily applicable in clinical transplantation than ischemic preconditioning of the graft itself. 
At present, clinical studies in which remote ischemic preconditioning of the lower limb is 
explored to improve outcome of kidney transplantation have been initiated and patients are 
being recruited (www.clinicaltrials.gov). 
Catecholamines
Before transplantation, the graft is exposed to harmful periods of warm and cold ischemia. 
Dopamine is capable of protecting endothelial cells from damage during cold preservation 
by inducing protective enzymes, such as heme oxygenase-1 (HO-1).37,38 Dopamine could 
therefore be a good donor pretreatment candidate, rendering the kidney graft more 
resistant to I/R injury. In a rat allogeneic kidney transplantation model it was shown that 
donor dopamine pretreatment diminished histological damage, monocyte infiltration and 
cytokine expression in the kidney graft. Moreover, both short- and long-term graft function 
significantly improved.39,40 Other catecholamines, like dobutamine and norepinefrin, did not 
influence post transplantation kidney function.41
This preclinical experimental evidence resulted in a clinical trial of donor dopamine 
pretreatment.42 Almost 300 brain dead donors were randomized to receive low dose 
dopamine pretreatment or placebo. Donors had to be stable on low dose noradrenalin and 
dopamine was continuously infused at a standard rate. The main outcome measure, need for 
dialysis during the first week after transplantation, was significantly reduced in recipients 
of a dopamine pretreated graft. Dopamine pretreatment however, did not affect graft 
or patient survival. Donors in the dopamine administered group showed a significant but 
clinically not relevant increase in systolic blood pressure. In addition, effects of dopamine 
pretreatment were more pronounced with increasing cold ischemia time, supporting the 
hypothesis that the beneficial effects of dopamine are mediated by its protective effects 
on the endothelium. Dopamine pretreatment may therefore even have the largest effects 
in marginal donors.42
Heme oxygenase-1
The ischemic period before transplantation can induce oxidative stress, which on its turn 










































a product of HO-1 metabolism, are potential candidates for donor pretreatment. Induced 
expression of HO-1 in rat kidney donors led to decreased cell infiltration, downregulation 
of inflammatory genes and diminished histological signs of chronic rejection, resulting in 
increased graft function and survival after transplantation.43
The effects of HO-1 may be mediated by its downstream CO production, since induction 
of CO in the donor improved graft function similarly to HO-1, and both HO-1 and CO were 
able to diminish donor immunogenicity.44-47 Cellular effects however, may also be involved in 
the protective effect of HO-1. HO-1 induction in the donor decreased early post transplant 
alloreactivity, donor-derived dendritic cells, and T-cell reactivity in the recipient.48 
Moreover, donor pre-treatment with HO-1 has been shown to improve microcirculation after 
transplantation.49 Both HO-1 and CO appear promising opportunities for donor pretreatment. 
Whether their application is feasible and beneficial in clinical practice still remains uncertain. 
Anti-complement therapy
The inflammatory storm in the process of brain death may induce complement activation in 
the donor, thereby causing damage in the kidney graft before transplantation.50 Inhibition of 
complement activation in the donor could therefore be beneficial for the kidney graft. The 
complement system is part of the innate immune system and it can be activated through 
the classical, alternative and lectin pathway. Soluble complement receptor 1 (sCR1) acts 
as an inhibitor of the common part of all three complement pathways. Pretreatment of 
donor rats with sCR1 around induction of brain death prevented the increase in circulating 
C3d and significantly improved renal function immediately after transplantation.51 These 
first encouraging results should be confirmed in further animal experiments applying other 
complement inhibitors, before translation to clinical application can be made. 
Erythropoietin 
Erythropoietin (EPO) was originally identified for its role in erythropoiesis, but is now known 
for its anti-apoptotic and cytoprotective effects as well. These protective effects are 
mediated by different receptors and mechanisms than the ones regulating the hematopoietic 
effects and may defend the kidney from I/R injury, potentially even when administered 
to the donor. This is particularly interesting considering the conceivably unfavorable side 
effects of systemic EPO treatment to the recipient. 
Two very recent animal studies addressed donor pretreatment with EPO.52, 53 In a rat model, 
brain dead donors were pretreated with EPO or carbamylated EPO (cEPO), which lacks 
the hematopoietic effects of EPO. Although kidneys were not actually transplanted, short 












































cEPO diminished the influx of polymorphonuclear cells into the kidney and grafts showed 
a normalization of creatinine clearance in this isolated perfused kidney model.53 In a study 
with larger animals, involving porcine kidney transplantation, cardiac dead donors were 
pretreated with EPO. In as little as 4 hours after reperfusion, renal injury and inflammation 
decreased and renal function improved in the EPO pretreated group.52
Immunosuppressive and anti-inflammatory agents
The period of donor brain death is well known for causing a systemic, nonspecific inflammatory 
reaction, and organs from brain dead donors are influenced by this inflammatory state.17, 
54-57 Moreover, the ongoing inflammatory reaction after transplantation is responsible for 
reperfusion induced tissue damage.58 When translating findings of animal experiments 
into human therapies, the general immunosuppressive effects of corticosteroids could be 
suitable to suppress the inflammatory response in brain dead donors. Methylprednisolone is 
frequently administered in donor management as part of hormone replacement therapy, but 
may also be administrated at a higher dose than normally given for replacement therapy, to 
decrease the inflammatory response. Limited recent data from a large randomized, blind, 
placebo-controlled trial on donor steroid pretreatment are available. The results show 
that expression of pro-inflammatory genes in brain dead donors normalized after steroid 
pretreatment. Although the incidence and duration of delayed graft function did not change 
with steroid pretreatment, the follow-up period was fairly short and information on longer 
term graft function is not available as yet.59,60 Nevertheless, reducing the pro-inflammatory 
storm after brain death remains a promising approach, as illustrated by the improved kidney 
graft survival rate in rats after donor pretreatment with JNK signal transduction inhibition.61 
Preconditioning of rat donors with calcineurin inhibitors cyclosporine A or tacrolimus 
decreased structural damage and resulted in improved graft function after kidney 
transplantation.62 Pretreatment with tacrolimus combined with rapamycin even improved 
outcome synergistically.63 Not all studies could confirm these results, potentially explained 
by gross differences in experimental set-up and dosing of immunosuppressives between 
studies.64 
The basic mechanism behind immunosuppressive donor pretreatment remains unknown. 
The responsible mechanism appears not to be, as expected, an additional inhibition of 
the alloimmune response. An effect on renal I/R injury is more likely, since the protective 












































Photosensitizer + UVA (PUVA) treatment was applied in a series of studies nearly 30 years 
ago. Donor rats were pretreated with a photosensitizer and during hypothermic storage the 
kidney was irradiated with UVA. PUVA pretreatment improved graft survival in rats, with a 
dose-response relationship of the irradiation period.66 The positive effect is attributed to 
decreased graft immunogenicity.67-69 To validate these results, a clinical study was performed 
in 1986 showing that PUVA pretreated grafts had a significantly lower number of rejection 
episodes, although all other outcome parameters were not different.70 Altogether, PUVA 
pretreatment showed some successes but since then results have never been validated 
or reproduced by others. Multiple rodent studies report on donor pretreatment with 
various substances with antioxidant capacities. Among others N-acetylcysteine (NAC), 
melatonin, danshen, and taurine were applied in animal kidney donors. Most studies showed 
improvements in biochemical parameters or secondary endpoints only, although some also 
demonstrated increased survival rates.71-74 Nevertheless, unconfirmed results of these single 
studies on various antioxidants will probably not have a great impact on clinical donor 
pretreatment in the next few years, unless confirmed or applied in clinical studies. 
Miscellaneous studies using diverse donor pretreatment strategies have been published the 
last few years with varying results. Vagus nerve stimulation was applied as donor pretreatment 
in brain dead donors for its potential anti-inflammatory effects. Vagus nerve stimulation 
decreased the expression of pro-inflammatory genes, decreased TNF-α production, 
diminished monocyte infiltration and more importantly, improved post-transplantation graft 
function.75 Another study showed that donor statin pretreatment increased graft function 
and reduced renal inflammation in a rat kidney transplantation model.76 Others showed that 
ICAM-1 inhibition in rat kidney donors improved graft survival, although effects were even 
larger when ICAM-1 was inhibited in the recipient or during preservation.77 Disappointing 
results in animal studies have also been reported; glutamine donor pretreatment did not 
affect the post-transplantation renal function in rats.78 
Finally, in humans a remarkable randomised clinical trial showed that hyperoxic donor 
pretreatment resulted in improved urine production and creatinine clearance after 
transplantation.79 Previous animal experiments involving renal I/R without transplantation 
showed identical results.80,81 It may be speculated that hyperoxia induces oxidative stress 
in the donor, which enhances endogenous antioxidant mechanisms of the kidney. Another 
explanation is that hyperoxia leads to an improved oxygen reserve capacity of the kidney 
that protects the energy metabolism during the ischemic period. Finally, there have been 
reports on successes of hyperthermic donor preconditioning in rodent experiments. Two 












































function and graft survival after transplantation. Hyperthermia induced renal expression of 
heat shock proteins was held responsible for the beneficial effects.82, 83
Future perspectives 
Although the principle of donor pretreatment is not new, the clinical trend to use more 
marginal donors for transplantation only recently necessitated the search for new ways to 
optimize donor organ quality. Much preclinical research on donor pretreatment has been 
done, with promising results. The first human trials have recently shown protective effects 
of donor pretreatment with dopamine and corticosteroids, and these are likely to be of 
great influence in the years to come. Despite all the promising results from preclinical 
studies, clinical trials studying donor pretreatment are scarce, especially studies aiming 
specifically at the effects in marginal donor grafts. It has been suggested that the great 
amount of groups of interests involved in transplantation, the difficult ethical debate 
concerning informed consent of deceased donors and the effect of pretreatment on other 
organs considered for transplantation hampers the translation into the clinical setting.9,84 
In the near future we expect results from some ongoing clinical trials, studying the effects 
of glucose, ischemic preconditioning, HO-1 induction and dopamine. Donor pretreatment 
targeting the immune system or oxidative stress responses remain interesting topics, but 
still have to prove themselves in the clinical setting. 
In this review we focused on kidney transplantation. Research on transplantation of other 
organs will also provide new targets for pretreatment of kidney donors. Animal experiments 
with 17β-Estradiol as donor pretreatment, for example, showed improved outcome after 
transplantation of several different organs.85 Donor pretreatment with metformin improved 
acute and chronic rejection in cardiac transplantation in mice.86 Ultimately, it is expected 
that a combination of agents will be used as tailored donor pretreatment, and timing may 
turn out to be crucial in the success of donor pretreatment.
Ethical considerations
In trying to translate donor pretreatment strategies to the clinical setting, ethical issues 
may be raised, particularly involving deceased donors. Most issues are related to the fact 
that manipulations will not benefit the donor directly in any way. Living donors provide 
the simplest situation, where the donor is fully aware of the donation procedure and can 
provide detailed consent, with prolonged time for consideration and reflection. It is obvious 
that donor pretreatment may never harm the living donor. The situation is more difficult 
for deceased donors. The act of joining an organ donor register or carrying a donor card is 
considered as consent to organ donation, but it is not clear whether such consent would 










































need to establish whether pretreatment could be seen as no different from other medical 
interventions, such as the administration of heparin to donors. One can argue that consent 
to organ donation suggests consent to all techniques required to allow optimal quality of 
grafts. Pretreatment may represent part of the normal process of organ donation in the near 
future, and therefore should not require further consent or lack of objection beyond that 
associated with organ donation itself. 
The timing of pretreatment may be crucial, particularly with regard to agents that require 
a significant length of time prior to donation, to provide the beneficial effect. Thus, there 
may be requirements to commence administration of the agent before lack of objection is 
obtained. Although this might be an unusual principle, this type of approach has already 
been approved by ethical committees and has been used in clinical trials on organ donors.87 
Deceased donors are often multiple organ donors. Intervention on behalf of one organ may 
be harmful to other potentially transplantable organs or at least affect them differentially. 
Donor pretreatment should be carefully tested for the effects on other potential grafts. 
With progression of the clinical applications of pretreatment, potential new ethical issues 
will arise and boundaries have to be continuously redefined. 
Conclusion
Nowadays we are facing a scarcity of donor organs, hence it is absolutely necessary to search 
for therapeutical options to render more marginal donor organs suitable for transplantation 
and to improve graft quality. During and before the process of transplantation the graft is 
exposed to various noxious events, which will lead to functional deterioration. Prevention 
of injury already in the donor could facilitate transplantation of more marginal donor grafts 
and provide better outcomes. Donor management is the first step to prevent derangements 
in the donor and has been much improved by standardization. Further, more specific 
improvement of graft condition is the aim of donor pretreatment. Donor pretreatment by 
various strategies, including ischemic preconditioning, HO-1 induction, anti-inflammatory 
and anti-complement interventions, erythropoietin and catecholamines has been successful 
in animal experiments. Although many of these promising results in animals have yet to be 
confirmed in human kidney transplantation, the first pretreatment strategies have already 













































 1.  McDonald SP, Russ GR. Survival of recipients of 
cadaveric kidney transplants compared with 
those receiving dialysis treatment in Australia 
and New Zealand, 1991-2001. Nephrol Dial 
Transplant 2002: 17: 2212.
 2.  Schnuelle P, Lorenz D, Trede M, van der Woude 
FJ. Impact of renal cadaveric transplantation 
on survival in end-stage renal failure: evidence 
for reduced mortality risk compared with 
hemodialysis during long-term follow-up. J Am 
Soc Nephrol 1998: 9: 2135.
 3.  Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang 
K. Comparison of survival probabilities for 
dialysis patients vs cadaveric renal transplant 
recipients. JAMA 1993: 270: 1339.
 4.  Marcen R, Teruel JL. Patient outcomes after 
kidney allograft loss. Transplant Rev (Orlando ) 
2008: 22: 62.
 5.  Marcen R, Pascual J, Teruel JL et al. Outcome 
of cadaveric renal transplant patients treated 
for 10 years with cyclosporine: is chronic 
allograft nephropathy the major cause of late 
graft loss? Transplantation 2001: 72: 57.
 6.  Meier-Kriesche HU, Schold JD, Kaplan B. Long-
term renal allograft survival: have we made 
significant progress or is it time to rethink 
our analytic and therapeutic strategies? Am J 
Transplant 2004: 4: 1289.
 7.  Ravanan R, Udayaraj U, Steenkamp R, Ansell 
D. UK Renal Registry 11th Annual Report 
(December 2008): Chapter 5 Demographics 
and biochemistry profile of kidney transplant 
recipients in the UK in 2007: national and 
centre-specific analyses. Nephron Clin Pract 
2009: 111 Suppl 1: c69-c96.
 8.  Harper AM, Rosendale JD. The UNOS OPTN 
Waiting List and Donor Registry: 1988-1996. Clin 
Transpl 1996: 69.
 9.  Smith JM, Biggins SW, Haselby DG et al. Kidney, 
pancreas and liver allocation and distribution 
in the United States. Am J Transplant 2012: 12: 
3191.
 10.  Terasaki PI, Cecka JM, Gjertson DW, Takemoto 
S. High survival rates of kidney transplants from 
spousal and living unrelated donors. N Engl J 
Med 1995: 333: 333.
 11.  Pratschke J, Wilhelm MJ, Kusaka M, Hancock 
WW, Tilney NL. Acute rejection of rat renal 
allografts is accelerated by donor brain death. 
Transplant Proc 1999: 31: 874.
 12.  Goes N, Urmson J, Ramassar V, Halloran PF. 
Ischemic acute tubular necrosis induces an 
extensive local cytokine response. Evidence for 
induction of interferon-gamma, transforming 
growth factor-beta 1, granulocyte-macrophage 
colony-stimulating factor, interleukin-2, and 
interleukin-10. Transplantation 1995: 59: 565.
 13.  van der Woude FJ, Schnuelle P, Yard BA. 
Preconditioning strategies to limit graft 
immunogenicity and cold ischemic organ injury. 
J Investig Med 2004: 52: 323.
 14.  van der Hoeven JA, Molema G, Ter Horst 
GJ et al. Relationship between duration of 
brain death and hemodynamic (in)stability 
on progressive dysfunction and increased 
immunologic activation of donor kidneys. 
Kidney Int 2003: 64: 1874.
 15.  Weiss S, Kotsch K, Francuski M et al. 
Brain death activates donor organs and is 
associated with a worse I/R injury after liver 
transplantation. Am J Transplant 2007: 7: 1584.
 16.  Schuurs TA, Morariu AM, Ottens PJ et al. 
Time-dependent changes in donor brain death 
related processes. Am J Transplant 2006: 6: 
2903.
 17.  de Vries DK, Lindeman JH, Ringers J et al. 
Donor brain death predisposes human kidney 
grafts to a proinflammatory reaction after 
transplantation. Am J Transplant 2011: 11: 
1064.
 18.  Rosendale JD, Chabalewski FL, McBride MA et 
al. Increased transplanted organs from the use 
of a standardized donor management protocol. 
Am J Transplant 2002: 2: 761.
 19.  Audibert G, Charpentier C, Seguin-Devaux C et 
al. Improvement of donor myocardial function 
after treatment of autonomic storm during 
brain death. Transplantation 2006: 82: 1031.
 20.  Pennefather SH, Bullock RE, Dark JH. The 
effect of fluid therapy on alveolar arterial 
oxygen gradient in brain-dead organ donors. 










































 21.  Minambres E, Rodrigo E, Ballesteros MA et al. 
Impact of restrictive fluid balance focused to 
increase lung procurement on renal function 
after kidney transplantation. Nephrol Dial 
Transplant 2010: 25: 2352.
 22.  Rosendale JD, Kauffman HM, McBride MA et al. 
Aggressive pharmacologic donor management 
results in more transplanted organs. 
Transplantation 2003: 75: 482.
 23.  Murry CE, Jennings RB, Reimer KA. 
Preconditioning with ischemia: a delay of lethal 
cell injury in ischemic myocardium. Circulation 
1986: 74: 1124.
 24.  Fuller TF, Freise CE, Feng S, Niemann CU. 
Ischemic preconditioning improves rat 
kidney graft function after severe ischemia/
reperfusion injury. Transplant Proc 2005: 37: 
377.
 25.  Jia RP, Xie JJ, Luo FY, Zhu JG. Ischemic 
preconditioning improves rat kidney allograft 
function after ischemia/reperfusion injury: the 
role of tumor necrosis factor-alpha. Transplant 
Proc 2008: 40: 3316.
 26.  Jia RP, Zhu JG, Wu JP, Xie JJ, Xu LW. 
Experimental study on early protective effect 
of ischemic preconditioning on rat kidney graft. 
Transplant Proc 2009: 41: 69.
 27.  Reutzel-Selke A, Pratschke J, Martins PN et al. 
Ischemic preconditioning produces systemic 
protective and adoptively transferable effects. 
Kidney Int 2008: 74: 622.
 28.  Grenz A, Osswald H, Eckle T et al. The reno-
vascular A2B adenosine receptor protects the 
kidney from ischemia. PLoS Med 2008: 5: e137.
 29.  Ogawa T, Nussler AK, Tuzuner E et al. 
Contribution of nitric oxide to the protective 
effects of ischemic preconditioning in ischemia-
reperfused rat kidneys. J Lab Clin Med 2001: 
138: 50.
 30.  Yamasowa H, Shimizu S, Inoue T, Takaoka 
M, Matsumura Y. Endothelial nitric oxide 
contributes to the renal protective effects of 
ischemic preconditioning. J Pharmacol Exp Ther 
2005: 312: 153.
 31.  Kinsey GR, Huang L, Vergis AL, Li L, Okusa MD. 
Regulatory T cells contribute to the protective 
effect of ischemic preconditioning in the 
kidney. Kidney Int 2010: 77: 771.
 32.  Patschan D, Krupincza K, Patschan S et al. 
Dynamics of mobilization and homing of 
endothelial progenitor cells after acute 
  renal ischemia: modulation by ischemic 
preconditioning. Am J Physiol Renal Physiol 
2006: 291: F176-F185.
 33.  Behrends M, Walz MK, Kribben A et al. No 
protection of the porcine kidney by ischaemic 
preconditioning. Exp Physiol 2000: 85: 819.
 34.  Kosieradzki M, Ametani M, Southard JH, 
Mangino MJ. Is ischemic preconditioning of the 
kidney clinically relevant? Surgery 2003: 133: 
81.
 35.  Wever KE, Warle MC, Wagener FA et al. Remote 
ischaemic preconditioning by brief hind limb 
ischaemia protects against renal ischaemia-
reperfusion injury: the role of adenosine. 
Nephrol Dial Transplant 2011: 26: 3108.
 36.  Kharbanda RK, Nielsen TT, Redington 
AN. Translation of remote ischaemic 
preconditioning into clinical practice. Lancet 
2009: 374: 1557.
 37.  Salahudeen AK, Yang M, Huang H, Dore S, Stec 
DE. Fenoldopam preconditioning: role of heme 
oxygenase-1 in protecting human tubular cells 
and rodent kidneys against cold-hypoxic injury. 
Transplantation 2011: 91: 176.
 38.  Yard B, Beck G, Schnuelle P et al. Prevention 
of cold-preservation injury of cultured 
endothelial cells by catecholamines and related 
compounds. Am J Transplant 2004: 4: 22.
 39.  Gottmann U, Notheisen A, Brinkkoetter PT 
et al. Influence of donor pretreatment with 
dopamine on allogeneic kidney transplantation 
after prolonged cold storage in rats. 
Transplantation 2005: 79: 1344.
 40.  Liu Z, Hoeger S, Schnuelle P et al. Donor 
dopamine pretreatment inhibits tubulitis in 
renal allografts subjected to prolonged cold 
preservation. Transplantation 2007: 83: 297.
 41.  Gottmann U, Brinkkoetter PT, Bechtler M et al. 
Effect of pre-treatment with catecholamines 
on cold preservation and ischemia/reperfusion-
injury in rats. Kidney Int 2006: 70: 321.
 42.  Schnuelle P, Gottmann U, Hoeger S et al. 
Effects of donor pretreatment with dopamine 
on graft function after kidney transplantation: 
a randomized controlled trial. JAMA 2009: 302: 
1067.
 43.  Tullius SG, Nieminen-Kelha M, Buelow R et al. 
Inhibition of ischemia/reperfusion injury and 
chronic graft deterioration by a single-donor 
treatment with cobalt-protoporphyrin for the 













































 44.  Martins PN, Reutzel-Selke A, Jurisch A et al. 
Induction of carbon monoxide in donor animals 
prior to organ procurement reduces graft 
immunogenicity and inhibits chronic allograft 
dysfunction. Transplantation 2006: 82: 938.
 45.  Martins PN, Reuzel-Selke A, Jurisch A et al. 
Induction of carbon monoxide in the donor 
reduces graft immunogenicity and chronic graft 
deterioration. Transplant Proc 2005: 37: 379.
 46.  Kotsch K, Martins PN, Klemz R et al. Heme 
oxygenase-1 ameliorates ischemia/reperfusion 
injury by targeting dendritic cell maturation 
and migration. Antioxid Redox Signal 2007: 9: 
2049.
 47.  Caumartin Y, Stephen J, Deng JP et al. Carbon 
monoxide-releasing molecules protect against 
ischemia-reperfusion injury during kidney 
transplantation. Kidney Int 2011: 79: 1080.
 48.  Martins PN, Kessler H, Jurisch A et al. Induction 
of heme oxygenase-1 in the donor reduces graft 
immunogenicity. Transplant Proc 2005: 37: 384.
 49.  Holzen JP, August C, Bahde R et al. Influence 
of heme oxygenase-1 on microcirculation after 
kidney transplantation. J Surg Res 2008: 148: 
126.
 50.  Damman J, Nijboer WN, Schuurs TA et al. Local 
renal complement C3 induction by donor brain 
death is associated with reduced renal allograft 
function after transplantation. Nephrol Dial 
Transplant 2011: 26: 2345.
 51.  Damman J, Hoeger S, Boneschansker L et al. 
Targeting complement activation in brain-
dead donors improves renal function after 
transplantation. Transpl Immunol 2011: 24: 233.
 52.  Maio R, Sepodes B, Patel NS et al. 
Erythropoietin preserves the integrity and 
quality of organs for transplantation after 
cardiac death. Shock 2011: 35: 126.
 53.  Nijboer WN, Ottens PJ, van DA et al. Donor 
pretreatment with carbamylated erythropoietin 
in a brain death model reduces inflammation 
more effectively than erythropoietin while 
preserving renal function. Crit Care Med 2010: 
38: 1155.
 54.  Nijboer WN, Schuurs TA, van der Hoeven JA 
et al. Effects of brain death on stress and 
inflammatory response in the human donor 
kidney. Transplant Proc 2005: 37: 367.
 55.  Nijboer WN, Schuurs TA, van der Hoeven JA et 
al. Effect of brain death on gene expression 
and tissue activation in human donor kidneys. 
Transplantation 2004: 78: 978.
 56.  Schuurs TA, Gerbens F, van der Hoeven JA et 
al. Distinct transcriptional changes in donor 
kidneys upon brain death induction in rats: 
insights in the processes of brain death. Am J 
Transplant 2004: 4: 1972.
 57.  Stangl M, Zerkaulen T, Theodorakis J et al. 
Influence of brain death on cytokine release in 
organ donors and renal transplants. Transplant 
Proc 2001: 33: 1284.
 58.  Eltzschig HK, Eckle T. Ischemia and reperfusion-
-from mechanism to translation. Nat Med 2011: 
17: 1391.
 59.  Kuecuek O, Mantouvalou L, Klemz R et al. 
Significant reduction of proinflammatory 
cytokines by treatment of the brain-dead 
donor. Transplant Proc 2005: 37: 387.
 60.  Kainz A, Wilflingseder J, Mitterbauer C et 
al. Steroid pretreatment of organ donors to 
prevent postischemic renal allograft failure: a 
randomized, controlled trial. Ann Intern Med 
2010: 153: 222.
 61.  Chen L, Xu D, Gao Y et al. Effect of Donor JNK 
Signal Transduction Inhibition on Transplant 
Outcome in Brain Dead Rat Model. Inflammation 
2011.
 62.  Shihab FS, Bennett WM, Andoh TF. Donor 
preconditioning with a calcineurin inhibitor 
improves outcome in rat syngeneic kidney 
transplantation. Transplantation 2009: 87: 326.
 63.  Cicora F, Roberti J, Vasquez D et al. 
Preconditioning donor with a combination 
of tacrolimus and rapamacyn to decrease 
ischaemia-reperfusion injury in a rat syngenic 
kidney transplantation model. Clin Exp Immunol 
2012: 167: 169.
 64.  Martinez-Palli G, Hirose R, Liu T et al. Donor 
pre-treatment with everolimus or cyclosporine 
does not reduce ischaemia-reperfusion injury 
in a rat kidney transplant model. Nephrol Dial 
Transplant 2011: 26: 1813.
 65.  Shihab FS, Bennett WM, Andoh TF. Role 
of cellular cholesterol in pharmacologic 
preconditioning with cyclosporine in 
experimental kidney transplantation. Am J 
Nephrol 2010: 31: 134.
 66.  Oesterwitz H, Scholz D, Kaden J, Mebel M. 
Prolongation of rat renal allograft survival time 
by donor pretreatment with 8-methoxypsoralen 
and longwave ultraviolet irradiation of the graft 
(PUVA therapy). Urol Res 1985: 13: 95.
 67.  Oesterwitz H, Kaden J, Scholz D, Mrochen 










































pretreatment with 8-methoxypsoralen and 
ultraviolet irradiation of the graft plus 
azathioprine and prednisolone therapy in 
prolonging rat renal allograft survival. Urol Res 
1986: 14: 21.
 68.  Oesterwitz H, Kaden J, Schneider W, Schirrow 
R, Scholz D. Synergistic effect of photochemical 
donor pretreatment and cyclosporin therapy 
of the recipient on rat renal allograft survival. 
Nephrol Dial Transplant 1987: 2: 42.
 69.  Kaden J, Oesterwitz H, Schirrow R. Effects 
of photochemical donor pretreatment on the 
pattern of dog renal allograft infiltrating cells. 
Urol Res 1989: 17: 131.
 70.  Oesterwitz H, Scholz D, Kaden J et al. 
Photochemical donor pretreatment in clinical 
kidney transplantation--preliminary report. 
Urol Res 1987: 15: 211.
 71.  Fuller TF, Serkova N, Niemann CU, Freise 
CE. Influence of donor pretreatment with 
N-acetylcysteine on ischemia/reperfusion injury 
in rat kidney grafts. J Urol 2004: 171: 1296.
 72.  Li Z, Nickkholgh A, Yi X et al. Melatonin 
protects kidney grafts from ischemia/
reperfusion injury through inhibition of NF-
kB and apoptosis after experimental kidney 
transplantation. J Pineal Res 2009: 46: 365.
 73.  Guan X, Dei-Anane G, Liang R et al. Donor 
preconditioning with taurine protects 
kidney grafts from injury after experimental 
transplantation. J Surg Res 2008: 146: 127.
 74.  Guan X, Dei-Anane G, Bruns H et al. Danshen 
protects kidney grafts from ischemia/
reperfusion injury after experimental 
transplantation. Transpl Int 2009: 22: 232.
 75.  Hoeger S, Bergstraesser C, Selhorst J et al. 
Modulation of brain dead induced inflammation 
by vagus nerve stimulation. Am J Transplant 
2010: 10: 477.
 76.  Gottmann U, Brinkkoetter PT, Hoeger S 
et al. Atorvastatin donor pretreatment 
prevents ischemia/reperfusion injury in renal 
transplantation in rats: possible role for aldose-
reductase inhibition. Transplantation 2007: 84: 
755.
 77.  Stepkowski SM, Wang ME, Condon TP et al. 
Protection against allograft rejection with 
intercellular adhesion molecule-1 antisense 
oligodeoxynucleotides. Transplantation 1998: 
66: 699.
 78.  Fuller TF, Rose F, Singleton KD et al. Glutamine 
donor pretreatment in rat kidney transplants 
with severe preservation reperfusion injury. J 
Surg Res 2007: 140: 77.
 79.  Montazeri K, Vakily M, Honarmand A et al. 
Short-time intermittent preexposure of living 
human donors to hyperoxia improves renal 
function in early posttransplant period: a 
double-blind randomized clinical trial. J 
Transplant 2011: 2011: 204843.
 80.  Wahhabaghai H, Rasoulian B, Esmaili M et al. 
Hyperoxia-induced protection against rat’s 
renal ischemic damage: relation to oxygen 
exposure time. Ren Fail 2009: 31: 514.
 81.  Rasoulian B, Mohammadhosseniakbari H, 
Kadkhodaee M et al. Preconditioning with 
oxygen attenuates rat renal ischemia-
reperfusion injury. J Surg Res 2008: 146: 282.
 82.  Redaelli CA, Tien YH, Kubulus D et al. 
Hyperthermia preconditioning induces renal 
heat shock protein expression, improves cold 
ischemia tolerance, kidney graft function and 
survival in rats. Nephron 2002: 90: 489.
 83.  Redaelli CA, Wagner M, Kulli C et al. 
Hyperthermia-induced HSP expression 
correlates with improved rat renal isograft 
viability and survival in kidneys harvested from 
non-heart-beating donors. Transpl Int 2001: 14: 
351.
 84.  Feng S. Donor intervention and organ 
preservation: where is the science and what 
are the obstacles? Am J Transplant 2010: 10: 
1155.
 85.  Yang X, Qin L, Liu J, Tian L, Qian H. 17beta-
Estradiol protects the liver against cold 
ischemia/reperfusion injury through the Akt 
kinase pathway. J Surg Res 2012.
 86.  Chin JT, Troke JJ, Kimura N et al. A 
novel cardioprotective agent in cardiac 
transplantation: metformin activation of 
AMP-activated protein kinase decreases acute 
ischemia-reperfusion injury and chronic 
rejection. Yale J Biol Med 2011: 84: 423.
 87.  Guesde R, Barrou B, Leblanc I et al. 
Administration of desmopressin in brain-dead 
donors and renal function in kidney recipients. 
Lancet 1998: 352: 1178.
11.2
Mesenchymal stromal cells in treatment of renal 
ischemia/reperfusion injury 
D.K. de Vries, A.F.M. Schaapherder, M.E.J. Reinders






















































































Ischemia/reperfusion (I/R) injury is the exacerbation of tissue damage upon reestablishment 
of circulation after a period of ischemia. I/R injury is considered a major contributor to 
tissue damage in multiple clinical situations such as myocardial infarction, stroke and organ 
transplantation. In many clinical settings, the duration of ischemia is beyond control, and 
preventive and therapeutical measures are required to reduce the extent of I/R injury. 
Unfortunately, current treatment is primarily supportive. The pathophysiology of I/R injury 
is multifactorial and only partially understood. However, the general local reaction to 
reperfusion is thought to involve an inflammatory response that leads to tissue damage. 
In the quest for new therapeutical options for renal I/R injury, stem cells have come into 
play. With their multipotent immune modulating properties they hold promise to lead to 
improvement in the repair phase after I/R injury is evident. 
Renal repair
In recent years, it has become clear that not only fibrotic repair but also restoration of 
damaged kidney tissue can occur. This has been best established for acute kidney injury, 
where resident tubular epithelial cells that survive a given damage dedifferentiate and 
subsequently re-enter the cell cycle and replace the necrotic tubular epithelium. In this 
process they take up an immature mesenchymal phenotype and re-express transcription 
factors that are involved in fetal nephrogenesis. More recently, glomerular epithelial 
repair, involving both local resident cells as well as multipotent progenitor cells has been 
described.1 
Dedifferentiated cells outside the injured kidney may also migrate to the site of injury 
within the kidney. Kidney biopsies in male recipients of a female donor kidney with acute 
tubular necrosis showed presence of the male Y chromosome in renal tubular cells. No Y 
chromosome staining was seen in patients without acute tubular necrosis. This provides 
evidence that extra-renal cells may participate in renal regeneration.2;3 
The call for better treatment strategies for I/R injury has directed research toward more 
encompassing cellular-based therapies, particularly aimed at the use of stem cells. The 
multi-factorial pathophysiology of I/R injury makes a pharmacological agent that has a 
single mechanistic target less likely to be therapeutically effective. In contrast, stem cells 
are versatile, and able to target a whole cascade of repair mechanisms simultaneously and 











































Of all bone marrow-derived cells, mesenchymal stromal cells (MSCs) hold special promise 
in attenuating kidney injury, since nephrons are largely of mesenchymal origin and stromal 
cells are of crucial importance for signalling, leading to differentiation of both nephrons 
and collecting ducts. MSCs are characterized by three main criteria; 1) The ability to 
differentiate into osteoblasts, adipocytes and chondroblasts in vitro, 2) the expression of 
surface makers CD73, CD90 and CD105, and 3) plastic adherence in culture.4 
MSCs have the ability to secrete numerous growth factors and cytokines that collectively 
stimulate mitogenesis, inhibit apoptosis and modulate immune responses. MSCs can alter 
cytokine secretion profiles of naïve and effector T cells,5 DCs and natural killer cells to induce 
a more anti-inflammatory or tolerant phenotype.6;7 It is proposed that in an inflammatory 
microenvironment, MSCs promote a Th1 to Th2 shift. Furthermore, MSCs have been reported 
to induce T-cell division arrest,8 to inhibit differentiation and maturation of DCs9 and to 
decrease production of inflammatory cytokines by various immune cell populations.6 These 
immune modulating effects could be achieved both with autologous and allogeneic MSCs. 
The mechanism of MSC-induced kidney repair has been addressed in numerous studies. 
There is growing evidence that the process of transdifferentiation is rare and it probably 
does not have any relevance to renal repair in vivo. The primary means of these cells 
most likely involve paracrine and endocrine effects; including mitogenic, anti-apoptotic, 
anti-inflammatory, antifibrotic and angiogenic influences (Figure 1).10 The factors that 
mediate the paracrine effects are obviously of great interest. Several factors, such as IDO, 













































Figure 1: MSCs diminish damage and induce repair. Schematic illustration of the paracrine effects of 
MSCs on their environment. While stimulating repair by mitogenic and angiogenic effects, MSCs inhibit 
ongoing inflammation, apoptosis and later fibrosis of injured tissue.
An important aspect of the effect of MSCs is their ability to home to areas of injury or 
inflammation. Both animal and human studies have provided evidence that stem cells from 
hematopoietic tissues are able to engraft in nephrons as cells with tubular phenotype.12;13 
Exogenously administered MSCs can engraft into various injured structures in the kidney.14-16 
Recently, studies have shed light on the exact factors that facilitate homing of MSCs. 
Amid them, CD44 and hyaluronic acid interactions were shown to be crucial in recruiting 
exogenous MSCs to injured renal tissue and to enhance renal regeneration. Others have 
shown that stromal-derived factor-1 (SDF-1) and CXCR4 interactions may play a role in 
tubular homing.14;17
Sources of MSCs
While initially isolated from the bone marrow (bm), MSCs have now been identified within 
most tissues and are thought to represent a perivascular cell population involved in normal 
tissue homeostasis.18 Indeed, MSCs have been isolated from adipose tissue, umbilical cord 
(uc) blood, placenta and different organs.19-23 Recently MSCs have also been isolated from 
the human and mouse kidney. In mice these cells were extensively compared to bm cells.24 
Transcriptome and immunophenotype analysis of the renal MSC-like populations supported 
strong congruence with bmMSCs. Interestingly, despite this molecular congruence, distinct 
identities were found within the renal MSC-like population, suggesting organ-specific 
functions.24 In addition, it is suggested that the adult mouse kidney contains interstitial 
mesenchymal cell progenitors that are able to provide paracrine support for surrounding 
vessels and tubular epithelial cells.25 Future studies are needed to elucidate whether 
regeneration and functional repair of damaged kidney epithelium and endothelium can 










































characterized population and currently more than 200 clinical trials are ongoing using 
bmMSCs (www.clinicaltrials.gov).
MSCs ameliorate renal ischemia/reperfusion injury in vivo
Although MSCs most probably do not replace damaged cells, evidence on beneficial effects 
of MSCs in renal I/R injury is accumulating in animal experiments. Intravenous injection 
of bm derived lineage–negative pluripotent cells after experimental renal I/R significantly 
attenuated the creatinine rise.26 Peripherally administered purified MSCs were quickly 
present in peritubular capillaries and glomeruli after reperfusion, and functional and 
histological damage was significantly attenuated by MSC therapy.27 Even when administered 
24 hours after I/R injury, MSCs still were able to ameliorate damage.27;28
Different studies have reported beneficial effects of human MSCs on acute repair in the 
kidney.29 The therapeutic potential of human bmMSCs was studied in immunodeficient NOD-
SCID mice. Infused bmMSCs reduced renal cell apoptosis and increased proliferation after 
cisplatin-induced acute renal failure. bmMSCs also preserved the integrity of the tubular 
epithelium and peritubular vessels, and prolonged survival.30 In search for new sources of 
MSCs for renal repair, human ucMSCs were shown to ameliorate both renal dysfunction 
and tubular cell injury, and prolong survival in cisplatin-induced acute kidney injury.31 
Furthermore, IGF-1 gene-silenced MSCs were limited in their protective effects. These 
findings indicate that MSCs exert beneficial effects on tubular cell repair in acute kidney 
injury by producing the mitogenic and pro-survival factor IGF-1.32 
Clinical applications of MSCs in renal disease
There are only limited clinical data concerning MSC therapy in renal disease. The first phase 
I trial of autologous MSCs in kidney injury enrolls cardiac surgery patients with preexisting 
renal risk factors and therefore at high risk for developing acute kidney injury.33 In addition, 
the first safety and feasibility data of autologous MSC administration in the week after 
kidney transplantation were recently published.34 Although data are limited to two patients, 
MSC infusion appeared feasible and restricted memory T cell expansion while enlarging 
Treg population. However, both patients showed a transient increase in serum creatinine 
levels within two weeks after cell infusion. In one patient a renal biopsy was performed, 
which demonstrated a focal inflammatory infiltrate in the renal interstitium, consisting 
mainly of granulocytes with very few lymphocytes. It was suggested that the various soluble 
factors produced by MSCs also include proinflammatory mediators,35-37 which eventually 
may have contributed to the intragraft recruitment of granulocytes, and deterioration of 
renal function. This may suggest that timing of infusion is of particular importance. Indeed, 












































the timing of their infusion.38-40 Importance of timing is probably related to the necessity 
for the appropriate micro-environment to allow MSCs to acquire their anti-inflammatory 
properties. In our clinical trial we investigate safety and feasibility of autologous bmMSC 
treatment in patients with subclinical rejection and/or IF/TA in the renal biopsy at 4 weeks 
or 6 months after renal transplantation (Clinical trials NCT00734396). Hereby we expect to 
provide additional information about the importance of timing in the transplant setting.
Autologous versus allogeneic MSCs
Until now, most studies have focused on the use of autologous cells, since allogeneic cell 
transplantation has been reported to be connected with allograft rejection and possibly 
sensitization.41;42 However, the use of autologous MSCs also has disadvantages. The cells 
need weeks of culture and it is still unclear whether autologous MSCs are affected by the 
renal disease. A few studies have reported influence of renal failure on MSC behavior. In 
mice, functional incompetence of MSCs was reported under uremic conditions.43 In addition, 
in human MSCs it was shown that uremic serum induced an osteoblast-like phenotype in 
MSCs accompanied by matrix remodeling and calcification.44 
MSC number, route of administration, and interaction with immunosuppressives
Alongside the cell source, the number of MSCs and the timing of administration are critical. 
In clinical trials to date, most investigators have used doses of 0,4x106 to 10x106/kg body 
weight.45-47 However, no clear correlations have been made between cell dose and clinical 
effect. Dose escalation studies to monitor safety and efficacy are one of the major objectives 
for future studies of MSCs. 
In most human trials, MSCs have been administered intravenously. Another possible successful 
route of administration includes intra-arterial or intrarenal infusion.48-50 An advantage of 
these routes may be the direct administration at the place of injury, whereas disadvantages 
include the complexity and possible side effects such as obstruction of capillaries. To date, 
there are no reports of these treatment modalities in humans.
Current immunosuppressive drugs cannot be withheld from patients receiving MSC 
treatment after renal transplantation. Therefore, it is of importance that an optimal 
concurrent immunosuppressive regimen is chosen in which drugs have no negative impact 
on MSC function and vice versa. So far, this interaction has mainly been assessed by in vitro 
studies 51;52 and future studies are needed to elucidate their interaction with concurrent 










































Possible hurdles of MSC treatment 
Although cell therapy with MSCs holds enormous promise for the treatment of many diseases, 
unwanted side effects of MSC infusions must be assessed with the greatest care. Experimental 
studies have demonstrated maldifferentiation after injecting MSC directly into damaged 
tissue.50;53 In addition, MSCs may adopt and unwanted, myofibroblast-like phenotype after 
administration.54;55 Another important concern is that MSCs may differentiate into neoplastic 
cells or may cause promotion of tumor cell growth,56-58 although an increased risk of tumor 
formation has never been confirmed in humans.59 Currently, more than 2000 patients have 
been treated with allogeneic or autologous MSCs worldwide for a variety of diseases and so 
far no major side effects have been reported. However, still little is known about long-term 
side effects.
Summary
The pathophysiology of I/R injury is complex and characterized by inflammation, leading 
to tissue injury and graft dysfunction. Given current shortage of donor organs and usage 
of marginal donor kidneys for transplantation, novel treatment options to minimize renal 
I/R injury are urgently needed. Recent developments in stem cell research and derived 
clinical stem cell therapies have given reason to believe that such cell based treatments will 
become generally available in the near future. Although substantial additional time for the 
maturation of these therapies for routine clinical use is needed, the first steps of MSC based 
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Kidney transplantation represents one of the most striking medical achievements of the 
20th century. Its clinical success, however is limited by ischemia/reperfusion (I/R) injury. 
Renal I/R injury can lead to fibrosis and both acute and chronic graft dysfunction. Because 
of the increasing shortage of donors, more kidney grafts from marginal donors are being 
considered for transplantation, with concomitantly more initial graft injury and limited 
organ and patient survival. This has led to an increased need for interventions aiming to 
minimize I/R injury in kidney transplantation. 
In chapter 1, the pathophysiology of renal I/R injury is discussed. The exact sequence of 
events leading to graft injury is complex and incompletely understood. Mainly based on 
animal experiments, inflammation is considered an important event in the development 
of tissue injury and graft dysfunction in renal I/R injury. Many individual factors, such as 
cytokines, complement and platelets have been suggested to be involved in the inflammatory 
response. Although some intervention studies in animals have shown promising results, 
results of studies in humans have generally been disappointing. Although this contrast 
may reflect species-related pharmacokinetic differences or differences in timing of the 
intervention, the poor translatability could also imply fundamental differences between 
experimental animals and humans in the pathophysiologic processes involved in I/R injury.
The research presented in this thesis aimed to assess which processes and factors are 
involved in I/R injury in human clinical kidney transplantation, in order to obtain new 
insights for therapeutic modalities. To be able to study local processes during I/R of the 
kidney, paired arteriovenous blood samples were collected during early reperfusion. In 
chapter 2, the first results of measurements in these arteriovenous samples are described. 
Interleukin (IL)-6 was released in large amounts from the graft in human living donor kidney 
transplantation, suggesting its potential role in the pathophysiology of I/R injury. However, 
in the consecutive intervention study utilizing a model of bilateral renal ischemia and 
reperfusion in mice, anti-IL-6 treatment did not protect from renal I/R injury. Moreover, 
kidney damage even increased in the intervention group. Another cytokine of interest was 
IL-9, which is exclusively released during reperfusion from deceased donor kidneys. Chapter 
3 describes that, similar to IL-6, inhibition of IL-9 during renal I/R injury in mice did not 
result in improvement of renal function, but instead worsened renal injury. These studies 
indicate that renal I/R injury apparently is not easily modifiable by inhibiting a single 
factor only. The complex interplay between cytokines possibly includes the ability of other 










































By measuring the release of multiple cytokines at once, we tried to gain insight in how 
the network of cytokines changes upon reperfusion in living, brain dead and cardiac dead 
donor kidney transplantation. In chapter 4 it is shown that brain dead donor kidneys display 
a massive inflammatory cytokine release upon reperfusion, while kidneys from living and 
cardiac dead donors showed a more modest cytokine response with release of IL-6 and small 
amounts of monocyte chemoattractant protein-1 (MCP-1). These released cytokines may 
originate from infiltrated T lymphocytes and macrophages. Already before transplantation, 
these cells were far more prevalent in brain dead donor kidneys than in living and cardiac 
dead donor kidneys. These observations suggest that brain dead donor kidneys have a pro-
inflammatory tendency, that induces the release of many cytokines upon reperfusion. Brain 
dead donor kidneys may therefore require a different approach in the prevention of I/R 
injury, aimed at inhibiting this inflammatory response.
While cytokines are signaling molecules, the complement system has both signaling and lytic 
functions within the innate immune system. Activation of either the classical, alternative, 
or mannan-binding lectin complement pathway ultimately leads to the formation of the 
membrane attack complex, C5b-9. Animal studies of renal I/R injury generally show that 
complement inhibition reduces post-reperfusion damage. In chapter 5.1 we assessed 
whether the complement cascade is activated during clinical renal I/R injury. Arteriovenous 
measurements showed no release of sC5b-9 from living donor kidneys, but a transient venous 
release of sC5b-9 from the reperfused graft in brain dead and cardiac dead donor kidney 
transplantation. This activation of the terminal complement cascade was not reflected 
by renal tissue deposition of C5b-9 in biopsies taken 45 minutes after reperfusion. These 
results indicate there is instantaneous, intravascular terminal complement activation upon 
reperfusion, that might be induced by intravascular cellular debris and hypoxic or injured 
endothelium. Besides measurements in blood and biopsy tissue, urinary sC5b-9 would also 
be an attractive biomarker to study. However in chapter 5.2 we show that urinary sC5b-
9 can be formed extra-renally in case of procedure-related (microscopic) hematuria and 
proteinuria. Therefore, sC5b-9 in urine is not a reliable reflection of complement activation 
after kidney transplantation. 
Platelets also have an important role in the innate immune response, and can serve as 
mediators of the innate immune system, apart from their primary function in haemostasis. 
Although in preclinical studies activated platelets have been implicated in the inflammatory 
response after reperfusion, their role in clinical human I/R injury is unknown. In chapter 6 
we used our method of arteriovenous measurements over the reperfused kidney to assess 
release of markers of platelet activation and degranulation. No evidence for platelet 












































measurement of more subtle changes in excitability of platelets. In the novel, bedside 
platelet excitability assay, platelets were stimulated and their response measured. 
Remarkably, platelets in renal venous blood were less easily and less intensely excitable 
than platelets in arterial blood. Since platelets were not trapped in the kidney, this may 
reflect true inhibition of platelet excitability upon passing the injured kidney, therefore 
suggesting platelets probably do not initiate the inflammatory response of I/R injury. 
The most important step preceding platelet activation would be endothelial damage. 
Interactions between endothelial cells and pericytes, the main supportive cells of the 
endothelium, are important in maintenance of vascular integrity. Angiopoietins are the 
signaling molecules facilitating these interactions. Experimental data have shown that 
enhancement of Angiopoietin (Ang)-1 signaling may be beneficial in renal I/R injury. Little 
is known however, about the behavior of angiopoietins in human renal I/R injury. In chapter 
7, endothelial cell activation and changes in angiopoeitins were assessed in human living 
and deceased donor kidney transplantation. Local release of angiopoietins was measured by 
arteriovenous measurements over the reperfused kidney. Results showed acute endothelial 
cell activation by a vast Ang-2 release from both living and deceased donor grafts shortly after 
reperfusion. Its counterpart Ang-1 was not released. Histological analysis of kidney biopsies 
showed endothelial cell loss after reperfusion. Baseline Ang-1 protein and mRNA expression 
was significantly reduced in deceased compared to living donors and declined further after 
reperfusion. These results showed that human renal I/R injury induces endothelial cell 
activation after reperfusion reflected by Ang-2 release from the kidney. Interventions aimed 
at maintenance of vascular integrity by modulating angiopoietin signaling may be promising 
in human clinical kidney transplantation.
Another way by which endothelial cells may be involved in the pathophysiology of renal 
I/R injury is by changes in expression of the adenosine generating enzymes CD39 and CD73. 
Recent animal experiments suggest that extracellular adenosine may be a critical mediator 
in protection from renal I/R injury. Information on adenosine production in human kidney 
transplantation however, is lacking. In chapter 8 changes in protein and mRNA expression of 
adenosine generating enzymes CD39 and CD73 in transplanted human kidneys were assessed. 
Results showed that CD39 protein is overrepresented in living compared to deceased donor 
kidneys before transplantation. However, CD39 mRNA expression was not different between 
groups and did not change upon reperfusion. CD73 mRNA expression was significantly 
downregulated after reperfusion, while its tissue protein expression did not change. Results 
showed that living donor kidneys may be protected by higher pre-transplantation CD39 
expression, although this effect may be counteracted by the decrease in CD73 expression 










































changes for renal adenosine generation and kidney graft injury. The results from chapter 6, 
7, and 8 together demonstrate that there is endothelial injury upon reperfusion, although 
this apparently does not lead to platelet activation. 
Oxidative damage has been considered a key factor in the initiation of I/R injury for decades 
now. Although findings from preclinical studies show that quenching reactive oxygen and 
nitrogen species (RONS) alleviates I/R injury, results from clinical intervention studies 
in humans are largely inconclusive. In chapter 9 we systematically evaluated release of 
established biomarkers of oxidative and nitrosative damage during reperfusion of the 
transplanted kidney. Interestingly, none of the measured biomarkers of oxidative and 
nitrosative damage (i.e. malondialdehyde, 15(S)-8-iso-prostaglandin F2α, nitrite, nitrate and 
nitrotyrosine) were released upon reperfusion. Cumulative urinary measurements confirmed 
plasma findings. The production of RONS during I/R is explicitly not questioned by these 
findings. Indeed, we found increased urinary PGE2 after reperfusion and activation of Nrf2, 
the master regulator of oxidative stress signaling. Together this illustrates that there is an 
increase in oxidative stress during early reperfusion. Yet, the generated RONS apparently 
do not induce tissue damage in human I/R. These observations suggest a very efficient anti-
oxidant system, providing an explanation for the limited efficacy of antioxidant therapy 
in human I/R injury. Overall, results of this study challenge the prevailing paradigm of 
prominent involvement of oxidative damage in the initiation of human I/R injury. 
Altogether, the studies presented in this thesis suggest that inflammation is the prevailing 
process in the early reperfusion period in human kidney transplantation. When assessing the 
mechanisms potentially underlying I/R injury however, it remained unclear what initiates 
I/R injury and what causes the differences in outcome between living and deceased donor 
kidneys. In contrast to the approach in the previous chapters, in chapter 10 we examined 
the genome-wide expression patterns of donor kidneys prior to and 45 minutes after 
reperfusion. The comparison of gene expression between living and deceased donor kidneys 
showed an explicit difference in metabolism related genes. Living donor kidneys regained 
the expression of genes associated with metabolism shortly after reperfusion, while these 
genes all remained downregulated after reperfusion in deceased donor kidneys. These 
fundamental differences provide a totally new viewpoint, indicating that failure to restart 
metabolism after reperfusion may lead to enhanced I/R injury in deceased donor kidney 
grafts. This hypothesis is strengthened by the abundant release of lactate from deceased 
donors, which is released in many times higher concentrations from deceased than living 
donor kidneys. More extensive studies to assess the mechanism and implications of the 












































Therapeutical modalities and current progress in prevention of I/R injury are discussed 
in chapter 11. The first intervention possibility is prior to transplantation. Before the 
actual transplantation, the graft is already exposed to various noxious events, including 
potential donor brain death and cold preservation. These non-immunological factors 
such as donor health and the duration of the ischemic period probably have substantial 
impact on short and long term graft function. Consequently, interventions in the donor, 
aimed at minimizing pre-transplantation graft injury, may potentially have large effects in 
preventing acute and long term graft dysfunction. In chapter 11.1 the various therapeutical 
interventions that have been tested in donors are reviewed. As suggested by the results 
in chapter 4, anti-inflammatory interventions in the donor may prevent consequent I/R 
injury after transplantation. Donor pretreatment by various other strategies, including 
ischemic preconditioning, HO-1 induction, anti-complement interventions, erythropoietin 
and catecholamines has been successful in animal experiments. Although many of these 
promising results in animals have yet to be confirmed in human kidney transplantation, the 
first clinical studies have already shown encouraging results. Next, during transplantation, 
I/R injury may be limited by modulation of the inflammatory response. In this perspective, 
mesenchymal stromal cells (MSCs) are under extensive investigation, since MSCs are able 
to exert immune regulatory and reparative effects. These versatile cells have been shown 
to migrate to sites of injury and to enhance repair by paracrine mechanisms instead of by 
differentiating and replacing the injured cells. In chapter 11.2 various preclinical studies 
are discussed that demonstrate the beneficial effects of MSCs in ameliorating renal injury 
and accelerating tissue repair. Moreover, the first phase I studies of MSCs in human renal 
I/R injury and kidney transplantation have been started, and results are awaited soon. 
Preliminary results from clinical studies and recent developments in stem cell research have 
given reason to believe that MSC-based treatments will become generally available in the 
near future. 
In conclusion, the studies in this thesis describe the systematical search for factors 
involved in the pathophysiology of human renal I/R injury. Many of the processes assumed 
to be involved in renal I/R injury based on animal studies could not be confirmed in our 
clinical study in humans. However, we found new evidence of complement activation and 
endothelial cell activation in human renal I/R injury. Moreover, there were large differences 
between deceased and living donor kidneys; brain dead donor kidneys have a unique pro-
inflammatory cytokine release after reperfusion. Finally it appears that both brain dead and 
cardiac dead donor kidneys are not able to upregulate their metabolism-related genes upon 
reperfusion as living donor kidneys do, indicating that failure to restart metabolism may be 
a factor expanding I/R injury. All of these findings contribute to the understanding of renal 
I/R injury in humans and instigate the further search for therapeutical modalities to limit 





















































































Samenvatting in het Nederlands
 
Niertransplantatie is een van de meest opvallende medische prestaties van de 20e eeuw. 
Helaas wordt het klinisch succes ervan nog altijd beperkt door ischemie/reperfusie (I/R) 
schade. I/R-schade veroorzaakt acute en chronische transplantaatdisfunctie en kan leiden 
tot fibrose en het falen van de getransplanteerde nier. Door het toenemende tekort aan 
donoren worden steeds vaker organen van marginale donoren gebruikt voor transplantatie, 
waarbij in de regel meer schade optreedt en de overleving van het transplantaat slechter 
is. Dit creëert een behoefte aan interventies gericht op het verminderen van I/R-schade in 
de getransplanteerde nier.
 
In hoofdstuk 1 wordt de pathofysiologie van I/R-schade van de nier besproken. De exacte 
volgorde van processen die leiden tot schade aan de getransplanteerde nier is complex en 
niet volledig bekend. Inflammatie wordt als cruciaal beschouwd in de ontwikkeling van 
weefselbeschadiging en transplantaatdisfunctie door nier I/R-schade. Van vele individuele 
factoren, zoals cytokines, complement en bloedplaatjes wordt gesuggereerd dat zij betrokken 
zijn bij de inflammatoire reactie. Helaas zijn de resultaten van de uitgevoerde onderzoeken 
bij mensen over het algemeen teleurstellend, hoewel sommige interventiestudies bij dieren 
veelbelovende resultaten hebben laten zien. Hoewel verschillen in de pharmacokinetiek of 
verschillen in timing van de interventie dit contrast tussen uitkomsten bij mens en proefdier 
zouden kunnen veroorzaken, impliceert de beperkte interspecies translatie tussen soorten 
dat er fundamentele verschillen zijn tussen proefdieren en mensen in de pathofysiologie 
van I/R-schade.
 
De studies beschreven in dit proefschrift zijn gericht op het ontrafelen van de processen 
en factoren die betrokken zijn bij I/R-schade bij klinische niertransplantaties, zodat er 
nieuwe inzichten kunnen ontstaan om doelgerichte therapieën te ontwikkelen. Om lokale 
processen te bestuderen tijdens reperfusie van de nier, werden arterio-veneus gepaarde 
bloedmonsters afgenomen tijdens de reperfusiefase. In hoofdstuk 2 worden de eerste 
resultaten van de metingen in deze arterio-veneuze monsters beschreven. Bij levende donor 
niertransplantatie kwam interleukine (IL)-6 in grote hoeveelheden vrij uit het transplantaat. 
Dit suggereert dat het een rol speelt in de pathofysiologie van I/R-schade. Uit de daarop 
volgende interventiestudie van bilaterale renale ischemie en reperfusie in muizen, bleek 
echter dat de anti-IL-6 behandeling niet tegen nier I/R-schade beschermt. De schade aan de 
nier was zelfs toegenomen in de interventiegroep. Een ander cytokine van belang was IL-9, 
dat uitsluitend vrijkwam uit overleden donor nieren na reperfusie. Hoofdstuk 3 beschrijft 
dat, net als bij IL-6, remming van IL-9 in nier I/R-schade bij muizen niet resulteerde in 










































studies geven aan dat nier I/R-schade bij niertransplantatie blijkbaar niet gemakkelijk te 
beïnvloeden is door het remmen van een enkele factor alleen. De complexe wisselwerking 
tussen cytokines onderling maakt het waarschijnlijk mogelijk dat andere cytokines de 
effecten van de geremde factor overnemen.
 
De suggestie dat cytokines of andere inflammatoire mediatoren betrokken zijn, wordt 
bevestigd in een volgende studie waarbij de arterioveneuze afgifte van verschillende cytokines 
systematisch vergeleken is tussen levende, hersendode en hartdode donorniertransplantaties. 
Door het vergelijken van de afgifte van meerdere cytokines, is getracht inzicht te krijgen 
in de manier waarop het cytokinenetwerk verandert na reperfusie in deze verschillende 
groepen. In hoofdstuk 4 wordt aangetoond dat nieren van hersendode donoren een massale 
inflammatoire reactie doormaken, waarbij meerdere cytokines vrijkomen na reperfusie. 
Getransplanteerde nieren van levende en hartdode donoren toonden een meer bescheiden 
cytokinerespons met afgifte van IL-6 en kleine hoeveelheden monocyte chemoattractant 
protein-1 (MCP-1). Deze vrijgekomen cytokines kunnen afkomstig zijn van de geïnfiltreerde 
T-lymfocyten en macrofagen die al vóór de transplantatie in nieren van hersendode donoren 
in veel grotere aantallen aanwezig waren dan in nieren van levende en hartdode donoren. 
De bevindingen in dit hoofdstuk suggereren dat nieren van hersendode donoren een pro-
inflammatoire tendens hebben, geïnduceerd door het vrijkomen van de vele cytokines 
na reperfusie. Daarom vereisen hersendode donoren mogelijk een aparte aanpak bij de 
preventie van I/R-schade, specifiek gericht op het remmen van deze inflammatoire reactie.
Cytokines zijn signaleringsmoleculen, het complementsysteem heeft echter zowel 
signalerings- als lytische functies binnen het aangeboren immuunsysteem. Activering 
van de klassieke, alternatieve of mannan-bindende lectineroute leidt uiteindelijk tot de 
vorming van het functionele complex C5b-9. Dierexperimenten laten over het algemeen 
zien dat complementremming de post-reperfusie nierschade vermindert. Mogelijk zijn deze 
resultaten te transleren van de muis naar de mens. Derhalve hebben we in hoofdstuk 5.1 
eerst onderzocht of de complementcascade wordt geactiveerd tijdens klinische nier I/R-
schade. In de arterioveneuze metingen kwam sC5b-9 niet vrij uit nieren van levende donoren, 
maar bij de hersendode en hartdode donor niertransplantaties kwam sC5b-9 wel kortdurend 
vrij uit het gereperfundeerde orgaan. Deze activering van de terminale complementcascade 
leidde niet tot de afzetting van C5b-9 in nierbiopsieën 45 minuten na reperfusie. Deze 
resultaten wijzen op acute, intravasculaire terminale complementactivatie na reperfusie, 
die mogelijk geïnduceerd wordt door intravasculaire celresten, of contact met hypoxisch of 
beschadigd endotheel. 
Naast de metingen in bloed en weefsel, zou sC5b-9 in urine ook een aantrekkelijke biomarker 












































gevormd in het geval van (operatie-gerelateerde) hematurie en proteïnurie. In hoofdstuk 
5.2 concluderen we dat de meting van sC5b-9 in urine niet betrouwbaar is als marker van 
complementactivatie na niertransplantatie.
Bloedplaatjes maken tevens onderdeel uit van het aangeboren afweersysteem. Naast 
hun primaire functie in hemostase, kunnen bloedplaatjes dienen als mediatoren van het 
aangeboren immuunsysteem. Hoewel in preklinische studies aangetoond is dat geactiveerde 
bloedplaatjes betrokken zijn bij de inflammatie na reperfusie, is hun rol bij humane 
klinische I/R-schade onbekend. In hoofdstuk 6 hebben we opnieuw gebruik gemaakt 
van arterioveneuze metingen over de gereperfundeerde nier, nu om het vrijkomen van 
markers van bloedplaatjesactivatie en -degranulatie te bepalen. Resultaten toonden geen 
bloedplaatjesactivatie of -degranulatie in de nier na reperfusie. Daarom werd vervolgens 
onderzocht of er meer subtiele veranderingen zijn in de activeerbaarheid van bloedplaatjes. 
In de nieuwe bloedplaatjesactiveerbaarheidsassay werden bloedplaatjes gestimuleerd in 
toenemende mate en hun reactie daarop gemeten. Het is opmerkelijk dat bloedplaatjes 
in het veneuze bloed uit de nier minder makkelijk en minder intens geactiveerd raakten 
dan bloedplaatjes in het arteriële bloed. Omdat de bloedplaatjes niet achterbleven in de 
nier, lijkt dit te berusten op een remming van de activeerbaarheid van de bloedplaatjes 
bij het passeren van de gereperfundeerde nier. Al met al suggereren de bevindingen dat 
bloedplaatjes waarschijnlijk niet de initiator zijn van de inflammatoire reactie bij I/R-
schade van de nier.
 
Endotheelschade wordt gezien als de belangrijkste stap voorafgaand aan activering van 
bloedplaatjes. Erg belangrijk bij het voorkómen van deze schade zijn de interacties tussen 
endotheelcellen en pericyten, de belangrijkste ondersteunende cellen van het endotheel. 
Deze interacties worden gefaciliteerd door signaalmoleculen, de angiopoietines. Uit 
dierexperimenten blijkt dat verhoging van angiopoietine (Ang)-1 signalering beschermend 
werkt bij nier I/R-schade. Er is echter weinig bekend over de rol van angiopoietines bij 
humane nier I/R-schade. In hoofdstuk 7 werden endotheelactivatie en de veranderingen in 
angiopoietines onderzocht en vergeleken bij niertransplantaties met levende en overleden 
donor. Het lokaal vrijkomen van angiopoietines werd bepaald in arterioveneuze metingen 
over de gereperfundeerd nier. De resultaten toonden acute activatie van het endotheel, 
blijkend uit het fors vrijkomen van Ang-2 uit de nieren van zowel levende als overleden 
donoren. De tegenhanger van Ang-2, Ang-1, kwam niet vrij uit de nier. Histologische analyse 
van nierbiopten toonde verlies van endotheelcellen na reperfusie. De eiwit- en mRNA-
expressie van Ang-1 was significant minder in biopten van nieren van overleden donoren 
vergeleken met levende donoren. De Ang-1 expressie daalde verder na reperfusie. Samen 










































raken, volgend uit de Ang-2 afgifte uit de nier na reperfusie. Interventies gericht op 
behoud van vasculaire integriteit door het beïnvloeden van de angiopoietinesignalering zijn 
veelbelovend voor humane klinische niertransplantatie.
 
Een andere manier waarop endotheelcellen betrokken kunnen zijn bij de pathofysiologie 
van nier I/R-schade, is door hun expressie van de adenosinegenererende enzymen CD39 en 
CD73. Recente dierexperimenten suggereren dat extracellulaire adenosine een belangrijke 
rol speelt in de bescherming tegen I/R-schade. Er is echter nog weinig bekend over de rol 
van extracellulair adenosine bij niertransplantaties in de mens. In hoofdstuk 8 werd de 
eiwit- en mRNA-expressie van adenosinegenererende enzymen CD39 en CD73 bepaald in 
getransplanteerde menselijke nieren. De resultaten toonden aan dat vóór transplantatie 
het CD39-eiwit meer aanwezig was in nieren van levende dan overleden donoren. De mRNA-
expressie van CD39 was niet verschillend tussen de groepen en veranderde ook niet na 
reperfusie. De mRNA-expressie van CD73 was significant minder na reperfusie, terwijl de 
eiwitexpressie niet veranderde. De resultaten suggereren dat nieren van levende donoren 
worden beschermd door hogere pre-transplantatie CD39-expressie, hoewel dit effect 
kan worden tegengegaan door de afname van CD73-expressie na reperfusie. Verdere 
studies zullen zich moeten richten op de gevolgen van deze enzymveranderingen op de 
adenosinegeneratie in de nier en het uiteindelijke letsel aan de nier. Samenvattend tonen 
de resultaten van hoofdstuk 6, 7 en 8 aan dat er endotheelschade is na reperfusie van de 
nier, hoewel dit niet leidt tot bloedplaatjesactivatie.
 
Ten slotte wordt oxidatieve schade al tientallen jaren beschouwd als een belangrijke factor 
in de initiatie van I/R-schade. Hoewel de bevindingen uit preklinische studies aantonen dat 
het verminderen van reactieve zuurstof- en stikstofradicalen I/R-schade kan verminderen, 
zijn de resultaten van klinische interventiestudies niet eenduidig. In hoofdstuk 9 hebben we 
het vrijkomen van biomarkers van oxidatieve en nitrosatieve schade tijdens reperfusie van 
de getransplanteerde nier systematisch onderzocht. Geen van de gemeten biomarkers van 
oxidatieve schade en nitrosative (bijvoorbeeld malondialdehyde, 15(S)-8-iso-prostaglandine 
F2α, nitriet, nitraat en nitrotyrosine) kwamen vrij na reperfusie. Cumulatieve metingen in 
urine bevestigden de bevindingen van de metingen in het bloed. De vorming van vrij-radicalen 
tijdens I/R wordt nadrukkelijk niet in twijfel getrokken door deze bevindingen. Dit werd 
juist bevestigd door de verhoogde concentraties van PGE2 in urine en activering van Nrf2, 
de hoofdregulator van de oxidatieve stress-signalering. Samen tonen deze een toename in 
oxidatieve stress aan kort na reperfusie. Desondanks leidt de oxidatieve stress blijkbaar niet 
tot oxidatieve weefselschade bij nier I/R in de mens. Deze belangrijke bevinding suggereert 
dat mensen een zeer efficiënt anti-oxidantsysteem hebben. Dat is direct ook de verklaring 












































geheel genomen gaan de resultaten van deze studie in tegen het heersende paradigma van 
prominente betrokkenheid van oxidatieve schade in de initiatie van I/R-schade in de mens.
 
Concluderend suggereren de studies in dit proefschrift dat inflammatie een belangrijk 
proces is in de reperfusieperiode van humane niertransplantatie. Echter, het blijft 
moeilijk in te schatten welke processen belangrijk zijn bij het veroorzaken van I/R-schade 
en wat de verschillen tussen nieren van levende en overleden donoren veroorzaakt. In 
tegenstelling tot de aanpak in de voorgaande hoofdstukken, is in hoofdstuk 10 gepoogd 
nieuwe aanknopingspunten te vinden door de expressiepatronen van het totale genoom 
te bepalen in nierbiopten, genomen voor en 45 minuten na reperfusie. De vergelijking van 
genexpressiepatronen tussen nieren van levende en overleden donoren toonde een expliciet 
verschil in metabolisme-gerelateerde genen. Terwijl bij nieren van levende donoren de 
expressie van genen geassocieerd met metabolisme kort na reperfusie herstelde, bleven 
deze genen in nieren van overleden donoren alle ge-downreguleerd na reperfusie. Deze 
fundamentele verschillen impliceren een totaal nieuwe hypothese, namelijk dat het 
onvermogen om het metabolisme te herstarten na reperfusie kan leiden tot toegenomen 
I/R-schade bij niertransplantaties met nieren van overleden donoren. Deze hypothese wordt 
versterkt door de resultaten van lactaatmetingen, waarbij lactaat na reperfusie in vele 
malen hogere concentraties vrijkwam uit nieren van overleden donoren dan van levende 
donoren. Deze bevindingen zullen echter moeten worden bevestigd in uitgebreidere 
studies naar het mechanisme en de implicaties van het falen van het herstarten van het 
celmetabolisme.
 
Tenslotte worden de therapeutische mogelijkheden en de huidige vooruitgang in de preventie 
van I/R-schade besproken in hoofdstuk 11. Het eerste moment waarop een therapie kan 
aangrijpen is al voor de transplantatie. Voor de eigenlijke implantatie wordt het transplantaat 
al blootgesteld aan verschillende schadelijke gebeurtenissen, waaronder bijvoorbeeld 
hersendood van de donor en de koude preservatie van het transplantaat. Deze niet-HLA-
afhankelijke factoren zoals de gezondheid van de donor en de duur van de ischemie hebben 
een aanzienlijk effect op de korte- en langetermijn transplantaatfunctie. Dientengevolge 
kunnen interventies in de donor, gericht op het minimaliseren van de transplantaatschade 
voor transplantatie, mogelijk al grote gevolgen hebben in het voorkomen van acute en lange 
termijn transplantaatdisfunctie. In hoofdstuk 11.1 worden de verschillende therapeutische 
donorinterventies opgesomd en besproken. Zoals reeds geïmpliceerd door de resultaten in 
hoofdstuk 4, kan anti-inflammatoire behandeling van de donor de daaruit voortvloeiende 
I/R-schade na transplantatie mogelijk verminderen. Donorvoorbehandeling met 
verschillende andere methoden, waaronder ischemische preconditionering, HO-1-inductie, 










































bij dierproeven. Alhoewel menig van deze veelbelovende resultaten bij dieren nog moeten 
worden bevestigd bij de mens, hebben de eerste klinische studies bij niertransplantatie al 
bemoedigende resultaten laten zien. 
Ten tweede kan tijdens transplantatie de I/R-schade beperkt worden door modulatie van 
de inflammatoire reactie. Vanuit dit perspectief zijn mesenchymale stromale cellen (MSC’s) 
uitgebreid onderzocht, omdat MSC’s in staat zijn om het immuunsysteem te beïnvloeden 
en herstellende effecten uit te oefenen. Van deze veelzijdige cellen is aangetoond dat ze 
migreren naar plaatsen van schade en daar herstel stimuleren door hun paracriene effecten 
en niet door differentiatie en vervanging van de beschadigde cellen. In hoofdstuk 11.2 
worden verschillende preklinische studies besproken die de gunstige effecten van MSC’s in 
het verminderen van schade aan de nieren en het versnellen van het weefselherstel tonen. 
Bovendien zijn de eerste fase 1-studies van MSC’s ter vermindering van I/R-schade bij 
klinische niertransplantatie gestart. De definitieve resultaten worden binnenkort verwacht, 
echter de voorlopige resultaten van klinische studies en recente ontwikkelingen in het 
onderzoek naar stamcellen geven reden te geloven dat behandelingen met MSC’s toegepast 
zullen gaan worden in de nabije toekomst.
 
De studies in dit proefschrift beschrijven de systematische zoektocht naar factoren die 
betrokken zijn bij de pathofysiologie van I/R-schade van de menselijke nier. Veel processen 
die op basis van dierstudies verondersteld waren betrokken te zijn bij deze I/R-schade 
konden niet worden bevestigd in onze klinische studies van niertransplantatie. We vonden 
echter nieuw bewijs voor de betrokkenheid van complement- en endotheelcelactivatie bij 
nier I/R-schade in de mens. Bovendien waren er grote verschillen tussen transplantaties 
met nieren van levende en overleden donoren. Hierbij bleek dat nieren van hersendode 
donoren een unieke combinatie van pro-inflammatoire cytokines afgeven na reperfusie. 
Een andere belangrijke bevinding is dat nieren van zowel hersendode als hartdode donoren 
nieren niet in staat lijken te zijn de metabole motor opnieuw op te starten na reperfusie. Al 
deze bevindingen dragen bij aan een beter begrip van I/R-schade van de nier en stimuleren 
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altijd concreet en constructief was. 
Dr. Ringers wil ik bedanken voor zijn steun als hoofd van de transplantatiechirurgie. De 
overige transplantatiechirurgen van het LUMC, dr. Baranski, Braat en Dubbeld wil ik van 
harte danken voor hun betrokkenheid bij mijn onderzoek en hun inzet om bloed en biopten 
te verzamelen. 
Collega’s van de afdeling nefrologie van het LUMC, in het bijzonder prof. Rabelink, prof. 
Van Kooten, Marlies Reinders en Pieter van der Pol, dank voor de fijne samenwerking. Het 
aantal gezamenlijke publicaties de afgelopen jaren getuigt van de mooie samenwerking die 
we hebben opgebouwd: ik hoop dat we zo doorgaan.
Alle co-auteurs die hebben bijgedragen aan het uitvoeren en (her)schrijven van de 
hoofdstukken opgenomen in dit proefschrift wil ik van harte danken voor hun bijdrage en 
de prettige samenwerkingen. 
D6-35 genoten Kirsten, Chantal, Vivianne, Mark, Alexander en vele anderen, het was alleen 
qua temperatuur dat we niet op één lijn zaten. Dank voor het groepsgevoel. Leonie, heel 
veel succes met de voortzetting van de prachtige I/R onderzoekslijn: je hebt nu al succes! 
Verder zijn zeker in het begin van mijn onderzoeksperiode de collega’s van het CKCL steun 
en toeverlaat geweest. Dank aan Hans, Nico, Fred, Ria, Hinke, Harm, Ruben, Marja en 










































Lieve oud-studiegenootjes Ellen, Suzanne, Marjan en Femke. Geweldig dat we allen 
(letterlijk) een andere kant op zijn gegaan maar elkaar toch altijd weten te vinden. Lieve 
Bubbels vriendinnen Jolanda, Inge, Michelle, Rieneke, Annemieke, Ruth, Eveline en Lenny, 
jullie zijn mij zo dierbaar!
Lianne Koens en Margreet Poot, bedankt dat jullie mijn paranimfen willen zijn. Lieve 
Margreet, onze vriendschap is zo met mijn leven verweven, het voelt goed je vandaag naast 
me te hebben! Lieve Lianne, de combi van pret op reis en altijd een serieus luisterend oor 
maken je goud waard! 
Lieve mama, door de stappen die jij terug hebt gedaan, was het voor ons mogelijk stappen 
vooruit te doen. Ik ben dankbaar dat je er altijd voor ons bent geweest, en ik verheug me op 
alle tijd samen die nog komen gaat! David en Bálint, jullie zijn topbroers! Dank voor jullie 
interesse. Lieve schoonouders, bedankt voor jullie steun en belangstelling in elke fase van 
mijn studies. 
Lieve kleine Brem, mama is zo blij dat jij er bent! Hoe trots ik ook ben dat dit proefschrift 
af is, jij hebt het me in een heel ander perspectief doen zien! Lieve Paul, jij hebt me altijd 
gesteund en gestimuleerd uitdagingen aan te gaan. Heel veel dank daarvoor!
Dorottya de Vries
November 2013
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